Small anti-viral compounds activate immune cells via t pathway

Nature Immunology 3, 196-200 DOI: 10.1038/ni758

Citation Report

#	Article	IF	CITATIONS
1	HSV-1 and 2: immunobiology and host response. , 2007, , 616-641.		2
2	Candidate anti-herpesviral drugs; mechanisms of action and resistance. , 0, , 1219-1250.		3
3	HYPOTHALAMIC ENDOCRINE DYSFUNCTION IN ANOREXIA NERVOSA. European Journal of Endocrinology, 1977, 85, 673-683.	3.7	27
4	Review: IFN- <i>α</i> / <i>β</i> Receptor Interactions to Biologic Outcomes: Understanding the Circuitry. Journal of Interferon and Cytokine Research, 2002, 22, 835-845.	1.2	174
5	Murine Plasmacytoid Pre-Dendritic Cells Generated from Flt3 Ligand-Supplemented Bone Marrow Cultures Are Immature APCs. Journal of Immunology, 2002, 169, 6711-6719.	0.8	217
6	Cutting Edge: Impaired Toll-Like Receptor Expression and Function in Aging. Journal of Immunology, 2002, 169, 4697-4701.	0.8	549
7	Whence Interferon? Variety in the Production of Interferon in Response to Viral Infection. Journal of Experimental Medicine, 2002, 195, F15-F18.	8.5	75
8	Interferon-α and Interleukin-12 Are Induced Differentially by Toll-like Receptor 7 Ligands in Human Blood Dendritic Cell Subsets. Journal of Experimental Medicine, 2002, 195, 1507-1512.	8.5	434
9	"For Whom the Bell Tolls!â€⊷ Innate Defense Mechanisms and Survival Strategies of the Intestinal Epithelium Against Lumenal Pathogens. Zeitschrift Fur Gastroenterologie, 2002, 40, 983-990.	0.5	39
10	Toll-like Receptor 9, CpG DNA and Innate Immunity. Current Molecular Medicine, 2002, 2, 545-556.	1.3	141
11	Dendritic Cells in Innate Immune Responses Against HIV. Current Molecular Medicine, 2002, 2, 739-756.	1.3	48
12	A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. International Immunology, 2002, 14, 783-791.	4.0	153
14	Toll-like Receptor (TLR) Signaling in Response toAspergillus fumigatus. Journal of Biological Chemistry, 2002, 277, 39320-39326.	3.4	273
15	Toll Receptors. Current Protocols in Immunology, 2002, 52, 14.12.1-14.12.11.	3.6	6
16	Discovery of 8-Hydroxyadenines as a Novel Type of Interferon Inducer. Journal of Medicinal Chemistry, 2002, 45, 5419-5422.	6.4	77
17	Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biology, 2002, 3, reviews3011.1.	9.6	149
18	CpG DNA in the Prevention and Treatment of Infections. BioDrugs, 2002, 16, 419-431.	4.6	36
19	Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. Journal of the American Academy of Dermatology, 2002, 47, 571-577.	1.2	121

ATION REDO

2

		EPORT	
# 20	ARTICLE IRF3 Mediates a TLR3/TLR4-Specific Antiviral Gene Program. Immunity, 2002, 17, 251-263.	IF 14.3	Citations
21	TLR-7 and antiviral immunity. Trends in Immunology, 2002, 23, 234.	6.8	1
22	Toll-like receptor signal transduction and the tailoring of innate immunity: a role for Mal?. Trends in Immunology, 2002, 23, 296-300.	6.8	150
23	Intracellular vs extracellular recognition of pathogens – common concepts in mammals and flies. Trends in Microbiology, 2002, 10, 193-199.	7.7	203
24	Dendritic cells and the complexity of microbial infection. Trends in Microbiology, 2002, 10, 425-431.	7.7	70
25	Origin and filiation of human plasmacytoid dendritic cells. Human Immunology, 2002, 63, 1081-1093.	2.4	51
26	Human and mouse plasmacytoid dendritic cells. Human Immunology, 2002, 63, 1103-1110.	2.4	102
27	Roles of toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. Human Immunology, 2002, 63, 1120-1125.	2.4	53
28	Natural type I interferon-producing cells as a link between innate and adaptive immunity. Human Immunology, 2002, 63, 1126-1132.	2.4	140
29	Cutting Edge: A Novel Toll/IL-1 Receptor Domain-Containing Adapter That Preferentially Activates the IFN-β Promoter in the Toll-Like Receptor Signaling. Journal of Immunology, 2002, 169, 6668-6672.	0.8	1,123
30	Cutting Edge: Role of Toll-Like Receptor 1 in Mediating Immune Response to Microbial Lipoproteins. Journal of Immunology, 2002, 169, 10-14.	0.8	1,186
31	Toll-Like Receptor Signaling and Regulation of Cytokine Gene Expression in the Immune System. BioTechniques, 2002, 33, S66-S75.	1.8	137
32	Signal Integration Following Toll-like Receptor Triggering. Critical Reviews in Immunology, 2002, 22, 34.	0.5	42
33	Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1592, 265-280.	4.1	351
34	Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cellular Immunology, 2002, 218, 74-86.	3.0	369
35	Bacterial fimbriae activate human peripheral blood monocytes utilizing TLR2, CD14 and CD11a/CD18 as cellular receptors. European Journal of Immunology, 2002, 32, 2543-2550.	2.9	92
36	Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunological Reviews, 2002, 188, 177-182.	6.0	94
37	Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunological Reviews, 2002, 190, 9-25.	6.0	185

#	Article	IF	CITATIONS
38	Control of adaptive immune responses by Toll-like receptors. Current Opinion in Immunology, 2002, 14, 380-383.	5.5	314
39	Interferon-producing cells: on the front line in immune responses against pathogens. Current Opinion in Immunology, 2002, 14, 373-379.	5.5	217
40	Making and breaking tolerance. Current Opinion in Immunology, 2002, 14, 744-759.	5.5	92
41	Inhibition of IgE Production by the Imidazoquinoline Resiquimod in Nonallergic and Allergic Donors. Journal of Investigative Dermatology, 2002, 119, 1059-1064.	0.7	36
42	Imiquimod: a potential role in dermatology?. British Journal of Dermatology, 2002, 147, 1-6.	1.5	46
43	Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clinical and Experimental Dermatology, 2002, 27, 571-577.	1.3	330
44	The future of vaccination as a treatment strategy in dermatological diseases. Clinical and Experimental Dermatology, 2002, 27, 608-613.	1.3	2
45	Discovery of immunopotentiatory drugs: current and future strategies. Clinical and Experimental Immunology, 2002, 130, 363-369.	2.6	29
46	Die Zukunft von Impfungen als Therapiestrategie bei dermatologischen Erkrankungen. The future of vaccination as a treatment strategy in dermatological diseases. Zeitschrift Für Hautkrankheiten, 2002, 77, 685-690.	0.0	0
47	Imiquimod und die Imidazochinolone: Wirkungsmechanismus und therapeutisches Potenzial. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Zeitschrift Für Hautkrankheiten, 2002, 77, 650-655.	0.0	0
48	Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature, 2002, 420, 324-329.	27.8	910
49	Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nature Immunology, 2002, 3, 499-499.	14.5	875
51	Toll-like receptors as potential therapeutic targets for multiple diseases. Nature Reviews Drug Discovery, 2002, 1, 797-807.	46.4	204
52	Novel agents and strategies to treat herpes simplex virus infections. Expert Opinion on Investigational Drugs, 2003, 12, 165-183.	4.1	54
53	Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides. Journal of Clinical Immunology, 2003, 23, 202-213.	3.8	17
54	Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA. Annals of the New York Academy of Sciences, 2003, 1002, 30-42.	3.8	42
55	Toll-like receptors stimulate human neutrophil function. Blood, 2003, 102, 2660-2669.	1.4	787
56	Therapeutic options for herpes simplex infections. Current Infectious Disease Reports, 2003, 5, 22-27.	3.0	2

#	Article	IF	CITATIONS
57	The Art of War: Innate and adaptive immune responses. Cellular and Molecular Life Sciences, 2003, 60, 2604-2621.	5.4	115
60	Prediction of the prototype of the human Toll-like receptor gene family from the pufferfish, Fugu rubripes, genome. Immunogenetics, 2003, 54, 791-800.	2.4	285
61	The plasmacytoid monocyte/interferon producing cells. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 703-717.	2.8	132
62	Antimicrobial peptides in innate immunity of the human intestine. Journal of Gastroenterology, 2003, 38, 717-726.	5.1	48
63	Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discovery Today, 2003, 8, 934-943.	6.4	238
64	Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. , 2003, 100, 171-194.		479
65	Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Research, 2003, 58, 101-114.	4.1	101
66	Tollâ€like receptor expression in murine DC subsets: lack of TLR7 expression by CD8î± ⁺ DC correlates with unresponsiveness to imidazoquinolines. European Journal of Immunology, 2003, 33, 827-833.	2.9	517
67	Role of Toll-like receptors in costimulating cytotoxic T cell responses. European Journal of Immunology, 2003, 33, 1465-1470.	2.9	156
68	The Tollâ€like receptor 7 (TLR7)â€specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. European Journal of Immunology, 2003, 33, 2987-2997.	2.9	487
69	Miniâ€review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of crossâ€priming and direct priming?. European Journal of Immunology, 2003, 33, 2645-2654.	2.9	164
70	Do microbes influence the pathogenesis of allergic diseases? Building the case for Toll-like receptor ligands. Current Opinion in Immunology, 2003, 15, 614-619.	5.5	36
71	Synthesis and structure–Activity relationships of 2-Amino-8-hydroxyadenines as orally active interferon inducing agents. Bioorganic and Medicinal Chemistry, 2003, 11, 5501-5508.	3.0	37
72	Some interfaces of dendritic cell biology. Apmis, 2003, 111, 675-697.	2.0	259
73	The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. British Journal of Dermatology, 2003, 149, 53-56.	1.5	110
74	Imiquimod: modes of action. British Journal of Dermatology, 2003, 149, 5-8.	1.5	124
75	Imiquimod in basal cell carcinoma: how does it work?. British Journal of Dermatology, 2003, 149, 57-58.	1.5	75
76	Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. British Journal of Dermatology, 2003, 149, 9-13.	1.5	74

	Сітатіо	CITATION REPORT	
#	Article	IF	CITATIONS
77	Treatment of lentigo maligna with topical imiquimod. British Journal of Dermatology, 2003, 149, 66-69.	1.5	176
78	Ringing the interferon alarm: differential regulation of gene expression at the interface between innate and adaptive immunity. Current Opinion in Immunology, 2003, 15, 52-58.	5.5	130
79	Mammalian Toll-like receptors. Current Opinion in Immunology, 2003, 15, 5-11.	5.5	527
80	Toll-like receptors and innate antiviral responses. Current Opinion in Immunology, 2003, 15, 402-407.	5.5	66
81	Recognition of microbial infection by Toll-like receptors. Current Opinion in Immunology, 2003, 15, 396-401.	5.5	509
82	Death receptors and their role in dermatology, with particular focus on tumor necrosis factor-related apoptosis-inducing ligand receptors. International Journal of Dermatology, 2003, 42, 3-17.	1.0	28
84	Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australasian Journal of Dermatology, 2003, 44, 123-125.	0.7	23
85	Toll-like receptor-9 induced by physical trauma mediates release of cytokines following exposure to CpG motif in mouse skin. Immunology, 2003, 110, 341-347.	4.4	39
86	Immunotherapy of Basal Cell Carcinoma: Evolving Approaches. Dermatologic Surgery, 2003, 29, 1027-1034.	0.8	37
87	Imiquimod to Treat Different Cancers of the Epidermis. Dermatologic Surgery, 2003, 29, 890-896.	0.8	42
88	Toll receptors and pathogen resistance. Cellular Microbiology, 2003, 5, 143-153.	2.1	265
89	A tumour necrosis factor alpha autocrine loop contributes to proliferation and nuclear factor-kappaB activation of Theileria parva-transformed B cells. Cellular Microbiology, 2003, 5, 709-716.	2.1	48
90	Innate immunity and biodefence vaccines. Cellular Microbiology, 2003, 5, 755-760.	2.1	25
91	A review of imiquimod 5% cream for the treatment of various dermatological conditions. Clinical and Experimental Dermatology, 2003, 28, 1-3.	1.3	10
92	Prion pathogenesis in the absence of Tollâ€like receptor signalling. EMBO Reports, 2003, 4, 195-199.	4.5	72
93	Toll-like receptors and their role in experimental models of microbial infection. Genes and Immunity, 2003, 4, 87-94.	4.1	246
95	TICAM-1, an adaptor molecule that participates in Toll-like receptor 3–mediated interferon-β induction. Nature Immunology, 2003, 4, 161-167.	14.5	1,107
96	TRAM is specifically involved in the Toll-like receptor 4–mediated MyD88-independent signaling pathway. Nature Immunology, 2003, 4, 1144-1150.	14.5	919

#	Article	IF	CITATIONS
97	Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nature Medicine, 2003, 9, 525-532.	30.7	311
98	Recent advances in the discovery and delivery of vaccine adjuvants. Nature Reviews Drug Discovery, 2003, 2, 727-735.	46.4	361
99	Innate immune sensing and its roots: the story of endotoxin. Nature Reviews Immunology, 2003, 3, 169-176.	22.7	1,135
100	Dendritic-cell control of pathogen-driven T-cell polarization. Nature Reviews Immunology, 2003, 3, 984-993.	22.7	1,235
101	Recognition of pathogen-associated molecular patterns by TLR family. Immunology Letters, 2003, 85, 85-95.	2.5	1,016
102	Imiquimod. Dermatologic Clinics, 2003, 21, 291-300.	1.7	69
103	Innate immune activation as a broad-spectrum biodefense strategy Prospects and research challenges. Journal of Allergy and Clinical Immunology, 2003, 112, 686-694.	2.9	68
104	The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-γ–producing cells. Journal of Allergy and Clinical Immunology, 2003, 111, 380-388.	2.9	90
105	An Angiogenic Switch in Macrophages Involving Synergy between Toll-Like Receptors 2, 4, 7, and 9 and Adenosine A2A Receptors. American Journal of Pathology, 2003, 163, 711-721.	3.8	250
106	Toll-Like Receptors. Annual Review of Immunology, 2003, 21, 335-376.	21.8	5,168
107	Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway. Science, 2003, 301, 640-643.	12.6	2,808
108	Role of Natural Interferon-α Producing Cells (Plasmacytoid Dendritic Cells) in Autoimmunity. Autoimmunity, 2003, 36, 463-472.	2.6	112
109	Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Letters, 2003, 544, 129-132.	2.8	216
110	Recombinant congenic strains of mice: a new tool for the genetic dissection of efficacy and toxicity of adjuvants. Vaccine, 2003, 21, 832-835.	3.8	1
111	Optimization of epicutaneous immunization for the induction of CTL. Vaccine, 2003, 21, 2890-2899.	3.8	65
112	CpG-induced immunomodulation and intracellular bacterial killing in a chicken macrophage cell line. Developmental and Comparative Immunology, 2003, 27, 823-834.	2.3	85
113	TOLL-like receptors linking innate and adaptive immune response. Veterinary Immunology and Immunopathology, 2003, 91, 1-12.	1.2	337
114	Toll-like Receptors and Their Signaling Mechanisms. Scandinavian Journal of Infectious Diseases, 2003, 35, 555-562.	1.5	237

#	Article	IF	CITATIONS
115	Topical and light-based treatments for actinic keratoses. Seminars in Cutaneous Medicine and Surgery, 2003, 22, 162-170.	1.6	21
116	Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Current Opinion in Pharmacology, 2003, 3, 396-403.	3.5	147
117	Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene Bmi-1. Trends in Immunology, 2003, 24, 522-524.	6.8	93
118	Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends in Immunology, 2003, 24, 519-522.	6.8	100
119	Toll-like Receptor Signaling. Journal of Biological Chemistry, 2003, 278, 38105-38108.	3.4	741
120	The Toll-like receptors and their role in septic shock. Expert Opinion on Therapeutic Targets, 2003, 7, 603-612.	3.4	58
121	Toll-Like Receptors and Their Function in Innate and Adaptive Immunity. International Archives of Allergy and Immunology, 2003, 130, 180-192.	2.1	145
122	Systemic lupus erythematosus and the type I interferon system. Arthritis Research, 2003, 5, 68.	2.0	132
123	How we detect microbes and respond to them: the Toll-like receptors and their transducers. Journal of Leukocyte Biology, 2003, 74, 479-485.	3.3	514
124	Oral Treponemes and Their Outer Membrane Extracts Activate Human Gingival Epithelial Cells through Toll-Like Receptor 2. Infection and Immunity, 2003, 71, 717-725.	2.2	53
125	The Immune Response Modifier and Toll-Like Receptor 7 Agonist S-27609 Selectively Induces IL-12 and TNF-α Production in CD11c+CD11b+CD8â~' Dendritic Cells. Journal of Immunology, 2003, 171, 1156-1163.	0.8	94
126	Virus–cell interactions in the induction of type 1 interferon by influenza virus in mouse spleen cells. Journal of General Virology, 2003, 84, 193-202.	2.9	30
127	Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research. Clinical Microbiology Reviews, 2003, 16, 96-113.	13.6	239
128	Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults. Antimicrobial Agents and Chemotherapy, 2003, 47, 3846-3852.	3.2	72
129	The Poxvirus Protein A52R Targets Toll-like Receptor Signaling Complexes to Suppress Host Defense. Journal of Experimental Medicine, 2003, 197, 343-351.	8.5	334
130	Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6646-6651.	7.1	540
131	Role of Toll-Like Receptors in Pathogen Recognition. Clinical Microbiology Reviews, 2003, 16, 637-646.	13.6	477
132	Soluble Branched β-(1,4)Glucans from Acetobacter Species Show Strong Activities to Induce Interleukin-12 in Vitro and Inhibit T-helper 2 Cellular Response with Immunoglobulin E Production in Vivo. Journal of Biological Chemistry, 2003, 278, 38571-38578.	3.4	35

#	Article	IF	CITATIONS
133	Reciprocal Modulation of Toll-like Receptor-4 Signaling Pathways Involving MyD88 and Phosphatidylinositol 3-Kinase/AKT by Saturated and Polyunsaturated Fatty Acids. Journal of Biological Chemistry, 2003, 278, 37041-37051.	3.4	452
134	Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod. Journal of the National Cancer Institute, 2003, 95, 1138-1149.	6.3	262
135	Toll-Like Receptor 2 (TLR2) and TLR9 Signaling Results in HIV-Long Terminal Repeat <i>Trans</i> -Activation and HIV Replication in HIV-1 Transgenic Mouse Spleen Cells: Implications of Simultaneous Activation of TLRs on HIV Replication. Journal of Immunology, 2003, 170, 5159-5164.	0.8	105
136	Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo Maturation. Journal of Immunology, 2003, 171, 6275-6282.	0.8	160
137	October 2003. Archives of Dermatology, 2003, 139, 1299.	1.4	0
138	Imiquimod. Archives of Dermatology, 2003, 139, 1347-50.	1.4	53
139	Lps2: a new locus required for responses to lipopolysaccharide, revealed by germline mutagenesis and phenotypic screening. Journal of Endotoxin Research, 2003, 9, 250-255.	2.5	34
140	Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Review of Vaccines, 2003, 2, 205-217.	4.4	64
141	The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood, 2003, 102, 956-963.	1.4	344
142	Vaccination with Plasmid DNA Activates Dendritic Cells via Toll-Like Receptor 9 (TLR9) but Functions in TLR9-Deficient Mice. Journal of Immunology, 2003, 171, 5908-5912.	0.8	189
143	The Toll-Like Receptor 5 Stimulus Bacterial Flagellin Induces Maturation and Chemokine Production in Human Dendritic Cells. Journal of Immunology, 2003, 170, 5165-5175.	0.8	353
144	Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses. Journal of Immunology, 2003, 171, 4320-4328.	0.8	285
145	Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic Cells. Journal of Immunology, 2003, 170, 4465-4474.	0.8	305
146	Expression and Function of Toll-Like Receptors in Eosinophils: Activation by Toll-Like Receptor 7 Ligand. Journal of Immunology, 2003, 171, 3977-3982.	0.8	281
147	IFN-α Skews Monocyte Differentiation into Toll-Like Receptor 7-Expressing Dendritic Cells with Potent Functional Activities. Journal of Immunology, 2003, 171, 3385-3393.	0.8	165
148	Heterogeneity of Dendritic Cells in the Mouse Liver: Identification and Characterization of Four Distinct Populations. Journal of Immunology, 2003, 170, 2323-2330.	0.8	119
149	<i>Lps2</i> : a new locus required for responses to lipopolysaccharide, revealed by germline mutagenesis and phenotypic screening. Journal of Endotoxin Research, 2003, 9, 250-255.	2.5	45
150	Myeloid Differentiation Factor 88–Dependent and –Independent Pathways in Toll‣ike Receptor Signaling. Journal of Infectious Diseases, 2003, 187, S356-S363.	4.0	128

		CITATION REI	PORT	
#	Article		IF	CITATIONS
151	Toll-like receptors in cardiovascular diseases. Cardiovascular Research, 2003, 60, 58-67.		3.8	96
152	Chapter 17: Genital Human Papillomavirus InfectionsCurrent and Prospective Therapies. the National Cancer Institute Monographs, 2003, 2003, 117-124.	Journal of	2.1	73
153	Regulation of Dendritic Cell Function Through Toll-Like Receptors. Current Molecular Med 2003, 3, 759-771.	icine,	1.3	147
154	Synthetic Vaccines: The Role of Adjuvants in Immune Targeting. Current Medicinal Chemis 1423-1439.	stry, 2003, 10,	2.4	77
155	Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo. A Dermatology, 2003, 139, 1325-32.	chives of	1.4	126
156	Imiquimod to Treat Different Cancers of the Epidermis. Dermatologic Surgery, 2003, 29, 8	90-896.	0.8	13
158	Immunotherapy of Basal Cell Carcinoma. Dermatologic Surgery, 2003, 29, 1027-1034.		0.8	10
159	Toll-like receptors and T-helper-1/T-helper-2 responses. Current Opinion in Infectious Disea 199-204.	ises, 2003, 16,	3.1	180
160	Toll receptors modulate allergic responses: interaction with dendritic cells, T cells and mas Current Opinion in Allergy and Clinical Immunology, 2003, 3, 487-494.	t cells.	2.3	25
161	A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering cells and constitutive expression in memory B cells. Blood, 2003, 101, 4500-4504.	; in naive B	1.4	606
162	Role of adapters in Toll-like receptor signalling. Biochemical Society Transactions, 2003, 3	1, 637-642.	3.4	170
164	Imiquimod Does not Affect Shedding of Viable Chlamydiae in a Murine Model ofChlamydia trachomatisGenital Tract Infection. Infectious Diseases in Obstetrics and Gynecology, 200	a 3, 11, 81-87.	1.5	2
166	Current vaccine adjuvants: an overview of a diverse class. Frontiers in Bioscience - Landma 2972.	ırk, 2004, 9,	3.0	49
167	Regulation of Innate Immunity Signaling and its Connection with Human Diseases. Inflam Allergy: Drug Targets, 2004, 3, 81-86.	mation and	3.1	41
168	Molecular Analysis of the Effect of Topical Imiquimod Treatment of HPV 2/27/57-Induced Warts. Skin Pharmacology and Physiology, 2004, 17, 258-266.	Common	2.5	13
169	Emerging therapies for herpes viral infections (types 1 – 8). Expert Opinion on Emerging 237-256.	g Drugs, 2004, 9,	2.4	8
170	Tollâ€Like Receptor (TLR)–3, but Not TLR4, Agonist Protects against Genital Herpes Infe Absence of Inflammation Seen with CpG DNA. Journal of Infectious Diseases, 2004, 190, 1	ection in the .841-1849.	4.0	131
171	Intracellular Bacterial Infection-Induced IFN-Î ³ Is Critically but Not Solely Dependent on To Receptor 4-Myeloid Differentiation Factor 88-IFN-αÎ ² -STAT1 Signaling. Journal of Immunol 6345-6353.	l-Like ogy, 2004, 172,	0.8	60

#	Article	IF	CITATIONS
172	Activation of Airway Epithelial Cells by Toll-Like Receptor Agonists. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 358-364.	2.9	429
173	Toll-like receptor 3-mediated activation of NF-ÂB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-Â. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3533-3538.	7.1	336
174	Endogenous ligands of Toll-like receptors. Journal of Leukocyte Biology, 2004, 76, 514-519.	3.3	625
175	Toll-like Receptor 9–Dependent and –Independent Dendritic Cell Activation by Chromatin–Immunoglobulin G Complexes. Journal of Experimental Medicine, 2004, 199, 1631-1640.	8.5	476
176	Replication-Dependent Potent IFN-α Induction in Human Plasmacytoid Dendritic Cells by a Single-Stranded RNA Virus. Journal of Immunology, 2004, 173, 5935-5943.	0.8	191
177	APC-Independent Activation of NK Cells by the Toll-Like Receptor 3 Agonist Double-Stranded RNA. Journal of Immunology, 2004, 172, 138-143.	0.8	220
178	Biology of Toll receptors: lessons from insects and mammals. Journal of Leukocyte Biology, 2004, 75, 18-26.	3.3	139
179	Toll-like receptors: emerging targets of immunomodulation. Expert Opinion on Therapeutic Patents, 2004, 14, 85-100.	5.0	9
180	Differential Requirement for TANK-binding Kinase-1 in Type I Interferon Responses to Toll-like Receptor Activation and Viral Infection. Journal of Experimental Medicine, 2004, 199, 1651-1658.	8.5	375
181	IMMUNOLOGY: After the Toll Rush. Science, 2004, 303, 1481-1482.	12.6	81
181 182	IMMUNOLOGY: After the Toll Rush. Science, 2004, 303, 1481-1482. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. Journal of Leukocyte Biology, 2004, 76, 585-593.	12.6 3.3	81
181 182 183	IMMUNOLOGY: After the Toll Rush. Science, 2004, 303, 1481-1482. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. Journal of Leukocyte Biology, 2004, 76, 585-593. Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway. Journal of Immunology, 2004, 172, 4926-4933.	12.6 3.3 0.8	81 17 245
181 182 183 184	IMMUNOLOGY: After the Toll Rush. Science, 2004, 303, 1481-1482. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. Journal of Leukocyte Biology, 2004, 76, 585-593. Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway. Journal of Immunology, 2004, 172, 4926-4933. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. Journal of Leukocyte Biology, 2004, 75, 504-514.	12.6 3.3 0.8 3.3	81 17 245 146
181 182 183 184 186	IMMUNOLOGY: After the Toll Rush. Science, 2004, 303, 1481-1482. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. Journal of Leukocyte Biology, 2004, 76, 585-593. Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway. Journal of Immunology, 2004, 172, 4926-4933. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. Journal of Leukocyte Biology, 2004, 75, 504-514. Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN. Journal of Experimental Medicine, 2004, 199, 775-784.	12.6 3.3 0.8 3.3 8.5	81 17 245 146 343
181 182 183 184 186 187	IMMUNOLOGY: After the Toll Rush. Science, 2004, 303, 1481-1482. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. Journal of Leukocyte Biology, 2004, 76, 585-593. Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway. Journal of Immunology, 2004, 172, 4926-4933. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. Journal of Leukocyte Biology, 2004, 75, 504-514. Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN. Journal of Experimental Medicine, 2004, 199, 775-784. TLR3-, TLR7-, and TLR9-Mediated Production of Proinflammatory Cytokines and Chemokines from Murine Connective Tissue Type Skin-Derived Mast Cells but Not from Bone Marrow-Derived Mast Cells. Journal of Immunology, 2004, 173, 531-541.	12.6 3.3 0.8 3.3 8.5 0.8	 81 17 245 146 343 241
181 182 183 184 186 187	IMMUNOLOGY: After the Toll Rush. Science, 2004, 303, 1481-1482. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. Journal of Leukocyte Biology, 2004, 76, 585-593. Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway. Journal of Immunology, 2004, 172, 4926-4933. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. Journal of Leukocyte Biology, 2004, 75, 504-514. Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN. Journal of Experimental Medicine, 2004, 199, 775-784. TLR3-, TLR7-, and TLR9-Mediated Production of Proinflammatory Cytokines and Chemokines from Murine Connective Tissue Type Skin-Derived Mast Cells but Not from Bone Marrow-Derived Mast Cells. Journal of Immunology, 2004, 173, 531-541. Selective Impairment of TLR-Mediated Innate Immunity in Human Newborns: Neonatal Blood Plasma Reduces Monocyte TNF1+ Induction by Bacterial Lipopeptides, Lipopolysaccharide, and Imiquimod, but Preserves the Response to R-848. Journal of Immunology, 2004, 173, 4627-4634.	12.6 3.3 0.8 3.3 8.5 0.8	 81 17 245 146 343 241 342
181 182 183 184 186 187 188	IMMUNOLOGY: After the Toll Rush. Science, 2004, 303, 1481-1482. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. Journal of Leukocyte Biology, 2004, 76, 585-593. Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway. Journal of Immunology, 2004, 172, 4926-4933. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. Journal of Leukocyte Biology, 2004, 75, 504-514. Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN. Journal of Experimental Medicine, 2004, 199, 775-784. TLR3-, TLR7-, and TLR9-Mediated Production of Proinflammatory Cytokines and Chemokines from Murine Connective Tissue Type Skin-Derived Mast Cells but Not from Bone Marrow-Derived Mast Cells. Journal of Immunology, 2004, 173, 531-541. Selective Impairment of TLR-Mediated Innate Immunity in Human Newborns: Neonatal Blood Plasma Reduces Monocyte TNF-1s. Induction by Bacterial Lipopeptides, Lipopolysaccharide, and Imiquimod, but Preserves the Response to R-848. Journal of Immunology, 2004, 173, 4627-4634. Immunomodulatory Effects of Inactivated Parapoxvirus Ovis (Orf Virus) on Human Peripheral Immune Cells: Induction of Cytokine Secretion in Monocytes and Th1-Like Cells. Journal of Virology, 2004, 78, 9400-9411.	12.6 3.3 0.8 3.3 8.5 0.8 0.8 3.4	 81 17 245 146 343 241 342 60

#	Article	IF	CITATIONS
191	Structure-Activity Relationship of Synthetic Toll-like Receptor 4 Agonists. Journal of Biological Chemistry, 2004, 279, 4440-4449.	3.4	139
192	Effect of Interferon-Alpha and Interferon-Inducers on West Nile Virus in Mouse and Hamster Animal Models. Antiviral Chemistry and Chemotherapy, 2004, 15, 67-75.	0.6	112
193	Ligand-regulated Chimeric Receptor Approach Reveals Distinctive Subcellular Localization and Signaling Properties of the Toll-like Receptors. Journal of Biological Chemistry, 2004, 279, 19008-19017.	3.4	204
194	IL-12p70-Dependent Th1 Induction by Human B Cells Requires Combined Activation with CD40 Ligand and CpG DNA. Journal of Immunology, 2004, 172, 954-963.	0.8	147
195	Imiquimod Treatment Induces Expression of Opioid Growth Factor Receptor. Clinical Cancer Research, 2004, 10, 4959-4970.	7.0	37
196	Identification and Characterization of pDC-Like Cells in Normal Mouse Skin and Melanomas Treated with Imiquimod. Journal of Immunology, 2004, 173, 3051-3061.	0.8	193
197	Gene expression profiles during human CD4+ T cell differentiation. International Immunology, 2004, 16, 1109-1124.	4.0	80
198	Innate Sensing of Viruses by Toll-Like Receptors. Journal of Virology, 2004, 78, 7867-7873.	3.4	236
199	Signaling Danger. Journal of the American Society of Nephrology: JASN, 2004, 15, 854-867.	6.1	346
200	Psoriasis Triggered by Toll-like Receptor 7 Agonist Imiquimod in the Presence of Dermal Plasmacytoid Dendritic Cell Precursors. Archives of Dermatology, 2004, 140, 1490-5.	1.4	364
201	Rat Plasmacytoid Dendritic Cells Are an Abundant Subset of MHC Class II+ CD4+CD11bâ^'OX62â^' and Type I IFN-Producing Cells That Exhibit Selective Expression of Toll-Like Receptors 7 and 9 and Strong Responsiveness to CpG. Journal of Immunology, 2004, 172, 7485-7494.	0.8	98
202	Therapy of cutaneous human Papillomavirus infections. Dermatologic Therapy, 2004, 17, 441-448.	1.7	84
203	Psoriasis induced by topical imiquimod. Australasian Journal of Dermatology, 2004, 45, 47-50.	0.7	133
204	Imiquimod: Potential risk of an immunostimulant. Australasian Journal of Dermatology, 2004, 45, 123-124.	0.7	44
205	Gene expression in actinic keratoses: pharmacological modulation by imiquimod. British Journal of Dermatology, 2004, 151, 1150-1159.	1.5	33
206	Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergenâ€induced Th2 responses, airway inflammation and airway hyperâ€reactivity in mice. Clinical and Experimental Allergy, 2004, 34, 1314-1320.	2.9	67
207	Tollâ€like receptor (TLR) expression and TLRâ€mediated cytokine/chemokine production by human uterine epithelial cells. Immunology, 2004, 112, 428-436.	4.4	301
208	Minireview: Functions of the renal tract epithelium in coordinating the innate immune response to infection. Kidney International, 2004, 66, 1334-1344.	5.2	53

#	Article	IF	CITATIONS
209	Topical Immunomodulation in Dermatology: Potential of Toll-like Receptor Agonists. Dermatologic Surgery, 2004, 30, 1101-1112.	0.8	60
210	Successful Treatment of Persistent Melanoma In Situ with 5% Imiquimod Cream. Dermatologic Surgery, 2004, 30, 1543-1545.	0.8	26
211	Avidity of antibodies to human herpesvirus 7 suggests primary infection in young adults with pityriasis rosea. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 738-740.	2.4	23
212	Painful geographic tongue (benign migratory glossitis) in a child. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 737-738.	2.4	15
213	Androgen receptor status in lesional and normal skin of patients with rosacea. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 736-737.	2.4	4
214	Areolar and periareolar pityriasis versicolor. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 740-741.	2.4	10
215	Treatment of vitiligo with topical imiquimod. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 741-742.	2.4	5
216	Psoriasis of the glans penis in a child successfully treated with Elidel ^R (pimecrolimus) cream. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 742-743.	2.4	38
217	'Pityriasis rosea-like' adverse reaction to lisinopril. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 743-745.	2.4	16
218	A case of Sweet's syndrome and pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 745-746.	2.4	6
219	Prophylactic short-term use of cyclosporin in refractory polymorphic light eruption. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 747-748.	2.4	7
220	Death Receptor-Independent Apoptosis in Malignant Melanoma Induced by the Small-Molecule Immune Response Modifier Imiquimod. Journal of Investigative Dermatology, 2004, 122, 1266-1276.	0.7	116
221	Imiquimod: Unexpected Killer. Journal of Investigative Dermatology, 2004, 122, xv-xvi.	0.7	10
222	Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunological Reviews, 2004, 199, 9-26.	6.0	641
223	Modulating vaccine responses with dendritic cells and Tollâ€like receptors. Immunological Reviews, 2004, 199, 227-250.	6.0	278
224	Induction of allergic inflammation by interleukinâ€18 in experimental animal models. Immunological Reviews, 2004, 202, 115-138.	6.0	74
225	Human primary immunodeficiency diseases: a perspective. Nature Immunology, 2004, 5, 23-30.	14.5	115
226	Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nature Immunology, 2004, 5, 1061-1068.	14.5	894

	CITATION	Report	
# 227	ARTICLE From plankton to pathogen recognition. Nature Medicine, 2004, 10, 1173-1174.	IF 30.7	CITATIONS
228	Toll-like receptor signalling. Nature Reviews Immunology, 2004, 4, 499-511.	22.7	7,318
229	Therapeutics targeting the innate immune system. Nature Reviews Immunology, 2004, 4, 512-520.	22.7	290
230	Multicenter Initiative Seeking Critical Genes in Respiratory Papillomatosis. Laryngoscope, 2004, 114, 349-357.	2.0	21
231	Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Research, 2004, 64, 79-83.	4.1	56
232	Immune modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod. Apoptosis: an International Journal on Programmed Cell Death, 2004, 9, 291-298.	4.9	94
233	Immunity to Influenza: The Challenges of Protecting an Aging Population. Immunologic Research, 2004, 29, 113-124.	2.9	77
234	Toll-like receptors in innate immunity. International Immunology, 2004, 17, 1-14.	4.0	2,786
235	Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Archives of Dermatological Research, 2004, 296, 6-11.	1.9	67
236	Mechanism of Action and Emerging Role of Immune Response Modifier Therapy in Dermatologic Conditions. Journal of Cutaneous Medicine and Surgery, 2004, 8, 3-12.	1.2	20
237	Role of Topical Therapies in the Management of Cutaneous Disease. Journal of Cutaneous Medicine and Surgery, 2004, 8, 22-31.	1.2	10
238	Viral and Nonviral Uses of Imiquimod: A Review. Journal of Cutaneous Medicine and Surgery, 2004, 8, 338-352.	1.2	81
239	Characterization of gene structure and expression of two toll-like receptors from Japanese flounder, Paralichthys olivaceus. Immunogenetics, 2004, 56, 38-46.	2.4	138
240	Toll-like receptors and sepsis. Current Infectious Disease Reports, 2004, 6, 361-366.	3.0	28
241	Toll-like receptors and immune response in allergic disease. Clinical Reviews in Allergy and Immunology, 2004, 26, 115-125.	6.5	55
242	Differential Expression and Function of Toll-like Receptors in Langerhans Cells: Comparison with Splenic Dendritic Cells. Journal of Investigative Dermatology, 2004, 122, 95-102.	0.7	80
243	Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. European Journal of Immunology, 2004, 34, 251-262.	2.9	537
244	Immunostimulating capacities of stabilized RNA molecules. European Journal of Immunology, 2004, 34, 537-547.	2.9	128

#	Article	IF	CITATIONS
245	Phylogenetics in the Bioinformatics Culture of Understanding. Comparative and Functional Genomics, 2004, 5, 128-146.	2.0	11
246	Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. Bioorganic and Medicinal Chemistry, 2004, 12, 1091-1099.	3.0	76
247	Genetic analysis of innate immunity: TIR adapter proteins in innate and adaptive immune responses. Microbes and Infection, 2004, 6, 1374-1381.	1.9	26
248	Pleiotropic function of Toll-like receptors. Microbes and Infection, 2004, 6, 1388-1394.	1.9	116
249	Acute exposure to ethanol affects Toll-like receptor signaling and subsequent responses: an overview of recent studies. Alcohol, 2004, 33, 235-239.	1.7	44
250	Toll-like receptors as key mediators in innate antifungal immunity. Medical Mycology, 2004, 42, 485-498.	0.7	202
251	Immunological Foundations to the Quest for New Vaccine Adjuvants. BioDrugs, 2004, 18, 79-93.	4.6	45
252	Microglia Initiate Central Nervous System Innate and Adaptive Immune Responses through Multiple TLRs. Journal of Immunology, 2004, 173, 3916-3924.	0.8	1,054
253	Role of Imiquimod in Skin Cancer Treatment. American Journal of Clinical Dermatology, 2004, 5, 453-458.	6.7	40
254	CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10116-10121.	7.1	412
255	Saturated Fatty Acid Activates but Polyunsaturated Fatty Acid Inhibits Toll-like Receptor 2 Dimerized with Toll-like Receptor 6 or 1. Journal of Biological Chemistry, 2004, 279, 16971-16979.	3.4	428
256	Modulation of immune responses – strategies for optimising vaccines. Expert Opinion on Biological Therapy, 2004, 4, 627-630.	3.1	3
257	Récepteurs de type Toll, réponse inflammatoire et sepsis. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2004, 13, 167-175.	0.1	6
258	Functions of Toll-like receptors: lessons from KO mice. Comptes Rendus - Biologies, 2004, 327, 581-581.	0.2	Ο
259	Therapeutic targeting of Toll-like receptors. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 299-304.	0.5	2
260	Microbial recognition by Toll-like receptors. Journal of Dermatological Science, 2004, 34, 73-82.	1.9	235
261	The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity. Rheumatic Disease Clinics of North America, 2004, 30, 559-574.	1.9	24
262	Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8. Science, 2004, 303, 1526-1529.	12.6	3,413

	CITATION R	EPORT	
#	Article	IF	CITATIONS
263	Forward genetic dissection of afferent immunity: the role of TIR adapter proteins in innate and adaptive immune responses. Comptes Rendus - Biologies, 2004, 327, 571-580.	0.2	25
264	Functions of Toll-like receptors: lessons from KO mice. Comptes Rendus - Biologies, 2004, 327, 581-589.	0.2	168
265	TLR signaling pathways. Seminars in Immunology, 2004, 16, 3-9.	5.6	2,017
266	Toll-like receptors and dendritic cells: for whom the bug tolls. Seminars in Immunology, 2004, 16, 27-34.	5.6	302
267	The role of Toll-like receptors in combating mycobacteria. Seminars in Immunology, 2004, 16, 35-41.	5.6	134
268	Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine, 2004, 22, 1799-1809.	3.8	91
269	Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine, 2004, 22, 1791-1798.	3.8	58
270	Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine, 2004, 22, 1782-1790.	3.8	56
271	C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology, 2004, 209, 141-154.	1.9	66
272	Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity. Immunobiology, 2004, 209, 191-198.	1.9	76
273	TLR9-Dependent Recognition of MCMV by IPC and DC Generates Coordinated Cytokine Responses that Activate Antiviral NK Cell Function. Immunity, 2004, 21, 107-119.	14.3	644
274	Educational outcomes among organ transplant recipients at high risk for skin cancer-randomized intervention of intensive versus standard education. Journal of the American Academy of Dermatology, 2004, 50, P7.	1.2	0
275	Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Journal of the American Academy of Dermatology, 2004, 50, P7.	1.2	0
276	Imiquimod 5% cream in the treatment of multiple superficial basal cell carcinoma. Journal of the American Academy of Dermatology, 2004, 50, P7.	1.2	1
277	Correlation of squamous cell carcinoma invasiveness with laminin 10 expression. Journal of the American Academy of Dermatology, 2004, 50, P7.	1.2	0
278	Imiquimod 5% cream effective in the treatment of large superficial BCC. Journal of the American Academy of Dermatology, 2004, 50, P123.	1.2	0
279	Acitretin suppression of squamous cell carcinoma. Journal of the American Academy of Dermatology, 2004, 50, P127.	1.2	0
280	Efficacy of imiquimod 5% cream in the treatment of superficial basal cell carcinoma. Journal of the American Academy of Dermatology, 2004, 50, P127.	1.2	0

#	Article	IF	CITATIONS
281	Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. Journal of the American Academy of Dermatology, 2004, 50, 850-853.	1.2	99
282	Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology, 2004, 50, 722-733.	1.2	468
283	Toll-like receptor gene family and TIR-domain adapters in Danio rerio. Molecular Immunology, 2004, 40, 759-771.	2.2	386
284	TIR domain-containing adaptors define the specificity of TLR signaling. Molecular Immunology, 2004, 40, 861-868.	2.2	324
285	Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro. Molecular Immunology, 2004, 40, 1307-1314.	2.2	38
286	CD8+ T-cell priming regulated by cytokines of the innate immune system. Trends in Molecular Medicine, 2004, 10, 366-371.	6.7	17
287	Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5598-5603.	7.1	1,650
288	Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell Stimulation. Leukemia and Lymphoma, 2004, 45, 257-264.	1.3	162
289	Journal of the American Academy of Dermatology Editorial Office. Journal of the American Academy of Dermatology, 2004, 50, 853.	1.2	0
290	Topical Immunomodulation in Dermatology. Dermatologic Surgery, 2004, 30, 1101-1112.	0.8	30
291	Ethanol suppresses cytokine responses induced through Toll-like receptors as well as innate resistance to Escherichia coli in a mouse model for bigge dripping. Alcohol 2004, 33, 147,155	17	80
	resistance to Escherichia con in a mouse moder for binge drinking. Alcohol, 2004, 55, 147-155.	1./	
292	Successful Treatment of Persistent Melanoma In Situ with 5% Imiquimod Cream. Dermatologic Surgery, 2004, 30, 1543-1545.	0.8	13
292 293	Successful Treatment of Persistent Melanoma In Situ with 5% Imiquimod Cream. Dermatologic Surgery, 2004, 30, 1543-1545.	0.8	13 0
292 293 294	Successful Treatment of Persistent Melanoma In Situ with 5% Imiquimod Cream. Dermatologic Surgery, 2004, 30, 1543-1545. Vaccination and Autoimmunity. , 2004, , . Isolation and Immunophenotyping of Human and Rhesus Macaque Dendritic Cells. Methods in Cell Biology, 2004, 75, 623-642.	0.8	13 O 13
292 293 294 295	Successful Treatment of Persistent Melanoma In Situ with 5% Imiquimod Cream. Dermatologic Surgery, 2004, 30, 1543-1545. Vaccination and Autoimmunity. , 2004, , . Isolation and Immunophenotyping of Human and Rhesus Macaque Dendritic Cells. Methods in Cell Biology, 2004, 75, 623-642. Viral and Nonviral Uses of Imiquimod: A Review. Journal of Cutaneous Medicine and Surgery, 2004, 8, 338-352.	1.7 0.8 1.1 1.2	13 0 13 70
292 293 294 295 296	Vaccination and Autoimmunity. , 2004, , . Isolation and Immunophenotyping of Human and Rhesus Macaque Dendritic Cells. Methods in Cell Biology, 2004, 75, 623-642. Viral and Nonviral Uses of Imiquimod: A Review. Journal of Cutaneous Medicine and Surgery, 2004, 8, 338-352. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Research, 2004, 64, 79-83.	1.7 0.8 1.1 1.2 4.1	13 0 13 70
292 293 294 295 296	Resignimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Research, 2004, 64, 79-83.	1.7 0.8 1.1 1.2 4.1 1.0	 13 0 13 70 43 14

~			<u> </u>	
C	ITA'	τιον	I KF	PORT
\sim	11/1			

#	Article	IF	CITATIONS
299	Medical Management of Vulvar Intraepithelial Neoplasia. Journal of Lower Genital Tract Disease, 2005, 9, 206-212.	1.9	13
300	??1-Adrenergic Receptor Antagonists Induce Production of IL-18 and Expression of ICAM-1 and CD40 in Human Monocytes. Journal of Immunotherapy, 2005, 28, 40-43.	2.4	5
301	Current and Potential Uses of Imiquimod. Southern Medical Journal, 2005, 98, 913-919.	0.7	62
302	Thematic review series: The Immune System and Atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. Journal of Lipid Research, 2005, 46, 404-411.	4.2	99
303	The Induction of Dendritic Cell Activation and Maturation by Toll-Like Receptor Signaling. , 2005, , 147-161.		0
304	Structures and Motifs Involved in Toll Signaling. , 2005, , 56-93.		2
305	Professional type I Interferon-producing cells - A Unique Subpopulation of Dendritic Cells. Acta Microbiologica Et Immunologica Hungarica, 2005, 52, 443-462.	0.8	7
307	Long-Term Clinical Outcomes Following Treatment of Actinic Keratosis with Imiquimod 5% Cream. Dermatologic Surgery, 2005, 31, 659-663.	0.8	29
308	Discovery of novel immunostimulants by dendritic-cell–based functional screening. Blood, 2005, 106, 3082-3089.	1.4	55
309	PPAR-Î ³ agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-κB pathways. Blood, 2005, 106, 3888-3894.	1.4	168
310	Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood, 2005, 106, 2424-2432.	1.4	102
312	Direct T-cell stimulations by drugs—bypassing the innate immune system. Toxicology, 2005, 209, 95-100.	4.2	60
313	Toll-Like Receptor Activation in the Pathogenesis of Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 2005, 1062, 242-251.	3.8	50
314	Plasmacytoid Dendritic Cells: In Search of their Niche in Immune Responses. Immunologic Research, 2005, 32, 075-084.	2.9	27
315	Pathogen recognition with Toll-like receptors. Current Opinion in Immunology, 2005, 17, 338-344.	5.5	503
316	Immunity in response to particulate antigen-delivery systems. Advanced Drug Delivery Reviews, 2005, 57, 333-355.	13.7	277
317	Toll-like receptors as key sensors of viral infection. , 2006, , 143-171.		1
318	Toll-like receptor 9 and systemic autoimmune diseases. , 2006, , 41-61.		0

#	Article	IF	CITATIONS
319	HLA class I transgenic mice: development, utilisation and improvement. Expert Opinion on Biological Therapy, 2005, 5, 919-938.	3.1	38
320	Unraveling innate immunity using large scale N-ethyl-N-nitrosourea mutagenesis. Tissue Antigens, 2005, 65, 395-401.	1.0	24
321	Activation of plasmacytoid dendritic cells. Immunology and Cell Biology, 2005, 83, 571-577.	2.3	35
322	Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. International Journal of Dermatology, 2005, 44, 428-434.	1.0	50
323	Various members of the Tollâ€like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology, 2005, 114, 531-541.	4.4	305
324	Identification and characterization of a functional, alternatively spliced Tollâ€ike receptor 7 (TLR7) and genomic disruption of TLR8 in chickens. Immunology, 2005, 114, 507-521.	4.4	195
325	Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. British Journal of Dermatology, 2005, 152, 122-129.	1.5	67
326	Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. British Journal of Dermatology, 2005, 152, 939-947.	1.5	217
327	Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clinical and Experimental Allergy, 2005, 35, 1591-1598.	2.9	57
328	Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?. Clinical and Experimental Immunology, 2005, 140, 1-10.	2.6	55
329	Activation of the mammalian immune system by siRNAs. Nature Biotechnology, 2005, 23, 1399-1405.	17.5	321
330	Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nature Medicine, 2005, 11, 138-145.	30.7	356
331	Targeting the innate immune response with improved vaccine adjuvants. Nature Medicine, 2005, 11, S63-S68.	30.7	475
332	The host type I interferon response to viral and bacterial infections. Cell Research, 2005, 15, 407-422.	12.0	303
333	The Role of Toll-like Receptors in the Pathogenesis and Treatment of Dermatological Disease. Journal of Investigative Dermatology, 2005, 125, 1-8.	0.7	171
334	The road to new antiviral therapies. Clinical and Applied Immunology Reviews, 2005, 5, 65-76.	0.4	5
335	Mechanisms of innate immune responses mediated by Toll-like receptors. Clinical and Applied Immunology Reviews, 2005, 5, 167-183.	0.4	6
336	The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cellular Immunology, 2005, 233, 90-96.	3.0	147

#	Article	IF	CITATIONS
337	Dendritic Cell Deficiency in the Blood of Kidney Transplant Patients on Long-Term Immunosuppression: Results of a Prospective Matched-Cohort Study. American Journal of Transplantation, 2005, 5, 2945-2953.	4.7	37
338	Pulmonary DNA vaccination: Concepts, possibilities and perspectives. Journal of Controlled Release, 2005, 107, 1-29.	9.9	73
339	The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. Journal of Immunological Methods, 2005, 300, 93-99.	1.4	26
340	Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. European Journal of Immunology, 2005, 35, 2184-2190.	2.9	175
341	Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology, 2005, 42, 724-731.	7.3	221
342	Innate immune recognition of nucleic acids: Beyond toll-like receptors. International Journal of Cancer, 2005, 117, 517-523.	5.1	59
343	The adaptive immune response in neonatal cerebral white matter damage. Annals of Neurology, 2005, 58, 821-828.	5.3	77
344	Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. Seminars in Immunopathology, 2005, 26, 221-229.	4.0	174
345	Reading the viral signature by Toll-like receptors and other pattern recognition receptors. Journal of Molecular Medicine, 2005, 83, 180-192.	3.9	118
346	Modulation of Toll?interleukin 1 receptor mediated signaling. Journal of Molecular Medicine, 2005, 83, 258-266.	3.9	139
347	TLR-9 Activation of Marginal Zone B Cells in Lupus Mice Regulates Immunity Through Increased IL-10 Production. Journal of Clinical Immunology, 2005, 25, 29-40.	3.8	219
348	Manifold Mechanisms of Toll-Like Receptor-Ligand Recognition. Journal of Clinical Immunology, 2005, 25, 511-521.	3.8	100
349	Toll-like Receptors and their Adaptors in Innate Immunity. Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents, 2005, 4, 3-11.	0.4	5
352	Virus Induced Signaling to Initiate the Interferon Mediated Anti-Viral Host Response. , 2005, , 131-146.		0
353	Interleukin-1 Receptor/Toll-Like Receptor Signaling. , 2005, , 110-130.		0
354	Interleukin-1, Neutrophil Elastase, and Lipopolysaccharide: Key Pro- Inflammatory Stimuli Regulating Inflammation in Cystic Fibrosis. Current Respiratory Medicine Reviews, 2005, 1, 43-67.	0.2	6
355	MyD88-Dependent and -Independent Murine Cytomegalovirus Sensing for IFN-α Release and Initiation of Immune Responses In Vivo. Journal of Immunology, 2005, 175, 6723-6732.	0.8	186
356	Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership. Current Cancer Drug Targets, 2005, 5, 325-344.	1.6	90

#	Article	IF	CITATIONS
357	Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Therapy, 2005, 12, 1324-1332.	4.5	31
358	Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-α induction. Journal of Experimental Medicine, 2005, 201, 915-923.	8.5	446
359	The Interferon Regulatory Factor, IRF5, Is a Central Mediator of Toll-like Receptor 7 Signaling. Journal of Biological Chemistry, 2005, 280, 17005-17012.	3.4	340
360	Spontaneous Formation of Nucleic Acid-based Nanoparticles Is Responsible for High Interferon-α Induction by CpG-A in Plasmacytoid Dendritic Cells. Journal of Biological Chemistry, 2005, 280, 8086-8093.	3.4	160
361	TIR Domain-Containing Adaptors Regulate TLR Signaling Pathways. , 2005, 560, 1-9.		40
362	Randomized, Double-Blind Clinical Trial of Topical Imiquimod 5% with Parenteral Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis in Peru. Clinical Infectious Diseases, 2005, 40, 1395-1403.	5.8	111
363	Dendritic Cells and NK Cells Stimulate Bystander T Cell Activation in Response to TLR Agonists through Secretion of IFN- $\hat{1}$ ± $\hat{1}^2$ and IFN- $\hat{1}^3$. Journal of Immunology, 2005, 174, 767-776.	0.8	136
364	IFN-α Regulates TLR-Dependent Gene Expression of IFN-α, IFN-β, IL-28, and IL-29. Journal of Immunology, 2005, 174, 1932-1937.	0.8	217
365	Differential Roles of Toll-Like Receptors 2 and 4 in In Vitro Responses of Macrophages to Legionella pneumophila. Infection and Immunity, 2005, 73, 352-361.	2.2	84
366	Plasmacytoid Dendritic Cells Control TLR7 Sensitivity of Naive B Cells via Type I IFN. Journal of Immunology, 2005, 174, 4043-4050.	0.8	319
367	Varicella-Zoster Virus Activates Inflammatory Cytokines in Human Monocytes and Macrophages via Toll-Like Receptor 2. Journal of Virology, 2005, 79, 12658-12666.	3.4	141
368	Involvement of the Toll-Like Receptor 9 Signaling Pathway in the Induction of Innate Immunity by Baculovirus. Journal of Virology, 2005, 79, 2847-2858.	3.4	209
369	Dosing With 5% Imiquimod Cream 3 Times per Week for the Treatment of Actinic Keratosis. Archives of Dermatology, 2005, 141, 467-73.	1.4	146
370	Genetic Analysis of Innate Immunity: Identification and Function of the TIR Adapter Proteins. , 2005, 560, 29-39.		34
371	Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Molecular Therapy, 2005, 11, 112-119.	8.2	29
372	TLR7/8-Mediated Activation of Human NK Cells Results in Accessory Cell-Dependent IFN-γ Production. Journal of Immunology, 2005, 175, 1636-1642.	0.8	289
373	Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod. Journal of Immunology, 2005, 174, 2476-2480.	0.8	162
374	Dendritic Cell Maturation Induced by Muramyl Dipeptide (MDP) Derivatives: Monoacylated MDP Confers TLR2/TLR4 Activation. Journal of Immunology, 2005, 174, 7096-7103.	0.8	96

	CITATION RE	PORT	
ARTICLE		IF	CITATIONS
The TLR7 Agonist Imiquimod Enhances the Anti-Melanoma Effects of a RecombinantLi monocytogenesVaccine. Journal of Immunology, 2005, 175, 1983-1990.	steria	0.8	110
Increased Expression of TLR3 in Lymph Nodes during Simian Immunodeficiency Virus I Implications for Inflammation and Immunodeficiency. Journal of Immunology, 2005, 1	nfection: 75, 5314-5323.	0.8	57
Inhibition of IFN-Â signaling by a PKC- and protein tyrosine phosphatase SHP-2-depend Proceedings of the National Academy of Sciences of the United States of America, 200 10267-10272.	lent pathway.)5, 102,	7.1	50
Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient Toll-like receptor-7/8 agonist, imiquimod. Leukemia and Lymphoma, 2005, 46, 935-93	treated with the 9.	1.3	61
Innate Immunity in the Human Female Reproductive Tract: Antiviral Response of Uterin to the TLR3 Agonist Poly(I:C). Journal of Immunology, 2005, 174, 992-1002.	ne Epithelial Cells	0.8	260
Direct Stimulation of Human T Cells via TLR5 and TLR7/8: Flagellin and R-848 Up-Regu and IFN-Î ³ Production by Memory CD4+ T Cells. Journal of Immunology, 2005, 175, 15	ate Proliferation 51-1557.	0.8	380
Host Cell Targets in HCV Therapy: Novel Strategy or Proven Practice?. Antiviral Chemis Chemotherapy, 2005, 16, 69-90.	try and	0.6	9
The Mammalian Innate Immune System: Potential Targets for Drug Development. Curr Immune, Endocrine and Metabolic Disorders, 2005, 5, 237-247.	rent Drug Targets	1.8	4
Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8. Immunology, 2005, 174, 1259-1268.	Journal of	0.8	633
IFN-α Enhances TLR3-Mediated Antiviral Cytokine Expression in Human Endothelial an Up-Regulating TLR3 Expression. Journal of Immunology, 2005, 174, 4289-4294.	d Epithelial Cells by	0.8	181
TLR-Dependent Activation Stimuli Associated with Th1 Responses Confer NK Cell Stim to Mouse Dendritic Cells. Journal of Immunology, 2005, 175, 286-292.	ulatory Capacity	0.8	62
SIGIRR Inhibits Interleukin-1 Receptor- and Toll-like Receptor 4-mediated Signaling thro Mechanisms. Journal of Biological Chemistry, 2005, 280, 25233-25241.	bugh Different	3.4	193
Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Ce Imiquimod Treatment. Journal of the National Cancer Institute, 2005, 97, 1143-1153.	lls Following	6.3	173
TLR Activation Synergizes with Kilham Rat Virus Infection to Induce Diabetes in BBDR Inmunology, 2005, 174, 131-142.	Rats. Journal of	0.8	124
Gene Expression and Antiviral Activity of Alpha/Beta Interferons and Interleukin-29 in N Human Myeloid Dendritic Cells, Journal of Virology, 2005, 79, 9608-9617	/irus-Infected	3.4	163

	Human Myelold Dendritic Cells. Journal of Virology, 2003, 79, 9608-9617.		
390	The Pyrin Family of Fever Genes. Archives of Dermatology, 2005, 141, 242-7.	1.4	30
391	Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients. Archives of Dermatology, 2005, 141, 985-93.	1.4	99
392	Emerging drugs in cutaneous T-cell lymphomas. Expert Opinion on Emerging Drugs, 2005, 10, 381-392.	2.4	8

#

		CITATION REF	PORT	
#	Article		IF	Citations
393	Pathogen Recognition by Toll-like Receptors. NeuroImmune Biology, 2005, 5, 167-182.		0.2	9
394	TLR11 Activation of Dendritic Cells by a Protozoan Profilin-Like Protein. Science, 2005, 308, 1626-	1629.	12.6	862
395	Agents and strategies in development for improved management of herpes simplex virus infection disease. Expert Opinion on Investigational Drugs, 2005, 14, 135-161.	and	4.1	64
398	Molecular mechanisms of autoimmunity triggered by microbial infection. Arthritis Research and Therapy, 2005, 7, 215.		3.5	46
399	The Toll-Like Receptor 7 (TLR7) Agonist, Imiquimod, and the TLR9 Agonist, CpG ODN, Induce Antiv Cytokines and Chemokines but Do Not Prevent Vaginal Transmission of Simian Immunodeficiency When Applied Intravaginally to Rhesus Macaques. Journal of Virology, 2005, 79, 14355-14370.	iral Virus	3.4	126
400	Involvement of Toll-like Receptor 3 in the Immune Response of Lung Epithelial Cells to Double-stranded RNA and Influenza A Virus. Journal of Biological Chemistry, 2005, 280, 5571-558(D.	3.4	591
402	Nod2-Dependent Regulation of Innate and Adaptive Immunity in the Intestinal Tract. Science, 200 731-734.	5, 307,	12.6	1,643
403	Toll-Like Receptor 8-Mediated Reversal of CD4 ⁺ Regulatory T Cell Function. Science, 309, 1380-1384.	2005,	12.6	711
404	Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes. Molecular Immunology, 2005, 42, 957-968.		2.2	82
405	The role of Toll-like receptors in the host response to viruses. Molecular Immunology, 2005, 42, 859-867.		2.2	221
406	Interferon gene regulation: not all roads lead to Tolls. Trends in Molecular Medicine, 2005, 11, 403	-411.	6.7	31
407	Therapy for genital human papillomavirus-related disease. Journal of Clinical Virology, 2005, 32, 82	-90.	3.1	138
408	MacrophAging: A cellular and molecular review. Immunobiology, 2005, 210, 121-126.		1.9	78
409	Cell Type-Specific Involvement of RIG-I in Antiviral Response. Immunity, 2005, 23, 19-28.		14.3	1,221
410	Human TLR-7-, -8-, and -9-Mediated Induction of IFN-α/β and -λ Is IRAK-4 Dependent and Redunda Protective Immunity to Viruses. Immunity, 2005, 23, 465-478.	nt for	14.3	245
411	Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. Journal of the American Academy of Dermatology, 2005, 52, 275-280.		1.2	113
412	Infiltrative squamous cell carcinoma on the scalp after treatment with 5% imiquimod cream. Journ of the American Academy of Dermatology, 2005, 52, 716-717.	al	1.2	15
413	A case of mucocutaneous Behçet's disease responding to etanercept. Journal of the American Ac of Dermatology, 2005, 52, 717-719.	ademy	1.2	21

_	_
	REDUBL
CHATON	REI ORI

#	Article	IF	CITATIONS
414	The role of toll-like receptors in systemic autoimmune disease. International Congress Series, 2005, 1285, 42-49.	0.2	0
415	Characteristics of nucleic acid TLR ligands. International Congress Series, 2005, 1285, 34-41.	0.2	0
416	Expression patterns of chicken Toll-like receptor mRNA in tissues, immune cell subsets and cell lines. Veterinary Immunology and Immunopathology, 2005, 104, 117-127.	1.2	242
417	Toll-like receptor, MHC II, B7 and cytokine expression by porcine monocytes and monocyte-derived dendritic cells in response to microbial pathogen-associated molecular patterns. Veterinary Immunology and Immunopathology, 2005, 107, 235-247.	1.2	72
418	TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine, 2005, 23, 5263-5270.	3.8	145
419	Plasmacytoid dendritic cells—virus experts of innate immunity. Seminars in Immunology, 2005, 17, 253-261.	5.6	160
420	Regulation of the type I IFN induction: a current view. International Immunology, 2005, 17, 1367-1378.	4.0	301
421	Immunotherapy With Imiquimod 5% Cream for Eyelid Nodular Basal Cell Carcinoma. American Journal of Ophthalmology, 2005, 140, 1136-1139.	3.3	38
422	Recognition of Bacterial Products by Toll-Like Receptors. Chemical Immunology and Allergy, 2005, 86, 99-119.	1.7	37
423	Agonists of Toll-Like Receptor 9. , 2005, , 181-212.		5
424	Topical Immunotherapy: What's New. Dermatologic Clinics, 2005, 23, 245-258.	1.7	4
425	Negative Regulation of Cytokine and TLR Signalings by SOCS and Others. Advances in Immunology, 2005, 87, 61-122.	2.2	87
426	Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. Journal of Experimental Medicine, 2005, 201, 19-25.	8.5	537
427	Plasmacytoid Dendritic Cells: Linking Innate and Adaptive Immunity. Journal of Virology, 2005, 79, 17-27.	3.4	322
428	Toll-like receptor downstream signaling. Arthritis Research, 2005, 7, 12.	2.0	217
429	Renal Toll-like receptors: recent advances and implications for disease. Nature Clinical Practice Nephrology, 2006, 2, 568-581.	2.0	51
431	Pathological role of Toll-like receptor signaling in cerebral malaria. International Immunology, 2006, 19, 67-79.	4.0	144
432	The small-molecule immune response modifier imiquimod – its mode of action and clinical use in the treatment of skin cancer. Expert Opinion on Therapeutic Targets, 2006, 10, 69-76.	3.4	30

#	Article	IF	Citations
433	Immunostimulants for preventing respiratory tract infection in children. The Cochrane Library, 2006, , CD004974.	2.8	67
434	TLR7 Ligands Induce Higher IFN-α Production in Females. Journal of Immunology, 2006, 177, 2088-2096.	0.8	394
435	Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. Journal of Clinical Investigation, 2006, 116, 456-464.	8.2	329
436	Induction of an Anti-Inflammatory Cytokine, IL-10, in Dendritic Cells After Toll-like Receptor Signaling. Journal of Interferon and Cytokine Research, 2006, 26, 893-900.	1.2	74
437	Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. International Immunology, 2006, 18, 1115-1126.	4.0	146
438	Cooperative molecular and cellular networks regulate Tollâ€like receptorâ€dependent inflammatory responses. FASEB Journal, 2006, 20, 2153-2155.	0.5	76
439	Antiviral Signaling Through Pattern Recognition Receptors. Journal of Biochemistry, 2006, 141, 137-145.	1.7	398
440	The role of Toll: How therapies targeting Toll-like receptors treat skin diseases. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 75-80.	0.5	0
441	Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunology, Immunotherapy, 2006, 55, 1432-1442.	4.2	78
442	Toll-like receptors 2 and 4 are differentially involved in Fas dependent apoptosis in Peyer's patch and the liver at an early stage after bile duct ligation in mice. Gut, 2006, 55, 105-113.	12.1	13
443	Acides nucléiques microbiens dansÂlaÂphysiopathologie desÂglomérulonéphrites. Nephrologie Et Therapeutique, 2006, 2, 422-431.	0.5	2
444	HCV Immunopathogenesis: Virus-Induced Strategies against Host Immunity. Clinics in Liver Disease, 2006, 10, 753-771.	2.1	14
445	GENETIC ANALYSIS OF HOST RESISTANCE: Toll-Like Receptor Signaling and Immunity at Large. Annual Review of Immunology, 2006, 24, 353-389.	21.8	713
446	The role of Toll-like receptors in immune disorders. Expert Opinion on Biological Therapy, 2006, 6, 203-214.	3.1	42
447	Microparticles as vaccine delivery systems. , 2006, , 123-147.		5
448	Immune response modifiers: Imiquimod and future drugs for modulating the immune response. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 343-352.	0.5	4
449	Invited review: Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. Journal of Endotoxin Research, 2006, 12, 133-150.	2.5	22
450	Immune relevant genes of Japanese flounder, Paralichthys olivaceus. Comparative Biochemistry and Physiology Part D: Genomics and Proteomics, 2006, 1, 115-121.	1.0	24

#	Article	IF	CITATIONS
451	Conservation of Toll-like receptor signaling pathways in teleost fish. Comparative Biochemistry and Physiology Part D: Genomics and Proteomics, 2006, 1, 77-88.	1.0	113
452	Pathogen Recognition and Innate Immunity. Cell, 2006, 124, 783-801.	28.9	9,878
453	Vascular tumors of infancy and childhood: beyond capillary hemangioma. Cardiovascular Pathology, 2006, 15, 303-317.	1.6	118
454	Recognition and Signaling by Toll-Like Receptors. Annual Review of Cell and Developmental Biology, 2006, 22, 409-437.	9.4	612
455	Signaling through Toll-like Receptor 7/8 Induces the Differentiation of Human Bone Marrow CD34+ Progenitor Cells along the Myeloid Lineage. Journal of Molecular Biology, 2006, 364, 945-954.	4.2	150
456	Innate sensing of self and non-self RNAs by Toll-like receptors. Trends in Molecular Medicine, 2006, 12, 167-176.	6.7	166
457	Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guérin by Flt3-ligand generated dendritic cells. Immunobiology, 2006, 211, 557-565.	1.9	69
458	Toll-like Receptor 7-Dependent Loss of B Cell Tolerance in Pathogenic Autoantibody Knockin Mice. Immunity, 2006, 25, 429-440.	14.3	231
459	Therapeutic targeting of pattern-recognition receptors. International Immunopharmacology, 2006, 6, 863-869.	3.8	50
460	Toll-like receptors: Applications to dermatologic disease. Journal of the American Academy of Dermatology, 2006, 54, 951-983.	1.2	87
461	Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): A randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 2006, 54, 1025-1032.	1.2	157
462	Clinical and histopathologic observations of the action of imiquimod in an epithelioid hemangioendothelioma and Paget's mammary disease. Journal of the American Academy of Dermatology, 2006, 55, 75-79.	1.2	13
463	Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. Journal of the American Academy of Dermatology, 2006, 55, 324-327.	1.2	81
464	Regulatory T cells and Toll-like receptors in tumor immunity. Seminars in Immunology, 2006, 18, 136-142.	5.6	54
465	A review of CpGs and their relevance to aquaculture. Veterinary Immunology and Immunopathology, 2006, 112, 87-101.	1.2	60
466	Tweaking Innate Immunity: The Promise of Innate Immunologicals as Anti-Infectives. Canadian Journal of Infectious Diseases and Medical Microbiology, 2006, 17, 307-314.	1.9	11
467	Stimulation of Antigen Presenting Cells: from Classical Adjuvants to Toll-like Receptor (TLR) Ligands. , 2006, , 221-243.		1
468	Antigen Presenting Cells as Drug Targets. , 2006, , 539-584.		0

#	Article	IF	CITATIONS
470	In situ photoimmunotherapy for melanoma: preliminary clinical results. , 2006, 6087, 54.		0
471	U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood, 2006, 107, 3229-3234.	1.4	241
472	Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood, 2006, 108, 1284-1290.	1.4	157
473	Ikaros is required for plasmacytoid dendritic cell differentiation. Blood, 2006, 108, 4025-4034.	1.4	115
475	Human Papillomavirus Isolated from Transplant-Associated Porokeratoses of Mibelli Responsive to Topical 5% Imiquimod Cream. Dermatologic Surgery, 2006, 32, 858-861.	0.8	0
476	Successful Treatment of Earlobe Keloids with Imiquimod after Tangential Shave Excision. Dermatologic Surgery, 2006, 32, 380-386.	0.8	0
477	Systemic Inflammatory Response Syndrome (SIRS): Molecular Pathophysiology and Gene Therapy. Journal of Pharmacological Sciences, 2006, 101, 189-198.	2.5	161
478	Immune response modifiers ? mode of action. Experimental Dermatology, 2006, 15, 331-341.	2.9	100
479	Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australasian Journal of Dermatology, 2006, 47, 258-265.	0.7	34
480	Imiquimod: An Effective Alternative for the Treatment of Invasive Cutaneous Squamous Cell Carcinoma. Dermatologic Surgery, 2006, 31, 371-374.	0.8	21
481	Long-Term Clinical Outcomes Following Treatment of Actinic Keratosis with Imiquimod 5% Cream. Dermatologic Surgery, 2006, 31, 659-664.	0.8	30
482	Successful Treatment of Earlobe Keloids with Imiquimod after Tangential Shave Excision. Dermatologic Surgery, 2006, 32, 380-386.	0.8	56
483	Human Papillomavirus Isolated from Transplant-Associated Porokeratoses of Mibelli Responsive to Topical 5% Imiquimod Cream. Dermatologic Surgery, 2006, 32, 858-861.	0.8	18
484	Role of SLC11A1 (formerly NRAMP1) in regulation of signal transduction induced by Toll-like receptor 7 ligands. FEMS Immunology and Medical Microbiology, 2006, 47, 138-147.	2.7	10
485	Effect of Toll-Like Receptor (TLR) Agonists on TLR and Microbicide Expression in Uterine and Vaginal Tissues of the Mouse. American Journal of Reproductive Immunology, 2006, 55, 434-446.	1.2	64
486	Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. British Journal of Dermatology, 2006, 154, 72-78.	1.5	56
487	Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. British Journal of Dermatology, 2006, 155, 451-454.	1.5	72
488	Permanent facial hypopigmentation following treatment with imiquimod cream. Clinical and Experimental Dermatology, 2006, 31, 721-722.	1.3	22

#	Article	IF	CITATIONS
489	Phenytoin-induced DRESS with cross-reactivity to carbamazepine in a 10-year-old Indian child. Clinical and Experimental Dermatology, 2006, 31, 720-721.	1.3	16
490	In vitro-Generated Viral Double-Stranded RNA in Contrast to Polyinosinic : Polycytidylic Acid Induces Interferon-alpha in Human Plasmacytoid Dendritic Cells. Scandinavian Journal of Immunology, 2006, 63, 264-274.	2.7	24
491	Regulatory T Cells and Systemic Lupus Erythematosus. Scandinavian Journal of Immunology, 2006, 64, 211-218.	2.7	51
492	Herpes simplex virus 1 infection induces the expression of proinflammatory cytokines, interferons and TLR7 in human corneal epithelial cells. Immunology, 2006, 117, 167-176.	4.4	132
493	Effect of oestradiol on PAMP-mediated CCL20/MIP-3alpha production by mouse uterine epithelial cells in culture. Immunology, 2006, 118, 185-194.	4.4	33
494	Innate immune recognition of viral infection. Nature Immunology, 2006, 7, 131-137.	14.5	1,654
495	Toll-like receptors as molecular switches. Nature Reviews Immunology, 2006, 6, 693-698.	22.7	160
496	CATALYTIC RECEPTORS. British Journal of Pharmacology, 2006, 147, S127-S133.	5.4	74
497	Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature, 2006, 439, 204-207.	27.8	836
498	Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature, 2006, 439, 208-211.	27.8	791
499	Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature, 2006, 440, 233-236.	27.8	1,016
500	TLR signaling. Cell Death and Differentiation, 2006, 13, 816-825.	11.2	1,724
501	The Small Antitumoral Immune Response Modifier Imiquimod Interacts with Adenosine Receptor Signaling in a TLR7- and TLR8-Independent Fashion. Journal of Investigative Dermatology, 2006, 126, 1338-1347.	0.7	138
502	Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia, 2006, 20, 286-295.	7.2	79
503	NF-κB and the immune response. Oncogene, 2006, 25, 6758-6780.	5.9	1,050
504	IRAK-4: A key kinase involved in toll-like receptor signaling and resistance to bacterial infection. , 2006, , 173-192.		1
505	TLR9 and the Recognition of Self and Nonâ€Self Nucleic Acids. Annals of the New York Academy of Sciences, 2006, 1082, 31-43.	3.8	84
506	PRRs in pathogen recognition. Open Life Sciences, 2006, 1, 299-313.	1.4	3

#	Article	IF	CITATIONS
507	MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. Journal of Clinical Investigation, 2006, 116, 2262-2271.	8.2	402
508	Regulatory T cells and innate immune regulation in tumor immunity. Seminars in Immunopathology, 2006, 28, 17-23.	4.0	45
509	Toll-like receptors and innate immunity. Journal of Molecular Medicine, 2006, 84, 712-725.	3.9	377
510	Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: Towards synthetic epitope-based vaccines. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3258-3261.	2.2	23
511	Toll-like receptor (TLR) 2–9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cellular Immunology, 2006, 243, 48-57.	3.0	101
512	Treatment of intravaginal HSV-2 infection in mice: A comparison of CpG oligodeoxynucleotides and resiquimod (R-848). Antiviral Research, 2006, 69, 77-85.	4.1	33
513	Toll-like receptors, inflammation and cancer. Seminars in Cancer Biology, 2006, 16, 32-37.	9.6	129
514	Functional control of regulatory T cells and cancer immunotherapy. Seminars in Cancer Biology, 2006, 16, 106-114.	9.6	43
515	High-avidity antitumor T-cell generation by toll receptor 8–primed, myeloid- derived dendritic cells is mediated by IL-12 production. Surgery, 2006, 140, 170-178.	1.9	40
516	Influenza H2 haemagglutinin activates B cells via a MyD88-dependent pathway. European Journal of Immunology, 2006, 36, 95-106.	2.9	19
517	Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. European Journal of Immunology, 2006, 36, 1815-1826.	2.9	83
518	Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. European Journal of Immunology, 2006, 36, 2094-2105.	2.9	116
519	Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. European Journal of Immunology, 2006, 36, 3256-3267.	2.9	242
520	Tollâ€like receptors in central nervous system glial inflammation and homeostasis. Journal of Neuroscience Research, 2006, 83, 711-730.	2.9	319
521	Pharmacological Interaction of Drugs with Immune Receptors: The p-i Concept. Allergology International, 2006, 55, 17-25.	3.3	189
523	Type I Interferon as a Target of Treatment in SLE. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2006, 6, 323-330.	1.2	23
524	A tale of three Hs: HPV, HIV & HAART. Future Oncology, 2006, 2, 1-9.	2.4	2
525	Unraveling "the immunologist's dirty little secret― , 2006, , 1-16.		3

#	Article	IF	CITATIONS
526	Microbial nucleic acids pay a Toll in kidney disease. American Journal of Physiology - Renal Physiology, 2006, 291, F509-F516.	2.7	28
527	Toll-Like Receptors, Cytokines and the Immunotherapeutics of Asthma. Current Pharmaceutical Design, 2006, 12, 2365-2374.	1.9	9
528	Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. Journal of Endotoxin Research, 2006, 12, 133-150.	2.5	180
529	Intervention of Toll-like Receptor-Mediated Human Innate Immunity and Inflammation by Synthetic Compounds and Naturally Occurring Products. Current Medicinal Chemistry, 2006, 13, 1389-1395.	2.4	22
530	Expression of Toll-Like Receptors (TLR) and Responsiveness to TLR Agonists by Polarized Mouse Uterine Epithelial Cells in Culture1. Biology of Reproduction, 2006, 75, 131-139.	2.7	59
531	Toll-Like Receptors and Corneal Innate Immunity. Current Molecular Medicine, 2006, 6, 327-337.	1.3	109
532	The Emerging Role of Toll-Like Receptor Pathways in Surgical Diseases. Archives of Surgery, 2006, 141, 595.	2.2	12
533	TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L987-L995.	2.9	86
534	'Toll' Gates for Future Immunotherapy. Current Pharmaceutical Design, 2006, 12, 4135-4142.	1.9	63
535	Topical Imiquimod: Mechanism of Action and Clinical Applications. Mini-Reviews in Medicinal Chemistry, 2006, 6, 499-503.	2.4	39
536	Therapeutic Targeting of Toll-Like Receptors in Gastrointestinal Inflammation. Current Pharmaceutical Design, 2006, 12, 4215-4228.	1.9	36
537	Toll-Like Receptor-7 Modulates Immune Complex Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 141-149.	6.1	121
538	An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. Journal of Experimental Medicine, 2006, 203, 2021-2031.	8.5	170
539	The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity. Journal of Immunology, 2006, 176, 157-164.	0.8	193
540	Innate Immunity at the Mucosal Surface: Role of Toll-Like Receptor 3 and Toll-Like Receptor 9 in Cervical Epithelial Cell Responses to Microbial Pathogens1. Biology of Reproduction, 2006, 74, 824-831.	2.7	96
541	Oxidative Stress Promotes Polarization of Human T Cell Differentiation Toward a T Helper 2 Phenotype. Journal of Immunology, 2006, 176, 2765-2772.	0.8	111
542	Immunostimulatory combinations: designing the next generation of vaccine adjuvants. Journal of Leukocyte Biology, 2006, 80, 1084-1102.	3.3	64
543	A comprehensive map of the tollâ€like receptor signaling network. Molecular Systems Biology, 2006, 2, 2006.0015.	7.2	302

# 544	ARTICLE Efficacy of an Immune Modulator in ExperimentalChlamydia trachomatisInfection of the Female Genital Tract. Infectious Diseases in Obstetrics and Gynecology, 2006, 2006, 1-6.	IF 1.5	Citations 0
545	Vaccine Adjuvants. , 2006, , .		6
546	Toll-like Receptors. , 0, , 119-127.		0
547	Genetic Analysis of Innate Immunity. Advances in Immunology, 2006, 91, 175-226.	2.2	31
548	A <i>Tlr7</i> translocation accelerates systemic autoimmunity in murine lupus. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9970-9975.	7.1	567
549	Localization of TLR2 and MyD88 to Chlamydia trachomatis Inclusions. Journal of Biological Chemistry, 2006, 281, 1652-1659.	3.4	107
550	Conserved Features in the Extracellular Domain of Human Toll-like Receptor 8 Are Essential for pH-dependent Signaling. Journal of Biological Chemistry, 2006, 281, 27503-27511.	3.4	76
551	Cutting Edge: Activation of Murine TLR8 by a Combination of Imidazoquinoline Immune Response Modifiers and PolyT Oligodeoxynucleotides. Journal of Immunology, 2006, 177, 6584-6587.	0.8	182
552	Host-Derived Langerhans Cells Persist after MHC-Matched Allografting Independent of Donor T Cells and Critically Influence the Alloresponses Mediated by Donor Lymphocyte Infusions. Journal of Immunology, 2006, 177, 4414-4425.	0.8	36
553	Critical Role for Cryopyrin/Nalp3 in Activation of Caspase-1 in Response to Viral Infection and Double-stranded RNA. Journal of Biological Chemistry, 2006, 281, 36560-36568.	3.4	598
554	Identification of the Segments of the Mouse Transferrin Receptor 1 Required for Mouse Mammary Tumor Virus Infection. Journal of Biological Chemistry, 2006, 281, 10243-10249.	3.4	28
555	Intestinal Microvascular Endothelium and Innate Immunity in Inflammatory Bowel Disease: a Second Line of Defense?. Infection and Immunity, 2006, 74, 5425-5432.	2.2	38
556	Regulation of Intestinal Dendritic Cell Migration and Activation by Plasmacytoid Dendritic Cells, TNF-α and Type 1 IFNs after Feeding a TLR7/8 Ligand. Journal of Immunology, 2006, 176, 5205-5212.	0.8	104
557	TRAF3: A New Regulator of Type I Interferons. Cell Cycle, 2006, 5, 804-807.	2.6	43
558	The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis. Journal of Experimental Medicine, 2007, 204, 1559-1569.	8.5	137
559	Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Review of Vaccines, 2007, 6, 227-239.	4.4	63
560	Investigating Toll-Like Receptor Agonists for Potential To Treat Hepatitis C Virus Infection. Antimicrobial Agents and Chemotherapy, 2007, 51, 2969-2978.	3.2	56
561	The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. Journal of Cell Biology, 2007, 177, 265-275.	5.2	392

#	Article	IF	CITATIONS
562	Calcineurin Negatively Regulates TLR-Mediated Activation Pathways. Journal of Immunology, 2007, 179, 4598-4607.	0.8	94
563	Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling. Journal of Immunology, 2007, 178, 5533-5542.	0.8	111
564	IFN-αβ-Mediated Inflammatory Responses and Antiviral Defense in Liver Is TLR9-Independent but MyD88-Dependent during Murine Cytomegalovirus Infection. Journal of Immunology, 2007, 179, 6176-6183.	0.8	51
565	TLR Signaling Fine-Tunes Anti-Influenza B Cell Responses without Regulating Effector T Cell Responses. Journal of Immunology, 2007, 178, 2182-2191.	0.8	185
566	Differential Effects of CpG DNA on IFN-Î ² Induction and STAT1 Activation in Murine Macrophages versus Dendritic Cells: Alternatively Activated STAT1 Negatively Regulates TLR Signaling in Macrophages. Journal of Immunology, 2007, 179, 3495-3503.	0.8	44
567	Expression and functionality of Toll-like receptors in the skin: potential implication in skin inflammatory diseases. Expert Review of Dermatology, 2007, 2, 357-365.	0.3	1
568	Toll-like receptor signal transduction. Experimental and Molecular Medicine, 2007, 39, 421-438.	7.7	211
569	Toll-Like Receptors, New Horizons in Sepsis. Current Molecular Medicine, 2007, 7, 522-531.	1.3	7
570	Expression of MCP-4 by TLR ligand-stimulated nasal polyp fibroblasts. Acta Oto-Laryngologica, 2007, 127, 1304-1309.	0.9	10
571	Activation of the Innate Immune System in Atherosclerotic Disease. Current Pharmaceutical Design, 2007, 13, 983-994.	1.9	35
572	Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways. International Immunology, 2007, 19, 311-320.	4.0	74
573	Toll-like Receptors Impact on Safety and Efficacy of Gene Transfer Vectors. Molecular Therapy, 2007, 15, 1417-1422.	8.2	31
574	Murine Dendritic Cell Type I IFN Production Induced by Human IgG-RNA Immune Complexes Is IFN Regulatory Factor (IRF)5 and IRF7 Dependent and Is Required for IL-6 Production. Journal of Immunology, 2007, 178, 6876-6885.	0.8	157
575	Differential Role of TLR- and RLR-Signaling in the Immune Responses to Influenza A Virus Infection and Vaccination. Journal of Immunology, 2007, 179, 4711-4720.	0.8	271
576	Inhibition of Toll-Like Receptor-7 (TLR-7) or TLR-7 plus TLR-9 Attenuates Glomerulonephritis and Lung Injury in Experimental Lupus. Journal of the American Society of Nephrology: JASN, 2007, 18, 1721-1731.	6.1	200
577	Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. International Immunology, 2007, 19, 297-304.	4.0	30
578	Identification of Signaling Pathways in Macrophage Exposed to <i>Porphyromonas gingivalis</i> or to Its Purified Cell Wall Components. Journal of Immunology, 2007, 179, 7777-7790.	0.8	77
579	Toll-like Receptor-7 Tolerizes Malignant B Cells and Enhances Killing by Cytotoxic Agents. Cancer Research, 2007, 67, 1823-1831.	0.9	57

ARTICLE IF CITATIONS Sensitization to TLR7 Agonist in IFN-Î²-Preactivated Dendritic Cells. Journal of Immunology, 2007, 178, 580 0.8 55 6208-6216. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3990-3995. 7.1 98 582 Drugs as Haptens, Antigens, and Immunogens., 2007, , 55-65. 8 A critical role for IRAK4 kinase activity in Toll-like receptor–mediated innate immunity. Journal of Experimental Medicine, 2007, 204, 1025-1036. Menstrual cycle-dependent changes of Toll-like receptors in endometrium. Human Reproduction, 2007, 584 0.9 108 22, 586-593. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13750-13755. 7.1 Immunomodulatory Effects of Viral TLR Ligands on Experimental Asthma Depend on the Additive 586 0.8 110 Effects of IL-12 and IL-10. Journal of Immunology, 2007, 178, 7805-7813. Identification and Characterization of Novel Bone Marrow Myeloid DEC205+Gr-1+ Cell Subsets That 587 0.8 Differentially Express Chemokine and TLRs. Journal of Immunology, 2007, 178, 7833-7839. IFN-Î³ and R-848 Dependent Activation of Human Monocyte-Derived Dendritic Cells by <i>Neisseria 588 0.8 25 meningitidis </i> Adhesin A. Journal of Immunology, 2007, 179, 3904-3916. Role of Imiquimod and Parenteral Meglumine Antimoniate in the Initial Treatment of Cutaneous 589 5.8 Leishmaniasis. Clinical Infectious Diseases, 2007, 44, 1549-1554. Cross-talk between Toll-like receptors 5 and 9 on activation of human immune responses. Journal of 590 3.3 32 Leukocyte Biology, 2007, 82, 509-518. TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation. Journal of 3.3 29 Leukocyte Biology, 2007, 81, 221-228. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-α secretion in plasmacytoid dendritic cells. 592 7.1 190 Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3396-3401. Topical Resiquimod 0.01% Gel Decreases Herpes Simplex Virus Type 2 Genital Shedding: A Randomized, Controlled Trial. Journal of Infectious Diseases, 2007, 195, 1324-1331. The pharmacology of endosomal TLR agonists in viral disease. Biochemical Society Transactions, 2007, 594 3.4 38 35, 1468-1472. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochemical Society Transactions, 2007, 35, 1485-1491. Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon. 596 1.4 356 Blood, 2007, 109, 1131-1137. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood, 1.4 2007, 109, 5371-5379.

ARTICLE IF CITATIONS Factors governing the activation of adoptively transferred donor T cells infused after allogeneic 598 1.4 28 bone marrow transplantation in the mouse. Blood, 2007, 109, 4564-4574. Small Molecule Immunopotentiators as Vaccine Adjuvants., 0, , 175-189. 599 Sepsis since the discovery of Toll-like receptors: Disease concepts and therapeutic opportunities. 600 0.9 38 Critical Care Medicine, 2007, 35, 1404-1410. Th1 Polarization of CD4+ T Cells by Toll-Like Receptor 3-Activated Human Microglia. Journal of Neuropathology and Experimental Neurology, 2007, 66, 848-859. In situ photoimmunotherapy for melanoma: an ongoing phase I clinical trial., 2007, , . 602 1 Recent Developments in Patents Targeting Toll-Like Receptor Genes. Recent Patents on DNA & Gene Sequences, 2007, 1, 227-239. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by 604 3.8 46 individual DC-activating agonists. Vaccine, 2007, 25, 1379-1389. Viral recognition by Toll-like receptors. Seminars in Immunology, 2007, 19, 33-40. 5.6 187 Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in 606 3.8 28 mice by live influenza vaccine. Vaccine, 2007, 25, 8067-8076. Incorporation of low molecular weight molecules into $\hat{1}\pm 2$ -Macroglobulin by nucleophilic exchange. 2.1 Biochemical and Biophysical Research Communications, 2007, 357, 433-438. Characterization of twin toll-like receptors from rainbow trout (Oncorhynchus mykiss): 608 Evolutionary relationship and induced expression by Aeromonas salmonicida salmonicida. 2.392 Developmental and Comparative Immunology, 2007, 31, 499-510. Infectious salmon anemia virus is a powerful inducer of key genes of the type I interferon system of Atlantic salmon, but is not inhibited by interferon. Fish and Shellfish Immunology, 2007, 23, 378-389. 609 3.6 105 Oral resiguimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind 610 3.7 188 phase IIa studies. Journal of Hepatology, 2007, 47, 174-182. Gene Expression Analysis in Blood Cells in Response to Unmodified and 2â€²-Modified siRNAs Reveals 4.2 123 TLR-dependent and Independent Effects. Journal of Molecular Biology, 2007, 365, 90-108. Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. Journal of 612 6.5 62 Autoimmunity, 2007, 29, 52-59. Immunobiology of toll-like receptors in allergic disease. Immunobiology, 2007, 212, 521-533. 36 Alveolar Macrophages Are the Primary Interferon-α Producer in Pulmonary Infection with RNA Viruses. 614 14.3340 Immunity, 2007, 27, 240-252. Activation of Invariant NKT Cells by Toll-like Receptor 9-Stimulated Dendritic Cells Requires Type I 14.3 243 Interferon and Charged Glycosphingolipids. Immunity, 2007, 27, 597-609.

#	Article	IF	CITATIONS
616	Imiquimod as an antiaging agent. Journal of the American Academy of Dermatology, 2007, 56, 422-425.	1.2	27
617	Distinct role of MAPKAPK-2 in the regulation of TNF gene expression by Toll-like receptor 7 and 9 ligands. Molecular Immunology, 2007, 44, 3482-3491.	2.2	23
618	Therapeutic implications of the TLR and VDR partnership. Trends in Molecular Medicine, 2007, 13, 117-124.	6.7	100
619	Signaling to NF-κB by Toll-like receptors. Trends in Molecular Medicine, 2007, 13, 460-469.	6.7	1,932
620	Toll-like Receptors and Type I Interferons. Journal of Biological Chemistry, 2007, 282, 15319-15323.	3.4	434
621	Murine Cerebral Malaria Development Is Independent of Toll-Like Receptor Signaling. American Journal of Pathology, 2007, 170, 1640-1648.	3.8	93
623	Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Review of Vaccines, 2007, 6, 835-847.	4.4	72
624	Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biology, 2007, 8, R8.	9.6	100
626	Chronic Asthma–induced Airway Remodeling Is Prevented by Toll-like Receptor-7/8 Ligand S28463. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1241-1249.	5.6	116
628	2′-O-methyl-modified RNAs Act as TLR7 Antagonists. Molecular Therapy, 2007, 15, 1663-1669.	8.2	273
629	Inhibition of HIV Type 1 Replication in CD4+and CD14+Cells Purified from HIV Type 1-Infected Individuals by the 2-5A Agonist Immunomodulator, 2-5AN6B. AIDS Research and Human Retroviruses, 2007, 23, 123-134.	1.1	14
630	Toll-Like Receptors in Dermatology. Dermatologic Clinics, 2007, 25, 531-540.	1.7	16
631	Antitumor Effects of Imidazoquinolines in Urothelial Cell Carcinoma of the Bladder. Journal of Urology, 2007, 177, 2347-2351.	0.4	59
632	Tumor Microenvironment and the Immune Response. Surgical Oncology Clinics of North America, 2007, 16, 737-753.	1.5	7
633	Therapeutic use of Aldara in chronic myeloid leukemia. Journal of Translational Medicine, 2007, 5, 4.	4.4	3
634	Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. Journal of Translational Medicine, 2007, 5, 5.	4.4	54
635	Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. Journal of Translational Medicine, 2007, 5, 7.	4.4	45
636	Pharmacological Treatments for Basal Cell Carcinoma. Drugs, 2007, 67, 915-934.	10.9	26

	CITATION R	EPORT	
#	Article	IF	Citations
637	Toll‣ike Receptors. Current Protocols in Immunology, 2007, 77, Unit 14.12.	3.6	183
638	Structure and Function of Toll Receptors and Their Ligands. Annual Review of Biochemistry, 2007, 76, 141-165.	11.1	562
639	Interferon: The 50th Anniversary. Current Topics in Microbiology and Immunology, 2007, , .	1.1	11
640	The Biology of Toll-Like Receptors in Mice. , 2007, , 109-117.		0
641	Some Biological Features of Dendritic Cells in the Mouse. , 2007, , 135-154.		2
642	The Expression of TLR3 and Cytokines Induced by Poly I:C in Human Retinal Pigment Epithelial Cells. Journal of Bacteriology and Virology, 2007, 37, 241.	0.1	2
643	Fatos e mitos sobre imunomoduladores. Anais Brasileiros De Dermatologia, 2007, 82, 207-221.	1.1	6
644	Susceptibility to infectious diseases. , 0, , 277-301.		1
645	Toll like receptors and inflammatory factors in sepsis and differential expression related to age. Chinese Medical Journal, 2007, 120, 56-61.	2.3	4
646	TLR agonists induce the differentiation of human bone marrow CD34 ⁺ progenitors into CD11c ⁺ CD80/86 ⁺ DC capable of inducing a Th1â€type response. European Journal of Immunology, 2007, 37, 2834-2846.	2.9	78
647	Altered innate immunity in chronic hepatitis C infection: Cause or effect?. Hepatology, 2007, 46, 1279-1290.	7.3	38
648	Nucleic acid recognizing Toll-like receptors and autoimmunity. Current Opinion in Immunology, 2007, 19, 606-610.	5.5	23
649	Proteome analysis of human macrophages reveals the upregulation of manganese-containing superoxide dismutase after toll-like receptor activation. Proteomics, 2007, 7, 378-384.	2.2	31
650	Translational Mini-Review Series on Toll-like Receptors:†Recent advances in understanding the role of Toll-like receptors in anti-viral immunity. Clinical and Experimental Immunology, 2007, 147, 217-226.	2.6	38
651	Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nature Immunology, 2007, 8, 772-779.	14.5	406
652	Interferons at age 50: past, current and future impact on biomedicine. Nature Reviews Drug Discovery, 2007, 6, 975-990.	46.4	970
653	Tollâ€like receptors: structural pieces of a curveâ€shaped puzzle. Immunology and Cell Biology, 2007, 85, 406-410.	2.3	29
654	Tollâ€ŀike receptors, RIGâ€ŀâ€ŀike RNA helicases and the antiviral innate immune response. Immunology and Cell Biology, 2007, 85, 435-445.	2.3	209
ARTICLE IF CITATIONS Imiquimod Enhances the Systemic Immunity Attained by Local Cryosurgery Destruction of Melanoma 0.7 103 655 Lesions. Journal of Investigative Dermatology, 2007, 127, 1673-1680. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia, 2007, 21, 53-60. 7.2 93 657 Catalytic Receptors. British Journal of Pharmacology, 2007, 150, S122-S127. 5.42 How important are Toll-like receptors for antimicrobial responses?. Cellular Microbiology, 2007, 9, 658 139 1891-1901. Association of <i>TLR7</i> single nucleotide polymorphisms with chronic HCVâ€infection and response 659 2.0 62 to interferonâ€<i>a</i>â€based therapy. Journal of Viral Hepatitis, 2008, 15, 71-78. Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 1.5 agonist imiquimod. British Journal of Dermatology, 2007, 157, 1132-1147. Immune response profiles in human skin. British Journal of Dermatology, 2007, 157, 1-7. 661 1.555 Imiquimod: mode of action. British Journal of Dermatology, 2007, 157, 8-13. 662 1.5 291 A randomised study of topical 5% imiguimod vs. topical 5-fluorouracil vs. cryosurgery in 663 immunocompetent patients with actinic keratoses: a comparison of clinical and histological 240 1.5 outcomes including 1-year follow-up. British Journal of Dermatology, 2007, 157, 34-40. Explaining phenotype heterogeneity in patients with psoriasis. British Journal of Dermatology, 2008, 1.5 664 158, 437-441. Recognition of viruses by innate immunity. Immunological Reviews, 2007, 220, 214-224. 305 665 6.0 Human Tollâ \in like receptorâ \in dependent induction of interferons in protective immunity to viruses. 6.0 147 Immunological Reviews, 2007, 220, 225-236. Neoâ \in ligands for innate immune receptors and the etiology of sterile inflammatory disease. 667 6.0 60 Immunological Reviews, 2007, 220, 113-128. Toll-like receptors and their role in periodontal health and disease. Periodontology 2000, 2007, 43, 13.4 150 41-55. REVIEW ARTICLE: The Role of Tollâ€Like Receptor Ligands/Agonists in Protection Against Genital HSVâ€2 669 1.2 35 Infection. American Journal of Reproductive Immunology, 2008, 59, 35-43. The bacterium, nontypeable <i>Haemophilus influenzae</i>, enhances host antiviral response by 670 28 inducing Tollâ€like receptor 7 expression. FEBS Journal, 2007, 274, 3655-3668. Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. 671 2.266 BMC Immunology, 2007, 8, 26. Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. 672 74 Cellular Immunology, 2007, 250, 75-84.

#	Article	IF	CITATIONS
673	Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discovery Today, 2007, 12, 80-87.	6.4	74
674	Emerging host cell targets for hepatitis C therapy. Drug Discovery Today, 2007, 12, 209-217.	6.4	26
675	Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Research, 2007, 73, 1-11.	4.1	71
676	Expression of IL-27 p28 by Theiler's virus-infected macrophages depends on TLR3 and TLR7 activation of JNK-MAP-kinases. Antiviral Research, 2007, 76, 159-167.	4.1	26
677	Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double-blinded study. Gynecologic Oncology, 2007, 107, 219-222.	1.4	96
678	MHC expression and chemokine production in the murine vagina following intra-vaginal administration of ligands to toll-like receptors 3, 7 and 9. Journal of Reproductive Immunology, 2007, 73, 148-157.	1.9	16
679	Role of IFN-Î \pm /Î ² signaling in the prevention of genital herpes virus type 2 infection. Journal of Reproductive Immunology, 2007, 74, 114-123.	1.9	37
680	Phylogenetic and expression analysis of amphibian Xenopus Toll-like receptors. Immunogenetics, 2007, 59, 281-293.	2.4	118
681	Toll-like receptors in the skin. Seminars in Immunopathology, 2007, 29, 15-26.	6.1	131
682	Toll or Toll-Free Adjuvant Path Toward the Optimal Vaccine Development. Journal of Clinical Immunology, 2007, 27, 363-371.	3.8	146
683	Initiation of adaptive immune responses by transcutaneous immunization. Immunology Letters, 2007, 109, 13-20.	2.5	55
684	Macrophage tolerance induced by stimulation with Toll-like receptor 7/8 ligands. Immunology Letters, 2007, 111, 51-56.	2.5	16
685	15-Deoxy-Δ12,14-Prostaglandin J2 and Curcumin Modulate the Expression of Toll-like Receptors 4 and 9 in Autoimmune T Lymphocyte. Journal of Clinical Immunology, 2008, 28, 558-570.	3.8	55
686	Severe sepsis and Toll-like receptors. Seminars in Immunopathology, 2008, 30, 29-40.	6.1	34
687	Pathogen recognition by innate receptors. Journal of Infection and Chemotherapy, 2008, 14, 86-92.	1.7	187
688	Identification of plasmacytoid preâ€dendritic cells by oneâ€color flow cytometry for phenotype screening. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 254-258.	1.5	13
689	Viral danger signals control CD1d <i>de novo</i> synthesis and NKT cell activation. European Journal of Immunology, 2008, 38, 668-679.	2.9	40
690	<i>Yaa</i> autoimmune phenotypes are conferred by overexpression of TLR7. European Journal of Immunology, 2008, 38, 1971-1978.	2.9	150

#	Article	IF	CITATIONS
691	Viral 5′â€triphosphate RNA and non pG DNA aggravate autoimmunity and lupus nephritis <i>via</i> distinct TLRâ€independent immune responses. European Journal of Immunology, 2008, 38, 3487-3498.	2.9	55
692	Requirement of tollâ€like receptor 7 for pristaneâ€induced production of autoantibodies and development of murine lupus nephritis. Arthritis and Rheumatism, 2008, 58, 1107-1115.	6.7	116
693	Nucleic acid sensing Toll-like receptors in dendritic cells. Current Opinion in Immunology, 2008, 20, 408-413.	5.5	20
694	Accessing the therapeutic potential of immunostimulatory nucleic acids. Current Opinion in Immunology, 2008, 20, 389-395.	5.5	104
695	In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 6601-6610.	3.0	104
696	MAPPIT analysis of early Toll-like receptor signalling events. Immunology Letters, 2008, 116, 141-148.	2.5	12
697	Mucosal macrophages and the regulation of immune responses in the intestine. Immunology Letters, 2008, 119, 22-31.	2.5	103
698	Toll-Like Receptors in Skin. Advances in Dermatology, 2008, 24, 71-87.	2.0	207
699	Toll-like receptor 7 is not necessary for retroviral neuropathogenesis but does contribute to virus-induced neuroinflammation. Journal of NeuroVirology, 2008, 14, 492-502.	2.1	22
700	Immune Stimulatory Oligonucleotides. RSC Biomolecular Sciences, 2008, , 142-162.	0.4	2
701	Tollâ€like Receptor and RIGâ€1â€like Receptor Signaling. Annals of the New York Academy of Sciences, 2008, 1143, 1-20.	3.8	842
702	Immunotherapy with dendritic cells for cancer. Advanced Drug Delivery Reviews, 2008, 60, 173-183.	13.7	54
703	Toll-like receptors regulation of viral infection and diseaseâ~†. Advanced Drug Delivery Reviews, 2008, 60, 786-794.	13.7	73
704	Recognition of viral single-stranded RNA by Toll-like receptorsâ~†. Advanced Drug Delivery Reviews, 2008, 60, 813-823.	13.7	105
705	TLR9 as a key receptor for the recognition of DNAâ [~] †. Advanced Drug Delivery Reviews, 2008, 60, 795-804.	13.7	296
706	Nucleic acid-sensing Toll-like receptors: Beyond ligand searchâ~†. Advanced Drug Delivery Reviews, 2008, 60, 782-785.	13.7	9
707	Forward genetic analysis of TLR-signaling pathways: An evaluationâ~†. Advanced Drug Delivery Reviews, 2008, 60, 824-829.	13.7	23
708	<i>Cryptococcus neoformans</i> activates bone marrow-derived conventional dendritic cells rather than plasmacytoid dendritic cells and down-regulates macrophages. FEMS Immunology and Medical Microbiology, 2008, 52, 417-427.	2.7	27

#	Article	IF	Citations
709	Toll-like receptors control autophagy. EMBO Journal, 2008, 27, 1110-1121.	7.8	673
710	Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature, 2008, 452, 591-597.	27.8	868
711	Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene, 2008, 27, 208-217.	5.9	17
712	Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene, 2008, 27, 181-189.	5.9	133
713	TLR7 and TLR8 as targets in cancer therapy. Oncogene, 2008, 27, 190-199.	5.9	264
714	Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Moscow), 2008, 73, 555-561.	1.5	77
715	Catalytic Receptors. British Journal of Pharmacology, 2008, 153, S146.	5.4	0
716	Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nature Immunology, 2008, 9, 1407-1414.	14.5	420
717	Toll-like receptors — taking an evolutionary approach. Nature Reviews Genetics, 2008, 9, 165-178.	16.3	486
718	Pharmacokinetics and Safety of Imiquimod 5% Cream in the Treatment of Molluscum Contagiosum in Children. Pediatric Dermatology, 2008, 25, 88-95.	0.9	37
719	Tumour growth inhibition by an imidazoquinoline is associated with câ€Myc downâ€regulation in urothelial cell carcinoma. BJU International, 2008, 101, 894-901.	2.5	11
720	Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transplant Infectious Disease, 2008, 10, 59-62.	1.7	48
721	Activation of Tollâ€like receptor 2 by a novel preparation of cell wall skeleton from <i>Mycobacterium bovis</i> BCG Tokyo (SMPâ€105) sufficiently enhances immune responses against tumors. Cancer Science, 2008, 99, 1435-1440.	3.9	58
722	Interferon-α and viral triggers promote functional maturation of human monocyte-derived dendritic cells. British Journal of Dermatology, 2008, 158, 921-929.	1.5	42
723	A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. British Journal of Dermatology, 2008, 159, 205-210.	1.5	90
724	Characterization of the innate immune signalling pathways in hepatocyte cell lines. Journal of Viral Hepatitis, 2008, 15, 888-900.	2.0	68
725	TLR7/8 Ligand, Râ€848, Inhibits IgE Synthesis by Acting Directly on B Lymphocytes. Scandinavian Journal of Immunology, 2008, 67, 560-568.	2.7	22
726	Pityriasis rubra pilaris exacerbation with topical use of imiquimod. International Journal of Dermatology, 2008, 47, 1076-1078.	1.0	24

	C	itation Report	
#	Article	IF	Citations
727	Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunology, 2008, 9, 39.	2.2	103
728	Toll-like receptors and autoimmunity. Autoimmunity Reviews, 2008, 7, 204-208.	5.8	81
729	Bovine viral diarrhea viruses modulate toll-like receptors, cytokines and co-stimulatory molecules genes expression in bovine peripheral blood monocytes. Comparative Immunology, Microbiology and Infectious Diseases, 2008, 31, 403-418.	1.6	55
730	Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. Clinical Immunology, 2008, 126, 148-154.	3.2	57
731	Human monocytes represent a competitive source of interferon- $\hat{l}\pm$ in peripheral blood. Clinical Immunology, 2008, 127, 252-264.	3.2	36
732	Small Molecule Modulators of Toll-like Receptors. Journal of Medicinal Chemistry, 2008, 51, 6621-66	26. 6.4	46
733	Nucleic Acid Recognition Receptors in Autoimmunity. Handbook of Experimental Pharmacology, 200 129-151.	8, , 1.8	33
734	Clinical investigations of Toll-like receptor agonists. Expert Opinion on Investigational Drugs, 2008, 17, 1051-1065.	4.1	71
735	Chapter 2 New Insights into the Roles of Dendritic Cells in Intestinal Immunity and Tolerance. International Review of Cell and Molecular Biology, 2008, 272, 33-105.	3.2	19
736	Toll-like receptors as therapeutic targets in cystic fibrosis. Expert Opinion on Therapeutic Targets, 2008, 12, 1481-1495.	3.4	28
737	Innate Immunity of Plants, Animals, and Humans. Nucleic Acids and Molecular Biology, 2008, , .	0.2	3
739	Hepatitis C and Innate Immunity: Recent Advances. Clinics in Liver Disease, 2008, 12, 675-692.	2.1	49
740	Biopharmaceutical Drug Design and Development. , 2008, , .		2
742	The Forward Genetic Dissection of Afferent Innate Immunity. Current Topics in Microbiology and Immunology, 2008, 321, 3-26.	1.1	23
743	Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod. Molecular Immunolo 2008, 45, 3238-3243.	ogy, 2.2	56
744	CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections. International Journal of Medical Microbiology, 2008, 298, 39-44.	3.6	33
745	The role of viral nucleic acid recognition in dendritic cells for innate and adaptive antiviral immunity. Immunobiology, 2008, 212, 701-714.	1.9	43
746	Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9. Immunobiology 2008, 213, 315-328.	, 1.9	61

#	Article	IF	CITATIONS
747	Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-κB activation. Nitric Oxide - Biology and Chemistry, 2008, 19, 138-145.	2.7	25
748	Toll-like receptor genes are differentially expressed at the sites of infection during the progression of Johne's disease in outbred sheep. Veterinary Immunology and Immunopathology, 2008, 124, 132-151.	1.2	47
749	CD14+ cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands. Veterinary Immunology and Immunopathology, 2008, 126, 273-282.	1.2	14
750	Antiviral responses of human Fallopian tube epithelial cells to toll-like receptor 3 agonist poly(I:C). Fertility and Sterility, 2008, 89, 1497-1506.	1.0	32
751	Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice. Biochemical and Biophysical Research Communications, 2008, 367, 242-248.	2.1	14
752	Induction of interferon system genes in Atlantic salmon by the imidazoquinoline S-27609, a ligand for Toll-like receptor 7. Fish and Shellfish Immunology, 2008, 24, 514-522.	3.6	48
753	Dendritic cells and cytokines in immune rejection of cancer. Cytokine and Growth Factor Reviews, 2008, 19, 93-107.	7.2	57
754	IFN regulation and functions in myeloid dendritic cells. Cytokine and Growth Factor Reviews, 2008, 19, 21-32.	7.2	31
755	Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine and Growth Factor Reviews, 2008, 19, 3-19.	7.2	298
756	Type I interferon as a stimulus for cross-priming. Cytokine and Growth Factor Reviews, 2008, 19, 33-40.	7.2	108
757	Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. Journal of General Virology, 2008, 89, 1-47.	2.9	1,364
758	Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7. International Immunology, 2008, 20, 1-9.	4.0	49
759	Tumour immunity: effector response to tumour and role of the microenvironment. Lancet, The, 2008, 371, 771-783.	13.7	476
760	Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts. International Journal of STD and AIDS, 2008, 19, 441-444.	1.1	29
761	Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. Journal of Experimental Medicine, 2008, 205, 2221-2234.	8.5	210
762	The Scaffold MyD88 Acts to Couple Protein Kinase Cϵ to Toll-like Receptors. Journal of Biological Chemistry, 2008, 283, 18591-18600.	3.4	46
763	Signalling of Toll-Like Receptors. Handbook of Experimental Pharmacology, 2008, , 21-50.	1.8	119
764	Analysis of the Neuroinflammatory Response to TLR7 Stimulation in the Brain: Comparison of Multiple TLR7 and/or TLR8 Agonists. Journal of Immunology, 2008, 180, 7604-7612.	0.8	73

#	Article	IF	CITATIONS
765	TLR7 Is Involved in Sequence-Specific Sensing of Single-Stranded RNAs in Human Macrophages. Journal of Immunology, 2008, 180, 2117-2124.	0.8	145
766	Imidazoquinoline Acts as Immune Adjuvant for Functional Alteration of Thymic Stromal Lymphopoietin-Mediated Allergic T Cell Response. Journal of Immunology, 2008, 181, 5340-5349.	0.8	23
767	Toll-Like Receptors (TLRs) and Their Ligands. Handbook of Experimental Pharmacology, 2008, , 1-20.	1.8	149
768	Toll-Like Receptor-Agonists in the Treatment of Skin Cancer: History, Current Developments and Future Prospects. Handbook of Experimental Pharmacology, 2008, , 201-220.	1.8	12
769	Viral Infection: A Potent Barrier to Transplantation Tolerance. Clinical and Developmental Immunology, 2008, 2008, 1-14.	3.3	13
770	Two distinct activation states of plasmacytoid dendritic cells induced by influenza virus and CpG 1826 oligonucleotide. Journal of Leukocyte Biology, 2008, 83, 610-620.	3.3	41
771	Toll Like Receptor - Potential Drug Targets in Infectious Disease. Infectious Disorders - Drug Targets, 2008, 8, 221-231.	0.8	6
772	The covalent modification and regulation of TLR8 in HEK-293 cells stimulated with imidazoquinoline agonists. Biochemical Journal, 2008, 409, 275-287.	3.7	18
773	TLR7 Agonist 852A Inhibition of Tumor Cell Proliferation Is Dependent on Plasmacytoid Dendritic Cells and Type I IFN. Journal of Interferon and Cytokine Research, 2008, 28, 253-263.	1.2	32
774	Mode of action and clinical use of imiquimod. Expert Review of Dermatology, 2008, 3, 151-159.	0.3	10
775	Determinants of Cytokine Induction by Small Interfering RNA in Human Peripheral Blood Mononuclear Cells. Journal of Interferon and Cytokine Research, 2008, 28, 221-233.	1.2	50
776	Measles Virus V Protein Is a Decoy Substrate for llºB Kinase l± and Prevents Toll-Like Receptor 7/9-Mediated Interferon Induction. Journal of Virology, 2008, 82, 12365-12373.	3.4	81
777	Evidence for Genes in Addition toTlr7in theYaaTranslocation Linked with Acceleration of Systemic Lupus Erythematosus. Journal of Immunology, 2008, 181, 1556-1562.	0.8	240
778	Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant. Journal of Immunology, 2008, 181, 776-784.	0.8	230
779	Inhibitors of TLR8 Reduce TNF Production from Human Rheumatoid Synovial Membrane Cultures. Journal of Immunology, 2008, 181, 8002-8009.	0.8	85
780	Negative Feedback Regulation of RIG-I-Mediated Antiviral Signaling by Interferon-Induced ISG15 Conjugation. Journal of Virology, 2008, 82, 1474-1483.	3.4	204
781	Physiological Role of Plasmacytoid Dendritic Cells and Their Potential Use in Cancer Immunity. Clinical and Developmental Immunology, 2008, 2008, 1-10.	3.3	26
782	Pharmacological Space. , 2008, , 521-532.		4

#	ARTICLE	IF	CITATIONS
783	Pharmacological Space. , 2008, , 395-408.		0
784	Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R123-R132.	1.8	32
785	Pan-Vertebrate Toll-Like Receptors During Evolution. Current Genomics, 2008, 9, 488-493.	1.6	69
786	Targeting Toll-Like Receptor Signaling Pathways for Design of Novel Immune Therapeutics. Current Drug Discovery Technologies, 2008, 5, 29-38.	1.2	21
787	Toll-Like Receptors and Airway Inflammation. Allergology International, 2008, 57, 33-37.	3.3	26
788	Antigen-Induced Immunomodulation in the Pathogenesis of Atherosclerosis. Clinical and Developmental Immunology, 2008, 2008, 1-15.	3.3	47
789	Deoxynucleic Acids from <i>Cryptococcus neoformans</i> Activate Myeloid Dendritic Cells via a TLR9-Dependent Pathway. Journal of Immunology, 2008, 180, 4067-4074.	0.8	103
790	Memory Th1 Cells Augment Tumor-Specific CTL following Transcutaneous Peptide Immunization. Cancer Research, 2008, 68, 3941-3949.	0.9	9
791	Innate and adaptive immunity in the human female reproductive tract: influence of the menstrual cycle and menopause on the mucosal immune system in the uterus. Reproductive Medicine and Assisted Reproductive Techniques Series, 2008, , 493-523.	0.1	3
792	The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy. Oncologist, 2008, 13, 859-875.	3.7	192
793	Role for MyD88 Signaling in Murine Gammaherpesvirus 68 Latency. Journal of Virology, 2008, 82, 3853-3863.	3.4	45
794	Lymphocytoid Choriomeningitis Virus Activates Plasmacytoid Dendritic Cells and Induces a Cytotoxic T-Cell Response via MyD88. Journal of Virology, 2008, 82, 196-206.	3.4	110
795	Dependency of Caspase-1 Activation Induced in Macrophages by <i>Listeria monocytogenes</i> on Cytolysin, Listeriolysin O, after Evasion from Phagosome into the Cytoplasm. Journal of Immunology, 2008, 180, 7859-7868.	0.8	52
796	TLR7-dependent and Fc ^î ³R-independent production of type I interferon in experimental mouse lupus. Journal of Experimental Medicine, 2008, 205, 2995-3006.	8.5	199
797	Role of the Innate Immune System in Autoimmune Inflammatory Demyelination. Current Medicinal Chemistry, 2008, 15, 1105-1115.	2.4	60
798	Imiquimod Upregulates the Opioid Growth Factor Receptor to Inhibit Cell Proliferation Independent of Immune Function. Experimental Biology and Medicine, 2008, 233, 968-979.	2.4	58
799	Using innate immunity to characterize the host response to microbial invasion in severe sepsis. Future Microbiology, 2008, 3, 177-189.	2.0	7
800	Immunology, Phenotype First: How Mutations Have Established New Principles and Pathways in Immunology. Current Topics in Microbiology and Immunology, 2008, , .	1.1	2

#	Article	IF	CITATIONS
801	Immune modulators with defined molecular targets: Cornerstone to optimize rational vaccine design. Hum Vaccin, 2008, 4, 13-22.	2.4	20
802	Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors. Biological Chemistry, 2008, 389, 469-85.	2.5	58
803	TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood, 2008, 112, 3508-3516.	1.4	75
804	EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-l–associated adult T-cell leukemia/lymphoma. Blood, 2008, 111, 3770-3777.	1.4	36
805	Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists. Blood, 2008, 112, 1750-1758.	1.4	158
807	The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors. World Allergy Organization Journal, 2008, 1, 96-102.	3.5	59
808	Effect of Resiquimod 0.01% Gel on Lesion Healing and Viral Shedding When Applied to Genital Herpes Lesions. Antimicrobial Agents and Chemotherapy, 2008, 52, 477-482.	3.2	39
809	Toll-Like Receptor System in the Human Endometrium. Current Immunology Reviews, 2008, 4, 168-175.	1.2	1
810	Prevention and Management of Hypertrophic Scars and Keloids After Burns in Children. Journal of Craniofacial Surgery, 2008, 19, 989-1006.	0.7	119
811	Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma. Journal of Immunotherapy, 2008, 31, 520-527.	2.4	145
812	Pustular skin diseases refl ect distinct innate defense pathways. Expert Review of Dermatology, 2008, 3, 465-475.	0.3	2
813	Expression of Toll-Like Receptors in Verruca and Molluscum Contagiosum. Journal of Korean Medical Science, 2008, 23, 307.	2.5	34
814	Bowen's disease – a review of newer treatment options. Therapeutics and Clinical Risk Management, 0, Volume 4, 1085-1095.	2.0	44
815	Toll-like Receptor Responses in Neonatal Dendritic Cells. , 2008, , 106-134.		0
816	Immunomodulating pharmaceuticals. , 2008, , 1331-1339.		0
817	The Role of Plasmacytoid Dendritic Cell-Derived IFNα in Antiviral Immunity. Critical Reviews in Immunology, 2008, 28, 61-94.	0.5	31
819	No Longer an Innocent Bystander: Epithelial Toll-Like Receptor Signaling in the Development of Mucosal Inflammation. Molecular Medicine, 2008, 14, 645-659.	4.4	160
820	A Review of Topical Imiquimod in the Management of Basal Cell Carcinoma, Actinic Keratoses, and Other Skin Lesions. Clinical Medicine Therapeutics, 2009, 1, CMT.S1969.	0.1	ο

#	Article	IF	CITATIONS
821	A Case of Erythroplasia of Queyrat Treated with Imiquimod 5% Cream and Excision. Annals of Dermatology, 2009, 21, 419.	0.9	21
822	The Heterogeneous Allelic Repertoire of Human Toll-Like Receptor (TLR) Genes. PLoS ONE, 2009, 4, e7803.	2.5	43
823	Maternal TLR signaling is required for prenatal asthma protection by the nonpathogenic microbe <i>Acinetobacter lwoffii</i> F78. Journal of Experimental Medicine, 2009, 206, 2869-2877.	8.5	301
824	Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proceedings of the United States of America, 2009, 106, 2764-2769.	7.1	100
825	Toll-like receptor signaling controls reactivation of KSHV from latency. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11725-11730.	7.1	105
826	Myeloid heme oxygenase–1 regulates innate immunity and autoimmunity by modulating IFN-β production. Journal of Experimental Medicine, 2009, 206, 1167-1179.	8.5	184
827	Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy. Journal of Immunology, 2009, 182, 5217-5224.	0.8	86
828	Comparison of Rat and Human Responses to Toll-Like Receptor 7 Activation. Journal of Interferon and Cytokine Research, 2009, 29, 113-126.	1.2	4
829	Tumoricidal Effects of Activated Macrophages in a Mouse Model of Chronic Lymphocytic Leukemia. Journal of Immunology, 2009, 182, 6771-6778.	0.8	30
830	Protein Kinase D1 Is Essential for MyD88-Dependent TLR Signaling Pathway. Journal of Immunology, 2009, 182, 6316-6327.	0.8	54
831	CD2 Distinguishes Two Subsets of Human Plasmacytoid Dendritic Cells with Distinct Phenotype and Functions. Journal of Immunology, 2009, 182, 6815-6823.	0.8	162
832	IL-1R1/MyD88 Signaling Is Critical for Elastase-Induced Lung Inflammation and Emphysema. Journal of Immunology, 2009, 183, 8195-8202.	0.8	99
833	Recognition of <i>Borrelia burgdorferi</i> , the Lyme Disease Spirochete, by TLR7 and TLR9 Induces a Type I IFN Response by Human Immune Cells. Journal of Immunology, 2009, 183, 5279-5292.	0.8	108
834	Immunostimulatory RNA Oligonucleotides Induce an Effective Antitumoral NK Cell Response through the TLR7. Journal of Immunology, 2009, 183, 6078-6086.	0.8	42
835	Modified Adenine (9-Benzyl-2-Butoxy-8-Hydroxyadenine) Redirects Th2-Mediated Murine Lung Inflammation by Triggering TLR7. Journal of Immunology, 2009, 182, 880-889.	0.8	24
836	Signaling through Toll-Like Receptors Induces Murine Gammaherpesvirus 68 Reactivation In Vivo. Journal of Virology, 2009, 83, 1474-1482.	3.4	47
837	Polyanionic Microbicides Modify Toll-Like Receptor-Mediated Cervicovaginal Immune Responses. Antimicrobial Agents and Chemotherapy, 2009, 53, 1490-1500.	3.2	41
838	Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma. Archives of Dermatology, 2009, 145, 1431-8.	1.4	230

#	Article	IF	CITATIONS
839	TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. Journal of Leukocyte Biology, 2009, 85, 673-683.	3.3	101
840	A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids. Current Immunology Reviews, 2009, 5, 69-88.	1.2	7
841	Modulation of Regulatory T Cells in Health and Disease: Role of Toll-Like Receptors. Inflammation and Allergy: Drug Targets, 2009, 8, 124-129.	1.8	30
842	It's all in the family: multiple Toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection. Future Neurology, 2009, 4, 201-208.	0.5	10
843	The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases. Current Molecular Medicine, 2009, 9, 365-374.	1.3	106
844	Vaccination with the ML0276 Antigen Reduces Local Inflammation but Not Bacterial Burden during Experimental <i>M ycobacterium leprae</i> Infection. Infection and Immunity, 2009, 77, 5623-5630.	2.2	23
845	Modulation of the allergic asthma transcriptome following resiquimod treatment. Physiological Genomics, 2009, 38, 303-318.	2.3	20
846	Lipopolysaccharide Induces IL-6 Production in Respiratory Syncytial Virus-Infected Airway Epithelial Cells Through the Toll-Like Receptor 4 Signaling Pathway. Pediatric Research, 2009, 65, 156-162.	2.3	43
847	First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony. PLoS Neglected Tropical Diseases, 2009, 3, e491.	3.0	65
848	Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response. Immunotherapy, 2009, 1, 883-895.	2.0	25
849	Novel therapeutics for the treatment of metastatic melanoma. Future Oncology, 2009, 5, 543-557.	2.4	20
850	Toll-Like Receptors in Multiple Sclerosis. Current Topics in Microbiology and Immunology, 2009, 336, 155-168.	1.1	42
851	The Role of Toll-Like Receptor Pathways in the Mechanism of Type 1 Diabetes. Current Molecular Medicine, 2009, 9, 52-68.	1.3	74
852	A study on the use of imiquimod for the treatment of genital molluscum contagiosum and genital warts in female patients. Indian Journal of Sexually Transmitted Diseases and AIDS, 2009, 30, 84.	0.6	10
854	Toll-like Receptors of the Ascidian Ciona intestinalis. Journal of Biological Chemistry, 2009, 284, 27336-27343.	3.4	90
855	Activation of interferon regulatory factor-3 via toll-like receptor 3 and immunomodulatory functions detected in A549 lung epithelial cells exposed to misplaced U1-snRNA. Nucleic Acids Research, 2009, 37, 5041-5056.	14.5	26
856	Alveolar Macrophages and Lung Dendritic Cells Sense RNA and Drive Mucosal IgA Responses. Journal of Immunology, 2009, 183, 3788-3799.	0.8	67
857	Fullâ€length sequence and expression analysis of a myeloid differentiation factor 88 (MyD88) in halfâ€smooth tongue sole <i>Cynoglossus semilaevis</i> . International Journal of Immunogenetics, 2009, 36, 173-182.	1.8	22

		CITATION R	EPORT	
#	Article		IF	Citations
858	The Therapeutic Vaccine: Is it Feasible?. Archives of Medical Research, 2009, 40, 493-49	98.	3.3	15
859	Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune reastrocytes and microglia. Clia, 2010, 58, 650-664.	esponses by	4.9	95
860	Quantitation of imidazo[1,2â€ <i>a</i>]quinoxaline derivatives in human and rat plasm Journal of Separation Science, 2009, 32, 1363-1373.	a using LC/ESlâ€MS.	2.5	11
861	Elimination of high-risk human papillomavirus type HPV16 infection by â€~Praneem' women with early cervical intraepithelial lesions. Journal of Cancer Research and Clinica 2009, 135, 1701-1709.	M polyherbal tablet in al Oncology,	2.5	73
862	Toll-like Receptor 7 Mitigates Lethal West Nile Encephalitis via Interleukin 23-Depende Infiltration and Homing. Immunity, 2009, 30, 242-253.	nt Immune Cell	14.3	180
863	Atypical p-ANCA in PSC and AIH: A Hint Toward a "leaky gut�. Clinical Reviews in Immunology, 2009, 36, 40-51.	Allergy and	6.5	71
864	Innate immunity in the pathogenesis of polytropic retrovirus infection in the central ne Immunologic Research, 2009, 43, 149-159.	rvous system.	2.9	17
865	Characterization of equine and other vertebrate TLR3, TLR7, and TLR8 genes. Immunog 529-539.	genetics, 2009, 61,	2.4	35
866	NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in th B16-F10 melanoma model. Cancer Immunology, Immunotherapy, 2009, 58, 575-587.	e disseminated	4.2	27
867	Novel multiâ€peptide vaccination in Hlaâ€A2+ hormone sensitive patients with bioche prostate cancer. Prostate, 2009, 69, 917-927.	mical relapse of	2.3	97
868	Toll-like receptors and dermatology. International Journal of Dermatology, 2009, 48, 55	58-570.	1.0	7
869	Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activation receptor 2 at the glomerular filtration barrier. Immunology, 2009, 128, e206-21.	ng Tollâ€ i ike	4.4	63
870	Translational Mini-Review Series on Immunology of Vascular Disease: Inflammation, inf Toll-like receptors in cardiovascular disease. Clinical and Experimental Immunology, 20	ections and 09, 156, 386-394.	2.6	36
871	A class C CpG tollâ€like receptor 9 agonist successfully induces robust interferonâ€alp plasmacytoid dendritic cells from patients chronically infected with hepatitis C. Journal Hepatitis, 2009, 16, 315-324.	ha production by of Viral	2.0	12
872	Imiquimod, a Toll-Like Receptor 7 Agonist, Inhibits Melanogenesis and Proliferation of I Melanocytes. Journal of Investigative Dermatology, 2009, 129, 243-246.	luman	0.7	43
873	Imiquimod Enhances IFN-γ Production and Effector Function of T Cells Infiltrating Hum Cell Carcinomas of the Skin. Journal of Investigative Dermatology, 2009, 129, 2676-26	an Squamous 85.	0.7	87
874	Regulatory molecules required for nucleotideâ€sensing Tollâ€like receptors. Immunolo 2009, 227, 32-43.	gical Reviews,	6.0	84
875	Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory disea Immunological Reviews, 2009, 227, 248-263.	ses.	6.0	231

#	Article	IF	CITATIONS
876	CATALYTIC RECEPTORS. British Journal of Pharmacology, 2009, 158, S169.	5.4	1
877	The Use of Imiquimod to Minimize the Surgical Defect When Excising Invasive Malignant Melanoma Surrounded by Extensive Melanoma In Situ, Lentiginous Type. Dermatologic Surgery, 2009, 35, 868-874.	0.8	10
878	2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2249-2251.	2.2	22
879	Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2211-2214.	2.2	48
880	Toll-like Receptor 7 Selective Synthetic Oligoribonucleotide Agonists: Synthesis and Structureâ"Activity Relationship Studies. Journal of Medicinal Chemistry, 2009, 52, 6871-6879.	6.4	26
881	Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates. Bioconjugate Chemistry, 2009, 20, 1194-1200.	3.6	95
882	Developmental Biology of the Innate Immune Response: Implications for Neonatal and Infant Vaccine Development. Pediatric Research, 2009, 65, 98R-105R.	2.3	101
883	Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. Cytokine, 2009, 46, 325-331.	3.2	23
884	Porcine Toll-like receptors: The front line of pathogen monitoring and possible implications for disease resistance. Developmental and Comparative Immunology, 2009, 33, 353-361.	2.3	85
885	Identification of an Atlantic salmon IFN multigene cluster encoding three IFN subtypes with very different expression properties. Developmental and Comparative Immunology, 2009, 33, 547-558.	2.3	140
886	Identification and characterization of TLR8 and MyD88 homologs in Atlantic salmon (Salmo salar). Developmental and Comparative Immunology, 2009, 33, 1011-1017.	2.3	102
887	Polymorphism distribution and structural conservation in RNA-sensing Toll-like receptors 3, 7, and 8 in pigs. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 267-274.	2.4	26
888	Antitumor Effects of an Imidazoquinoline in Renal Cell Carcinoma. Urology, 2009, 73, 1156-1162.	1.0	14
889	A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine, 2009, 27, 1354-1364.	3.8	49
890	Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination. Vaccine, 2009, 27, 4938-4946.	3.8	28
891	Microbial antigens mediate HLA-B27 diseases via TLRs. Journal of Autoimmunity, 2009, 32, 172-177.	6.5	38
892	Toll-like receptor 7 cooperates with IL-4 in activated B cells through antigen receptor or CD38 and induces class switch recombination and IgG1 production. Molecular Immunology, 2009, 46, 1278-1288.	2.2	30
893	Small-Molecule Interferon Inducers. Toward the Comprehension of the Molecular Determinants through Ligand-Based Approaches. Journal of Chemical Information and Modeling, 2009, 49, 1777-1786.	5.4	8

	CITATION	Report	
#	Article	IF	CITATIONS
894	The roles of TLRs, RLRs and NLRs in pathogen recognition. International Immunology, 2009, 21, 317-337.	4.0	1,355
895	Targeting Toll-Like Receptor for the Induction of Immune and Antitumor Responses. , 2009, , 301-318.		0
896	Toll-like receptor 7–induced naive human B-cell differentiation and immunoglobulin production. Journal of Allergy and Clinical Immunology, 2009, 123, 224-230.e4.	2.9	46
897	Oxidative stress augments toll-like receptor 8 mediated neutrophilic responses in healthy subjects. Respiratory Research, 2009, 10, 50.	3.6	37
898	Pattern Recognition by Toll-like Receptors. Advances in Experimental Medicine and Biology, 2009, 653, 15-34.	1.6	82
899	Immune Modulators with Defined Molecular Targets: Cornerstone to Optimize Rational Vaccine Design. Advances in Experimental Medicine and Biology, 2009, 655, 171-188.	1.6	8
900	Immune Interventions of Human Diseases through Toll-Like Receptors. Advances in Experimental Medicine and Biology, 2009, 655, 63-80.	1.6	10
901	Pathogen recognition in the innate immune response. Biochemical Journal, 2009, 420, 1-16.	3.7	497
904	Target Pattern Recognition in Innate Immunity. Advances in Experimental Medicine and Biology, 2009, , .	1.6	10
905	Interferon Response and Viral Evasion by Members of the Family Rhabdoviridae. Viruses, 2009, 1, 832-851.	3.3	46
906	Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. Journal of Immunotoxicology, 2009, 6, 257-265.	1.7	42
907	Emerging therapies for ionizing radiation-associated skin field carcinogenesis. Expert Opinion on Pharmacotherapy, 2009, 10, 813-821.	1.8	7
908	Ligand recognition by the tollâ€like receptor family. Animal Cells and Systems, 2009, 13, 1-8.	2.2	2
909	Toll-like receptor agonists in cancer therapy. Immunotherapy, 2009, 1, 949-964.	2.0	258
910	Imiquimod inhibits the differentiation but enhances the maturation of human monocyte-derived dendritic cells. International Immunopharmacology, 2009, 9, 412-417.	3.8	13
911	Differential Responses Between Monocytes and Monocyte-Derived Macrophages for Lipopolysaccharide Stimulation of Calves. Cellular and Molecular Immunology, 2009, 6, 223-229.	10.5	15
912	Polymorphisms of TLR7 and TLR8 associated with risk of asthma and asthma-related phenotypes in a southeastern Chinese Han population. Journal of Nanjing Medical University, 2009, 23, 25-32.	0.1	5
913	Pharmacotherapy of actinic keratosis. Expert Opinion on Pharmacotherapy, 2009, 10, 3015-3031.	1.8	26

#	Article	IF	CITATIONS
914	Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells. Translational Oncology, 2009, 2, 73-IN5.	3.7	51
915	Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses. Clinical Microbiology Reviews, 2009, 22, 240-273.	13.6	2,488
916	The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections. Current Drug Metabolism, 2009, 10, 55-67.	1.2	46
917	Pathogen recognition by innate immunity and its signaling. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2009, 85, 143-156.	3.8	191
918	Hematopoietic cell–derived interferon controls viral replication and virus-induced disease. Blood, 2009, 113, 1045-1052.	1.4	48
919	Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood, 2009, 113, 377-388.	1.4	126
920	Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations. Current Drug Targets, 2009, 10, 60-70.	2.1	63
921	The Potential of Polyphosphazenes for Delivery of Vaccine Antigens and Immunotherapeutic Agents. Current Drug Delivery, 2010, 7, 13-20.	1.6	48
922	Delivery of Immunostimulatory RNA Oligonucleotides by Gelatin Nanoparticles Triggers an Efficient Antitumoral Response. Journal of Immunotherapy, 2010, 33, 935-944.	2.4	26
923	Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy. Future Microbiology, 2010, 5, 15-22.	2.0	10
924	Toll-Like Receptor Agonists. Cancer Journal (Sudbury, Mass), 2010, 16, 382-391.	2.0	144
925	Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients. International Journal of Immunopathology and Pharmacology, 2010, 23, 387-396.	2.1	20
926	Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood, 2010, 115, 1949-1957.	1.4	108
927	Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood, 2010, 116, 4542-4545.	1.4	45
928	Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunology, Immunotherapy, 2010, 59, 1877-1884.	4.2	61
929	Exhaustive exercise reduces TNF-α and IFN-α production in response to R-848 via toll-like receptor 7 in mice. European Journal of Applied Physiology, 2010, 110, 797-803.	2.5	16
930	Regulation of virus-triggered type I interferon signaling by cellular and viral proteins. Frontiers in Biology, 2010, 5, 12-31.	0.7	6
931	TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants. Current Infectious Disease Reports, 2010, 12, 4-12.	3.0	49

#	Article	IF	Citations
932	Polysaccharides from the root of Angelica sinensis promotes hematopoiesis and thrombopoiesis through the PI3K/AKT pathway. BMC Complementary and Alternative Medicine, 2010, 10, 79.	3.7	79
933	Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. European Journal of Pharmaceutical Sciences, 2010, 39, 23-29.	4.0	24
934	Influenza A virus replication is inhibited in IFN-λ2 and IFN-λ3 transfected or stimulated cells. Antiviral Research, 2010, 88, 329-333.	4.1	18
935	A human microsatellite DNA-mimicking oligodeoxynucleotide with CCT repeats negatively regulates TLR7/9-mediated innate immune responses via selected TLR pathways. Clinical Immunology, 2010, 134, 262-276.	3.2	19
936	Condensation of 5-aminobenzimidazoles with β-ketoester. Arabian Journal of Chemistry, 2010, 3, 9-12.	4.9	1
937	Intracellular Toll-like Receptors. Immunity, 2010, 32, 305-315.	14.3	1,173
938	Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity, 2010, 33, 492-503.	14.3	1,522
939	Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. Journal of Biomedical Science, 2010, 17, 32.	7.0	40
940	Recognition of viral nucleic acids in innate immunity. Reviews in Medical Virology, 2010, 20, 4-22.	8.3	265
941	Effect of 3M-003, an imidazoquinoline, on phagocyte candidacidal activity directly and via induction of peripheral blood mononuclear cell cytokines. FEMS Immunology and Medical Microbiology, 2010, 59, 81-89.	2.7	2
942	Chemokine expression by human keratinocyte cell lines after activation of Tollâ€like receptors. Experimental Dermatology, 2010, 19, e314-6.	2.9	51
943	The innate immune system in the intestine. Microbiology and Immunology, 2010, 54, 645-657.	1.4	29
944	Imiquimod simultaneously induces autophagy and apoptosis in human basal cell carcinoma cells. British Journal of Dermatology, 2010, 163, 310-320.	1.5	49
945	The dendritic cell mannose receptor mediates allergen internalization and maturation involving notch 1 signalling. Clinical and Experimental Immunology, 2010, 162, 251-261.	2.6	21
946	Toll-like receptor 7 mediates pruritus. Nature Neuroscience, 2010, 13, 1460-1462.	14.8	217
947	Pharmaceutical sciences in 2020. Nature Reviews Drug Discovery, 2010, 9, 99-100.	46.4	16
948	Targeting Toll-like receptors: emerging therapeutics?. Nature Reviews Drug Discovery, 2010, 9, 293-307.	46.4	721
949	Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Annals of the New York Academy of Sciences, 2010, 1183, 89- <u>103.</u>	3.8	169

#	Article	IF	CITATIONS
950	TLR8 deficiency leads to autoimmunity in mice. Journal of Clinical Investigation, 2010, 120, 3651-62.	8.2	181
951	5.1 Imiquimod. , 2010, , .		0
952	Cellular and Molecular Mechanisms Underlying the Strong Neonatal IL-12 Response of Lamb Mesenteric Lymph Node Cells to R-848. PLoS ONE, 2010, 5, e13705.	2.5	17
953	Mutations in Classical Swine Fever Virus NS4B Affect Virulence in Swine. Journal of Virology, 2010, 84, 1536-1549.	3.4	32
954	Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075. Journal of Immunology, 2010, 185, 738-747.	0.8	70
955	TLR3 and Rig-Like Receptor on Myeloid Dendritic Cells and Rig-Like Receptor on Human NK Cells Are Both Mandatory for Production of IFN-Î ³ in Response to Double-Stranded RNA. Journal of Immunology, 2010, 185, 2080-2088.	0.8	88
956	HIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7. Journal of Virology, 2010, 84, 5627-5636.	3.4	129
957	Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells. Journal of Leukocyte Biology, 2009, 87, 117-125.	3.3	37
958	B-cell receptor for antigen modulates B-cell responses to complex TLR9 agonists and antagonists: implications for systemic lupus erythematosus. Lupus, 2010, 19, 1290-1301.	1.6	8
959	MyD88 Signaling Is Indispensable for Primary Influenza A Virus Infection but Dispensable for Secondary Infection. Journal of Virology, 2010, 84, 12713-12722.	3.4	82
960	Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. Journal of Experimental Medicine, 2010, 207, 2921-2930.	8.5	292
961	Reciprocal Regulation of Activating and Inhibitory Fc ^ĵ 3 Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy. Clinical Cancer Research, 2010, 16, 2065-2075.	7.0	35
962	Stimulator of IFN Gene Is Critical for Induction of IFN-β during <i>Chlamydia muridarum</i> Infection. Journal of Immunology, 2010, 184, 2551-2560.	0.8	103
963	Toll-like receptor 7 and 8 agonists. Progress in Respiratory Research, 2010, , 87-93.	0.1	0
964	Contribution of TLR7 and TLR9 signaling to the susceptibility of MyD88-deficient mice to myocarditis. Autoimmunity, 2010, 43, 275-287.	2.6	35
965	Efficacy and Tolerability of Imiquimod 5% Cream to Treat Periocular Basal Cell Carcinomas. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 373-379.	1.4	26
966	The Capacity To Induce Cross-Presentation Dictates the Success of a TLR7 Agonist-Conjugate Vaccine for Eliciting Cellular Immunity. Journal of Immunology, 2010, 185, 4602-4608.	0.8	58
967	Induction of Homologous Rather than Heterologous Antigen-Specific CD4 T Cell Responses Is Critical for Functional CD8 T Cell Responses in Mice Transgenic for a Foreign Antigen. Journal of Immunology, 2010, 185, 4590-4601.	0.8	8

#	Article	IF	CITATIONS
968	Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets. Expert Review of Cardiovascular Therapy, 2010, 8, 1619-1635.	1.5	35
969	Plasmacytoid dendritic cells in HIV infection: striking a delicate balance. Journal of Leukocyte Biology, 2010, 87, 609-620.	3.3	116
970	Rabies Virus Infection Induces Type I Interferon Production in an IPS-1 Dependent Manner While Dendritic Cell Activation Relies on IFNAR Signaling. PLoS Pathogens, 2010, 6, e1001016.	4.7	93
971	Immune Evasion by Yersinia enterocolitica: Differential Targeting of Dendritic Cell Subpopulations In Vivo. PLoS Pathogens, 2010, 6, e1001212.	4.7	52
972	Pattern Recognition via the Toll-Like Receptor System in the Human Female Genital Tract. Mediators of Inflammation, 2010, 2010, 1-12.	3.0	113
973	Adjuvant Activity on Murine and Human Macrophages. Methods in Molecular Biology, 2010, 626, 117-130.	0.9	1
974	Toll-Like Receptors: Role in Dermatological Disease. Mediators of Inflammation, 2010, 2010, 1-16.	3.0	85
975	Targeted Activation of RNA Helicase Retinoic Acid–Inducible Gene-I Induces Proimmunogenic Apoptosis of Human Ovarian Cancer Cells. Cancer Research, 2010, 70, 5293-5304.	0.9	77
976	The Possible Use of Terpene Compounds in DC Immunotherapy against Cancer. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2010, 4, 69-74.	0.6	2
977	Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs. Current Medicinal Chemistry, 2010, 17, 1899-1914.	2.4	9
978	Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients. Cancer Biology and Therapy, 2010, 10, 1081-1087.	3.4	117
979	Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. Journal of Experimental Medicine, 2010, 207, 721-730.	8.5	100
980	Toll-like Receptor 7–triggered Immune Response in the Lung Mediates Acute and Long-Lasting Suppression of Experimental Asthma. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1207-1216.	5.6	98
981	Structureâ^'Activity Relationships in Human Toll-Like Receptor 7-Active Imidazoquinoline Analogues. Journal of Medicinal Chemistry, 2010, 53, 4450-4465.	6.4	131
982	Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-12-1b treatment in relapsing remitting MS. Pharmacogenomics, 2010, 11, 147-161.	1.3	42
983	Dendritic cells: Bridging innate and adaptive immunity in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2010, 125, 50-59.	2.9	87
984	The Role of Toll-Like Receptors in Host Defenses and Their Relevance to Dermatologic Diseases. American Journal of Clinical Dermatology, 2010, 11, 1-10.	6.7	47
985	Synthesis and Biological Evaluation of 8-Oxoadenine Derivatives as Toll-like Receptor 7 Agonists Introducing the Antedrug Concept. Journal of Medicinal Chemistry, 2010, 53, 2964-2972.	6.4	49

#	Article	IF	CITATIONS
986	Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design. Expert Review of Vaccines, 2010, 9, 1315-1324.	4.4	44
987	A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Molecular Immunology, 2010, 47, 1083-1090.	2.2	93
988	The fight between the teleost fish immune response and aquatic viruses. Molecular Immunology, 2010, 47, 2525-2536.	2.2	126
989	Alternating 2′-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology, 2010, 215, 559-569.	1.9	82
990	Antitumor Activity of Polyuridylic Acid in Human Soft Tissue and Bone Sarcomas. Journal of Surgical Research, 2010, 164, e107-e114.	1.6	5
991	Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. Journal of Autoimmunity, 2010, 34, 339-348.	6.5	189
992	Evidence that Yaa-induced loss of marginal zone B cells is a result of dendritic cell-mediated enhanced activation. Journal of Autoimmunity, 2010, 34, 349-355.	6.5	18
993	Identification, characterization and genetic mapping of TLR7, TLR8a1 and TLR8a2 genes in rainbow trout (Oncorhynchus mykiss). Developmental and Comparative Immunology, 2010, 34, 219-233.	2.3	95
994	Co-stimulation with TLR7/8 and TLR9 agonists induce down-regulation of innate immune responses in sheep blood mononuclear and B cells. Developmental and Comparative Immunology, 2010, 34, 572-578.	2.3	20
995	ISG15 and immune diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 485-496.	3.8	141
997	Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection. Veterinary Immunology and Immunopathology, 2010, 134, 75-81.	1.2	10
998	Characterization of the cytokine and maturation responses of pure populations of porcine plasmacytoid dendritic cells to porcine viruses and toll-like receptor agonists. Veterinary Immunology and Immunopathology, 2010, 135, 20-33.	1.2	41
999	Emerging drugs for actinic keratosis. Expert Opinion on Emerging Drugs, 2010, 15, 545-555.	2.4	19
1000	Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management. Expert Opinion on Pharmacotherapy, 2010, 11, 557-569.	1.8	24
1001	An Intranasally Delivered Toll-Like Receptor 7 Agonist Elicits Robust Systemic and Mucosal Responses to Norwalk Virus-Like Particles. Vaccine Journal, 2010, 17, 1850-1858.	3.1	45
1002	Vaccine Adjuvants. Methods in Molecular Biology, 2010, , .	0.9	4
1003	Transcutaneous Immunization: An Overview of Advantages, Disease Targets, Vaccines, and Delivery Technologies. Annual Review of Chemical and Biomolecular Engineering, 2010, 1, 175-201.	6.8	61
1004	The role of Toll-like receptors in renal diseases. Nature Reviews Nephrology, 2010, 6, 224-235.	9.6	168

		CITATION R	EPORT	
#	Article		IF	CITATIONS
1005	Prokaryotic and Eukaryotic Heat Shock Proteins in Infectious Disease. Heat Shock Prote	ins, 2010, , .	0.2	7
1006	Treatment with a Toll-like receptor inhibitory GpG oligonucleotide delays and attenuates nephritis in NZB/W mice. Autoimmunity, 2010, 43, 140-155.	lupus	2.6	28
1007	Immunomodulators: use in combined therapy against leishmaniasis. Expert Review of Ar Therapy, 2010, 8, 739-742.	iti-Infective	4.4	29
1008	Dendritic Cells in Systemic Lupus Erythematosus. International Reviews of Immunology, 184-209.	2010, 29,	3.3	26
1009	Synthesis and Characterization of PEGylated Toll Like Receptor 7 Ligands. Bioconjugate 2011, 22, 445-454.	Chemistry,	3.6	30
1010	Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines. Jo Immunology, 2011, 186, 4794-4804.	urnal of	0.8	516
1011	Innate Cellular Responses to the Periodontal Biofilm. Frontiers of Oral Biology, 2012, 15	, 41-55.	1.5	79
1012	Innate Immunity and Leishmania Vaccination Strategies. Dermatologic Clinics, 2011, 29	, 89-102.	1.7	25
1013	NF-κB in immunobiology. Cell Research, 2011, 21, 223-244.		12.0	802
1014	Novel adjuvants and delivery systems for enhancing immune responses induced by imm Review of Vaccines, 2011, 10, 227-251.	unogens. Expert	4.4	56
1015	Toll-like receptors in health and disease in the brain: mechanisms and therapeutic poten Science, 2011, 121, 367-387.	tial. Clinical	4.3	426
1016	Modulation of Endosomal Toll-Like Receptor-Mediated Immune Responses by Synthetic Oligonucleotides. Advances in Polymer Science, 2011, , 61-93.		0.8	8
1017	TLR-7 and -8 agonists as vaccine adjuvants. Expert Review of Vaccines, 2011, 10, 405-40)7.	4.4	40
1018	Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon–mediated immunity. Nature Immunology, 2011, 12, 733-741.		14.5	76
1019	The discovery of a novel prototype small molecule TLR7 agonist for the treatment of he infection. MedChemComm, 2011, 2, 185-189.	oatitis C virus	3.4	17
1020	Toll-Like Receptors as Interferon-Regulated Genes and Their Role in Disease. Journal of Ir Cytokine Research, 2011, 31, 13-25.	terferon and	1.2	43
1021	TLR7 and TLR9 Trigger Distinct Neuroinflammatory Responses in the CNS. American Jou Pathology, 2011, 179, 783-794.	rnal of	3.8	52
1022	Toll-like receptors and their role in animal reproduction. Animal Reproduction Science, 2	011, 125, 1-12.	1.5	68

#	Article	IF	CITATIONS
1023	TLR7/9-mediated monocytosis and maturation of Gr-1hi inflammatory monocytes towards Gr-1lo resting monocytes implicated in murine lupus. Journal of Autoimmunity, 2011, 37, 171-179.	6.5	20
1024	Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment. Immunobiology, 2011, 216, 12-23.	1.9	15
1025	TLRs, NLRs and RLRs: Innate sensors and their impact on allergic diseases – A current view. Immunology Letters, 2011, 139, 14-24.	2.5	24
1026	Innate immunity and cancer therapy. International Immunopharmacology, 2011, 11, 350-357.	3.8	23
1027	The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases. International Immunopharmacology, 2011, 11, 1422-1432.	3.8	98
1028	Association analysis of Toll-like receptor 7 gene polymorphisms and Behçet's disease in Japanese patients. Human Immunology, 2011, 72, 269-272.	2.4	11
1029	Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Human Immunology, 2011, 72, 1095-1116.	2.4	98
1030	Toll-like receptors on the fork roads between innate and adaptive immunity. Human Immunology, 2011, 72, 1188-1193.	2.4	50
1031	Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine, 2011, 29, 5434-5442.	3.8	138
1032	Host-response patterns of intramammary infections in dairy cows. Veterinary Immunology and Immunopathology, 2011, 144, 270-289.	1.2	274
1033	Toll-like receptors as targets for immune disorders. Trends in Pharmacological Sciences, 2011, 32, 435-442.	8.7	65
1034	Emerging Treatments and Signaling Pathway Inhibitors. Seminars in Cutaneous Medicine and Surgery, 2011, 30, S14-S18.	1.6	20
1035	Targeted antigen delivery and activation of dendritic cells in vivo: Steps towards cost effective vaccines. Seminars in Immunology, 2011, 23, 12-20.	5.6	118
1036	Toll-like receptors: key players in antiviral immunity. Current Opinion in Virology, 2011, 1, 447-454.	5.4	134
1037	Silencing or Stimulation? siRNA Delivery and the Immune System. Annual Review of Chemical and Biomolecular Engineering, 2011, 2, 77-96.	6.8	161
1040	Toll-Like Receptors and Myocardial Inflammation. International Journal of Inflammation, 2011, 2011, 1-21.	1.5	60
1041	Toll-like Receptors and Innate Immunity. Journal of Bacteriology and Virology, 2011, 41, 225.	0.1	67
1042	Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratoses. Clinical, Cosmetic and Investigational Dermatology, 2011, 4, 35.	1.8	13

#	Article	IF	CITATIONS
1043	Fungal Surface and Innate Immune Recognition of Filamentous Fungi. Frontiers in Microbiology, 2011, 2, 248.	3.5	33
1044	Toll-Like Receptors in SLE. , 2011, , 293-306.		0
1045	Loss of NK Stimulatory Capacity by Plasmacytoid and Monocyte-Derived DC but Not Myeloid DC in HIV-1 Infected Patients. PLoS ONE, 2011, 6, e17525.	2.5	16
1046	Comparative Analysis of Species-Specific Ligand Recognition in Toll-Like Receptor 8 Signaling: A Hypothesis. PLoS ONE, 2011, 6, e25118.	2.5	52
1047	Gamma-Irradiated Influenza Virus Uniquely Induces IFN-I Mediated Lymphocyte Activation Independent of the TLR7/MyD88 Pathway. PLoS ONE, 2011, 6, e25765.	2.5	16
1048	Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Research, 2011, 21, 235-243.	1.2	35
1049	Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. Melanoma Research, 2011, 21, 66-75.	1.2	22
1051	Laser immunotherapy for treatment of patients with advanced breast cancer and melanoma. Journal of Physics: Conference Series, 2011, 276, 012023.	0.4	0
1052	Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells. Blood, 2011, 117, 5683-5691.	1.4	33
1053	Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood, 2011, 118, 2322-2332.	1.4	96
1054	Immunohistochemical analysis of immune response in breast cancer and melanoma patients after laser immunotherapy. , 2011, , .		1
1055	Long-term remission of recurrent herpes labialis following topical imiquimod application on distant healthy skin: a clinical and immunological study. Antiviral Therapy, 2011, 16, 863-869.	1.0	4
1056	Pharmacokinetics and toxicity of intravesical TMXâ€101: a preclinical study in pigs. BJU International, 2011, 108, 1210-1214.	2.5	7
1057	Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Alimentary Pharmacology and Therapeutics, 2011, 34, 443-453.	3.7	49
1058	Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream. Clinical and Experimental Dermatology, 2011, 36, 509-511.	1.3	16
1059	Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation. Immunology, 2011, 134, 257-269.	4.4	43
1060	Guide to Receptors and Channels (GRAC), 5th edition. British Journal of Pharmacology, 2011, 164, S1-324.	5.4	827
1061	Consultants. British Journal of Pharmacology, 2011, 164, S3-S3.	5.4	10

		CITATION RE	PORT	
#	ARTICLE G PROTEIN OUPLED RECEPTORS, British Journal of Pharmacology, 2011, 164, S5,		IF 5.4	Citations
1063	LIGANDâ€GATED ION CHANNELS. British Journal of Pharmacology, 2011, 164, S115.		5.4	13
1064	ION CHANNELS. British Journal of Pharmacology, 2011, 164, S137.		5.4	22
1065	NUCLEAR RECEPTORS. British Journal of Pharmacology, 2011, 164, S175-S188.		5.4	0
1066	CATALYTIC RECEPTORS. British Journal of Pharmacology, 2011, 164, S189-S212.		5.4	1
1067	TRANSPORTERS. British Journal of Pharmacology, 2011, 164, S213.		5.4	2
1069	Immunogenomics and systems biology of vaccines. Immunological Reviews, 2011, 239	ə, 197-208.	6.0	65
1070	Use of defined TLR ligands as adjuvants within human vaccines. Immunological Review 178-196.	s, 2011, 239,	6.0	356
1071	Recognition of nucleic acids by patternâ€recognition receptors and its relevance in au Immunological Reviews, 2011, 243, 61-73.	coimmunity.	6.0	181
1072	RIGâ€lâ€like receptors: cytoplasmic sensors for nonâ€self RNA. Immunological Review	s, 2011, 243, 91-98.	6.0	288
1073	UV Exposure Boosts Transcutaneous Immunization and Improves Tumor Immunity: Cy Priming through the Skin. Journal of Investigative Dermatology, 2011, 131, 211-219.	totoxic T-Cell	0.7	24
1074	TLR ligands induce synergistic interferon-β and interferon-λ1 gene expression in huma monocyte-derived dendritic cells. Molecular Immunology, 2011, 48, 505-515.	n	2.2	46
1075	Zoonotic Brazilian Vaccinia virus: From field to therapy. Antiviral Research, 2011, 92, 1	50-163.	4.1	71
1076	Innate immunity and adjuvants. Philosophical Transactions of the Royal Society B: Biol 2011, 366, 2748-2755.	ogical Sciences,	4.0	125
1077	Nucleic Acid Recognition by the Innate Immune System. Annual Review of Immunology	v, 2011, 29, 185-214.	21.8	493
1078	Monocyte and macrophage heterogeneity and Toll-like receptors in the lung. Cell and ⁻ 2011, 343, 97-106.	īissue Research,	2.9	72
1080	Innate immunity and the pathogenesis of type 1 diabetes. Seminars in Immunopatholo	gy, 2011, 33, 57-66.	6.1	40
1081	Stimulation of TLR7 prior to polymicrobial sepsis improves the immune control of the i response in adult mice. Inflammation Research, 2011, 60, 271-279.	nflammatory	4.0	11

		ITATION REPC	DRT	
#	Article	I	F	CITATIONS
1082	Granulin Is a Soluble Cofactor for Toll-like Receptor 9 Signaling. Immunity, 2011, 34, 505-513.	1	.4.3	160
1083	Innate Immune Sensing of Retroviral Infection via Toll-like Receptor 7 Occurs upon Viral Entry. Immunity, 2011, 35, 135-145.		-4.3	84
1084	Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists. Bioorganic ar Medicinal Chemistry, 2011, 19, 3801-3811.	າd _ອ	3.0	42
1085	Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cel immunity. Age, 2011, 33, 363-376.	3	3.0	129
1086	Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. Journal of Translational Medicine, 2011, 9, 151.	4	ł.4	36
1087	Systems biology applied to vaccine and immunotherapy development. BMC Systems Biology, 2011,	5, 146. a	8.0	26
1088	An alternate route to the synthesis of imidazo[1,2â€a]quinolines using l ₂ â€Nal reagen Journal of Heterocyclic Chemistry, 2011, 48, 1202-1205.	t. 2	2.6	5
1089	5′â€₽hosphate oligodeoxynucleotides enhance the phosphodiesterâ€CpG DNAâ€induced inflam response in macrophages. European Journal of Immunology, 2011, 41, 425-436.	matory 2	2.9	2
1090	Treatment with the TLR7 agonist R848 induces regulatory T ellâ€mediated suppression of establi asthma symptoms. European Journal of Immunology, 2011, 41, 1992-1999.	shed 2	2.9	49
1091	Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. European Journal of Immunology, 2011, 41, 1334-1343.	2	2.9	48
1092	Temporal Dynamics of Host Molecular Responses Differentiate Symptomatic and Asymptomatic Influenza A Infection. PLoS Genetics, 2011, 7, e1002234.	ą	8.5	173
1093	A Point Mutation in the Amino Terminus of TLR7 Abolishes Signaling without Affecting Ligand Bindin Journal of Immunology, 2011, 186, 4213-4222.	ng. G).8	25
1094	Antigen-Specific T-Cell Responses to a Recombinant Fowlpox Virus Are Dependent on MyD88 and Interleukin-18 and Independent of Toll-Like Receptor 7 (TLR7)- and TLR9-Mediated Innate Immune Recognition. Journal of Virology, 2011, 85, 3385-3396.	3	3.4	12
1095	Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidit T-Cell Responses against Poorly Immunogenic Tumors. Cancer Research, 2011, 71, 3214-3224.	y o).9	63
1096	Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinom British Journal of Ophthalmology, 2011, 95, 1393-1396.	a. g	3.9	35
1097	Different Pathological Roles of Toll-Like Receptor 9 on Mucosal B Cells and Dendritic Cells in Murine IgA Nephropathy. Clinical and Developmental Immunology, 2011, 2011, 1-10.	3	3.3	26
1098	Pharmacotherapy of Basal Cell Carcinoma, Anogenital Warts, and Actinic Keratoses: Focus on Topic Imiquimod. Clinical Medicine Reviews in Oncology, 2011, 3, 13-27.	al c).0	0
1099	Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance. Cancer Research, 2011, 71, 5123-5133.).9	73

#	Article	IF	CITATIONS
1100	1-Isobutyl-4-methoxy-1H-imidazo[4,5-c]quinoline. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o2331-o2331.	0.2	0
1101	Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3371-3376.	7.1	80
1102	Immune response in the duck intestine following infection with low-pathogenic avian influenza viruses or stimulation with a Toll-like receptor 7 agonist administered orally. Journal of General Virology, 2011, 92, 534-543.	2.9	32
1103	Lentigo Maligna. Archives of Dermatology, 2011, 147, 1211.	1.4	12
1104	IFN-α produced by human plasmacytoid dendritic cells enhances T cell-dependent naÃ⁻ve B cell differentiation. Journal of Leukocyte Biology, 2011, 89, 811-821.	3.3	38
1105	Conventional Dendritic Cells Mount a Type I IFN Response against <i>Candida</i> spp. Requiring Novel Phagosomal TLR7-Mediated IFN-1² Signaling. Journal of Immunology, 2011, 186, 3104-3112.	0.8	104
1106	A Novel Aminosaccharide Compound Blocks Immune Responses by Toll-like Receptors and Nucleotide-binding Domain, Leucine-rich Repeat Proteins. Journal of Biological Chemistry, 2011, 286, 5727-5735.	3.4	10
1107	Secretory Leukocyte Protease Inhibitor Plays an Important Role in the Regulation of Allergic Asthma in Mice. Journal of Immunology, 2011, 186, 4433-4442.	0.8	38
1108	Characterization of Sparstolonin B, a Chinese Herb-derived Compound, as a Selective Toll-like Receptor Antagonist with Potent Anti-inflammatory Properties. Journal of Biological Chemistry, 2011, 286, 26470-26479.	3.4	111
1109	The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Review of Clinical Pharmacology, 2011, 4, 275-289.	3.1	163
1110	Mast Cells as Sensors of Cell Injury through IL-33 Recognition. Journal of Immunology, 2011, 186, 2523-2528.	0.8	182
1111	Pathological Role of Tonsillar B Cells in IgA Nephropathy. Clinical and Developmental Immunology, 2011, 2011, 1-8.	3.3	34
1112	CD200 Receptor Controls Sex-Specific TLR7 Responses to Viral Infection. PLoS Pathogens, 2012, 8, e1002710.	4.7	81
1113	Vaccine Development Against Leishmania donovani. Frontiers in Immunology, 2012, 3, 99.	4.8	45
1114	Immunomodulation by Imiquimod in Patients with High-Risk Primary Melanoma. Journal of Investigative Dermatology, 2012, 132, 163-169.	0.7	44
1115	Characteristics of Plasmacytoid Dendritic Cell and CD4+ T Cell in HIV Elite Controllers. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	5
1116	Glucocorticoids inhibit dendritic cell maturation induced by Toll-like receptor 7 and Toll-like receptor 8. Journal of Leukocyte Biology, 2011, 91, 105-117.	3.3	24
1117	The Toll-Like Receptor 3-Mediated Antiviral Response Is Important for Protection against Poliovirus Infection in Poliovirus Receptor Transgenic Mice. Journal of Virology, 2012, 86, 185-194.	3.4	88

#	Article		CITATIONS
1118	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncolmmunology, 2012, 1, 894-907.	4.6	194
1119	Recognition of Nucleic Acid Ligands by Toll-Like Receptors 7/8: Importance of Chemical Modification. Current Medicinal Chemistry, 2012, 19, 1365-1377.	2.4	11
1120	Innate Immunity: Ignored for Decades, but Not Forgotten. Journal of Investigative Dermatology, 2012, 132, 882-886.	0.7	29
1121	Plasmacytoid dendritic cells control T-cell response to chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3012-3017.	7.1	185
1122	Cellular and Molecular Mechanisms of TSLP Function in Human Allergic Disorders - TSLP Programs the "Th2 code―in Dendritic Cells. Allergology International, 2012, 61, 35-43.	3.3	76
1123	The role of innate immune signals in antitumor immunity. Oncolmmunology, 2012, 1, 189-194.	4.6	24
1124	RNA mediated toll-like receptor stimulation in health and disease. RNA Biology, 2012, 9, 828-842.	3.1	90
1125	A model for cancer-suppressive inflammation. Oncolmmunology, 2012, 1, 1146-1155.	4.6	64
1126	Extracellularly Delivered Single-Stranded Viral RNA Causes Neurodegeneration Dependent on TLR7. Journal of Immunology, 2012, 189, 1448-1458.	0.8	50
1127	Pharmacokinetics of Daily Selfâ€Application of Imiquimod 3.75% Cream in Adult Patients With External Anogenital Warts. Journal of Clinical Pharmacology, 2012, 52, 828-836.	2.0	6
1128	Atlantic Salmon Type I IFN Subtypes Show Differences in Antiviral Activity and Cell-Dependent Expression: Evidence for High IFNb/IFNc–Producing Cells in Fish Lymphoid Tissues. Journal of Immunology, 2012, 189, 5912-5923.	0.8	100
1129	Trial Watch. Oncolmmunology, 2012, 1, 699-739.	4.6	184
1130	Toll or Interleukin-1 Receptor (TIR) Domain-containing Adaptor Inducing Interferon-Î ² (TRIF)-mediated Caspase-11 Protease Production Integrates Toll-like Receptor 4 (TLR4) Protein- and NIrp3 Inflammasome-mediated Host Defense against Enteropathogens. Journal of Biological Chemistry, 2012, 287, 34474-34483.	3.4	211
1131	A GpC-Rich Oligonucleotide Acts on Plasmacytoid Dendritic Cells To Promote Immune Suppression. Journal of Immunology, 2012, 189, 2283-2289.	0.8	22
1132	Mechanism of Action of Inhibition of Allergic Immune Responses by a Novel Antedrug TLR7 Agonist. Journal of Immunology, 2012, 189, 5194-5205.	0.8	16
1133	NO Is a Macrophage Autonomous Modifier of the Cytokine Response to Streptococcal Single-Stranded RNA. Journal of Immunology, 2012, 188, 774-780.	0.8	16
1134	The 2′- <i>O</i> -methylation status of a single guanosine controls transfer RNA–mediated Toll-like receptor 7 activation or inhibition. Journal of Experimental Medicine, 2012, 209, 235-241.	8.5	101
1135	Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus Invasion. Journal of Virology, 2012, 86, 2900-2910.	3.4	506

# 1136	ARTICLE Update on Keloid Management: Clinical and Basic Science Advances. Advances in Wound Care, 2012, 1,	IF 5.1	CITATIONS 27
1137	200-206. Human Toll-Like Receptor 8 Can Be Cool Too: Implications for Foreign RNA Sensing. Journal of Interferon and Cytokine Research, 2012, 32, 350-361.	1.2	38
1138	Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer. Clinical Cancer Research, 2012, 18, 6748-6757.	7.0	183
1139	Crosstalk between Complement and Toll-Like Receptors. Toxicologic Pathology, 2012, 40, 174-182.	1.8	82
1140	1-{4-[(1-Isobutyl-1H-imidazo[4,5-c]quinolin-4yl)amino]phenyl}ethanone. MolBank, 2012, 2012, M788.	0.5	3
1141	MAPK Usage in Periodontal Disease Progression. Journal of Signal Transduction, 2012, 2012, 1-17.	2.0	40
1142	Adjuvants for Leishmania vaccines: from models to clinical application. Frontiers in Immunology, 2012, 3, 144.	4.8	64
1143	Antiviral applications of Toll-like receptor agonists. Journal of Antimicrobial Chemotherapy, 2012, 67, 789-801.	3.0	52
1144	Pharmacotherapy of actinic keratosis: an update. Expert Opinion on Pharmacotherapy, 2012, 13, 1847-1871.	1.8	28
1145	Targeting Dendritic Cells for Improved HIV-1 Vaccines. Advances in Experimental Medicine and Biology, 2012, 762, 263-288.	1.6	10
1146	Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression. Investigational New Drugs, 2012, 30, 2236-2251.	2.6	8
1147	Nucleic Acid-Sensing Toll-like Receptors Are Essential for the Control of Endogenous Retrovirus Viremia and ERV-Induced Tumors. Immunity, 2012, 37, 867-879.	14.3	161
1148	Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine. Vaccine, 2012, 30, 6501-6507.	3.8	10
1149	Identifying innate immune pathways of the chicken may lead to new antiviral therapies. Veterinary Immunology and Immunopathology, 2012, 148, 100-109.	1.2	20
1150	Effects of age and R848 stimulation on expression of Toll-like receptor 8 mRNA by foal neutrophils. Veterinary Immunology and Immunopathology, 2012, 150, 10-18.	1.2	5
1151	An orally available, small-molecule interferon inhibits viral replication. Scientific Reports, 2012, 2, 259.	3.3	42
1153	VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC. Clinical Cancer Research, 2012, 18, 499-509.	7.0	154
1154	Study on the anti-H1N1 virus effects of quercetin and oseltamivir and their mechanism related to TLR7 pathway. Journal of Asian Natural Products Research, 2012, 14, 877-885.	1.4	20

#	Article	IF	CITATIONS
1155	Toll-Like Receptor (TLR)-7 and -8 Modulatory Activities of Dimeric Imidazoquinolines. Journal of Medicinal Chemistry, 2012, 55, 1106-1116.	6.4	66
1156	Toll-like receptor 7-mediated enhancement of contextual fear memory in mice. Pharmacology Biochemistry and Behavior, 2012, 102, 495-501.	2.9	8
1157	Transcript profiling of pattern recognition receptors in a semi domesticated breed of buffalo, Toda, of India. Veterinary Immunology and Immunopathology, 2012, 147, 51-59.	1.2	3
1158	Interleukin-22 Is Produced by Invariant Natural Killer T Lymphocytes during Influenza A Virus Infection. Journal of Biological Chemistry, 2012, 287, 8816-8829.	3.4	159
1159	Upping the antedrug: is a novel antiâ€inflammatory Tollâ€ike receptor 7 agonist also a bronchodilator?. British Journal of Pharmacology, 2012, 166, 569-572.	5.4	9
1160	Biological characterization of a novel class of tollâ€like receptor 7 agonists designed to have reduced systemic activity. British Journal of Pharmacology, 2012, 166, 573-586.	5.4	34
1161	Structure–Activity Relationships in Human Toll-like Receptor 8-Active 2,3-Diamino-furo[2,3- <i>c</i>]pyridines. Journal of Medicinal Chemistry, 2012, 55, 8137-8151.	6.4	71
1162	Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Review of Vaccines, 2012, 11, 237-256.	4.4	120
1164	Effects of dietary protein sources on growth performance and immune response of weanling pigs. Livestock Science, 2012, 148, 1-9.	1.6	35
1165	Inhibition of translation initiation factors might be the potential therapeutic targets for HCV patients with hepatic iron overload. Medical Hypotheses, 2012, 78, 142-143.	1.5	7
1166	Monocyte-derived interferon-alpha primed dendritic cells in the pathogenesis of psoriasis: New pieces in the puzzle. International Immunopharmacology, 2012, 13, 215-218.	3.8	26
1167	Atlantic halibut experimentally infected with nodavirus shows increased levels of T-cell marker and IFNÎ ³ transcripts. Developmental and Comparative Immunology, 2012, 37, 139-150.	2.3	37
1168	Toll-like Receptor 7 Is Required for Effective Adaptive Immune Responses that Prevent Persistent Virus Infection. Cell Host and Microbe, 2012, 11, 643-653.	11.0	68
1169	Nucleic Acid Adjuvants. Advances in Immunology, 2012, 114, 1-32.	2.2	12
1170	Interventions for actinic keratoses. The Cochrane Library, 2012, 12, CD004415.	2.8	112
1171	Pattern Recognition Receptors in Immune Disorders Affecting the Skin. Journal of Innate Immunity, 2012, 4, 225-240.	3.8	13
1173	Innate Immune Signaling and Negative Regulators in Cancer. , 2012, , 61-88.		1
1174	Selective activation of Toll-like receptor 7 in activated hepatic stellate cells may modulate their profibrogenic phenotype. Biochemical Journal, 2012, 447, 25-34.	3.7	20

#	Article		CITATIONS
1175	Oral Acitretin and Topical Imiquimod as Neoadjuvant Treatment for Giant Basal Cell Carcinoma. Actas Dermo-sifiliogrÃ _i ficas, 2012, 103, 149-152.	0.4	3
1176	Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1–dependent pathways. Journal of Allergy and Clinical Immunology, 2012, 130, 195-204.e9.	2.9	115
1177	Mcl-1 determines the imiquimod-induced apoptosis but not imiquimod-induced autophagy in skin cancer cells. Journal of Dermatological Science, 2012, 65, 170-178.	1.9	15
1178	New developments in Toll-like receptor targeted therapeutics. Current Opinion in Pharmacology, 2012, 12, 510-518.	3.5	135
1180	Functional genomic studies on an immune- and antiviral-related gene of MyD88 in orange-spotted grouper, Epinephelus coioides. Science Bulletin, 2012, 57, 3277-3287.	1.7	10
1181	Resurrection of endogenous retroviruses in antibody-deficient mice. Nature, 2012, 491, 774-778.	27.8	198
1183	Investigation of the role of endosomal Toll-like receptors in murine collagen-induced arthritis reveals a potential role for TLR7 in disease maintenance. Arthritis Research and Therapy, 2012, 14, R142.	3.5	43
1184	High Throughput Screening for Small Molecule Enhancers of the Interferon Signaling Pathway to Drive Next-Generation Antiviral Drug Discovery. PLoS ONE, 2012, 7, e36594.	2.5	46
1185	Expression of Toll-Like Receptors in the Developing Brain. PLoS ONE, 2012, 7, e37767.	2.5	114
1186	Toll-Like Receptor 7 Agonist Therapy with Imidazoquinoline Enhances Cancer Cell Death and Increases Lymphocytic Infiltration and Proinflammatory Cytokine Production in Established Tumors of a Renal Cell Carcinoma Mouse Model. Journal of Oncology, 2012, 2012, 1-11.	1.3	17
1187	Mitogen-activated Protein Kinases in Inflammation. Journal of Bacteriology and Virology, 2012, 42, 189.	0.1	56
1188	Innate Immunity-Based Immunotherapy of Cancer. , 0, , .		1
1189	The type I interferon response during viral infections: a "SWOT―analysis. Reviews in Medical Virology, 2012, 22, 122-137.	8.3	4
1190	Sensing herpes: more than toll. Reviews in Medical Virology, 2012, 22, 106-121.	8.3	27
1191	Rorγt+ innate lymphocytes and γδT cells initiate psoriasiform plaque formation in mice. Journal of Clinical Investigation, 2012, 122, 2252-2256.	8.2	456
1192	TLR3 but Not TLR7/8 Ligand Induces Allergic Sensitization to Inhaled Allergen. Journal of Immunology, 2012, 188, 5123-5131.	0.8	38
1193	Cochrane Review: Immunostimulants for preventing respiratory tract infection in children. Evidence-Based Child Health: A Cochrane Review Journal, 2012, 7, 629-717.	2.0	40
1194	Toll-like receptor-7 ligand imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis. Inflammatory Bowel Diseases, 2012, 18, 955-967.	1.9	46

#		IF	CITATIONS
π	Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in		CHAHONS
1195	nonhuman primates. Blood, 2012, 119, 2044-2055.	1.4	140
1196	Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction. ACS Medicinal Chemistry Letters, 2012, 3, 501-504.	2.8	33
1197	Comparative transcutaneous immunization with imiquimod ontaining ointments and potential of <i>i>in vitro</i> methods to predict effects. Biopharmaceutics and Drug Disposition, 2012, 33, 218-228.	1.9	5
1198	Human Dendritic Cells in Cancer. , 2012, , 121-145.		0
1199	R848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclasts. Cytotechnology, 2012, 64, 331-339.	1.6	11
1200	Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Investigational New Drugs, 2012, 30, 1641-1645.	2.6	52
1201	TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunologic Research, 2012, 53, 58-77.	2.9	179
1202	Severe drug eruptions revisited. Immunologic Research, 2012, 53, 162-167.	2.9	1
1203	Emerging role of Toll-like receptors in the control of pain and itch. Neuroscience Bulletin, 2012, 28, 131-144.	2.9	274
1204	Toll-like receptor 7 stimulation by imiquimod induces macrophage autophagy and inflammation in atherosclerotic plaques. Basic Research in Cardiology, 2012, 107, 269.	5.9	54
1205	The 2011 Nobel Prize in Physiology or Medicine. Scandinavian Journal of Immunology, 2012, 75, 1-4.	2.7	22
1206	Potential efficacy of imiquimod on immunityâ€related cytokines in murine skin <i>in vivo</i> and in human Langerhans cells <i>in vitro</i> . International Journal of Dermatology, 2012, 51, 1116-1122.	1.0	4
1207	Innate immune sensing 2.0 $\hat{a} \in$ from linear activation pathways to fine tuned and regulated innate immune networks. Experimental Dermatology, 2012, 21, 61-69.	2.9	26
1208	CpG and poly(I:C) stimulation of dendritic cells and fibroblasts limits herpes simplex virus type 1 infection in an IFNβ-dependent and -independent way. Antiviral Research, 2012, 93, 39-47.	4.1	20
1209	Third generation dendritic cell vaccines for tumor immunotherapy. European Journal of Cell Biology, 2012, 91, 53-58.	3.6	47
1210	Induction of Cyclooxygenase (<scp>COX</scp>)â€⊋ in Human Vaginal Epithelial Cells in Response to <scp>TLR</scp> ligands and <scp>TNF</scp> â€i±. American Journal of Reproductive Immunology, 2012, 67, 482-490.	1.2	18
1211	IFN-α and TRAIL: A double edge sword in HIV-1 disease?. Experimental Cell Research, 2012, 318, 1260-1268.	2.6	17
1212	Controlling systems of nucleic acid sensing-TLRs restrict homeostatic inflammation. Experimental Cell Research, 2012, 318, 1461-1466.	2.6	11

#	Article	IF	CITATIONS
1213	Identification and expression profiles of grass carp <i>Ctenopharyngodon idella <scp>tlr</scp>7</i> in responses to doubleâ€stranded RNA and virus infection. Journal of Fish Biology, 2012, 80, 2605-2622.	1.6	33
1214	Association of <i>TLR</i> polymorphisms with development of tuberculosis in Indonesian females. Tissue Antigens, 2012, 79, 190-197.	1.0	39
1215	Prophylactic and therapeutic implications of tollâ€like receptor ligands. Medicinal Research Reviews, 2012, 32, 294-325.	10.5	60
1216	Toll-Like Receptor-7 Agonist Decoration Enhances the Adjuvanticity of Chitosan–DNA Nanoparticles. Journal of Pharmaceutical Sciences, 2012, 101, 1166-1177.	3.3	20
1217	Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine. Immunogenetics, 2012, 64, 219-228.	2.4	26
1218	Characterisation and expression analysis of the Atlantic halibut (Hippoglossus hippoglossus L.) cytokines: IL-11², IL-6, IL-11, IL-121² and IFN1³. Molecular Biology Reports, 2012, 39, 2201-2213.	2.3	74
1219	Intratracheal and oral administration of SMâ€276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. International Journal of Cancer, 2013, 132, 580-590.	5.1	23
1220	Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still's disease. Arthritis Research and Therapy, 2013, 15, R39.	3.5	44
1221	Unique features of chicken Toll-like receptors. Developmental and Comparative Immunology, 2013, 41, 316-323.	2.3	129
1222	Toll-like receptor 9 processing: The key event in Toll-like receptor 9 activation?. Immunology Letters, 2013, 149, 85-87.	2.5	25
1223	Defense genes missing from the flight division. Developmental and Comparative Immunology, 2013, 41, 377-388.	2.3	139
1224	Drug Resistance in Leishmania Parasites. , 2013, , .		13
1225	TLR7 Negatively Regulates Dendrite Outgrowth through the Myd88-c-Fos-IL-6 Pathway. Journal of Neuroscience, 2013, 33, 11479-11493.	3.6	60
1226	Toll-like receptor regulation of effector T lymphocyte function. Trends in Immunology, 2013, 34, 511-519.	6.8	119
1227	Current Treatment of Locoregional Recurrence of Melanoma. Current Oncology Reports, 2013, 15, 465-472.	4.0	25
1228	New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms?. Pflugers Archiv European Journal of Physiology, 2013, 465, 1671-1685.	2.8	154
1229	Imiquimod: The biochemical mechanisms of immunomodulatory and anti-inflammatory activity. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2013, 7, 136-145.	0.4	4
1230	Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection. Acta Pharmacologica Sinica, 2013, 34, 1075-1083.	6.1	63

#	Article	IF	CITATIONS
1231	Structure–activity relationships in Toll-like receptor 7 agonistic 1H-imidazo[4,5-c]pyridines. Organic and Biomolecular Chemistry, 2013, 11, 6526.	2.8	35
1232	Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis. Journal of Medicinal Chemistry, 2013, 56, 7324-7333.	6.4	61
1233	The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Review of Vaccines, 2013, 12, 809-819.	4.4	214
1234	Activation of the human immune system via tollâ€ike receptors by the oncolytic parvovirus Hâ€1. International Journal of Cancer, 2013, 132, 2548-2556.	5.1	32
1235	Structural basis of innate immune recognition of viral RNA. Cellular Microbiology, 2013, 15, 386-394.	2.1	54
1236	The Transcription Factor IRF3 Triggers "Defensive Suicide―Necrosis in Response to Viral and Bacterial Pathogens. Cell Reports, 2013, 3, 1840-1846.	6.4	64
1237	Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic Ligands. Science, 2013, 339, 1426-1429.	12.6	288
1238	Polymericâ€Micelleâ€Based Nanomedicine for siRNA Delivery. Particle and Particle Systems Characterization, 2013, 30, 211-228.	2.3	34
1239	Acidic Amino Acid Residues in the Juxtamembrane Region of the Nucleotide-Sensing TLRs Are Important for UNC93B1 Binding and Signaling. Journal of Immunology, 2013, 190, 5287-5295.	0.8	34
1240	TLR8 and NOD signaling synergistically induce the production of IL- 1^2 and IL-23 in monocyte-derived DCs and enhance the expression of the feedback inhibitor SOCS2. Immunobiology, 2013, 218, 533-542.	1.9	41
1241	Langerin ^{neg} conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10723-10728.	7.1	158
1242	Enter at your own risk: How enteroviruses navigate the dangerous world of pattern recognition receptor signaling. Cytokine, 2013, 63, 230-236.	3.2	34
1243	Key roles of adjuvants in modern vaccines. Nature Medicine, 2013, 19, 1597-1608.	30.7	1,091
1244	Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. Neuro-Oncology, 2013, 15, 1457-1468.	1.2	115
1245	Immunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle. Vaccine, 2013, 31, 5250-5255.	3.8	14
1246	Characterization and comprehensive analysis of the miiuy croaker TLR2 reveals a direct evidence for intron insert and loss. Fish and Shellfish Immunology, 2013, 34, 119-128.	3.6	19
1247	Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein and Cell, 2013, 4, 40-52.	11.0	126
1248	GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees. Gastroenterology, 2013, 144, 1508-1517.e10.	1.3	337

ARTICLE

IF CITATIONS

Identification and characterization of TLR7, TLR8a2, TLR8b1 and TLR8b2 genes in Atlantic salmon (Salmo) Tj ETQq0.00 rgBT $\frac{1}{48}$ verlock 1

1250	Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2013, 189, 2077-2082.	0.4	35
1251	Aldara activates TLR7-independent immune defence. Nature Communications, 2013, 4, 1560.	12.8	211
1252	Macrophage Scavenger Receptor A Promotes Tumor Progression in Murine Models of Ovarian and Pancreatic Cancer. Journal of Immunology, 2013, 190, 3798-3805.	0.8	107
1253	TLR7 Contributes to the Rapid Progression but Not to the Overall Fatal Outcome of Secondary Pneumococcal Disease following Influenza A Virus Infection. Journal of Innate Immunity, 2013, 5, 84-96.	3.8	19
1254	Nr4a1-Dependent Ly6Clow Monocytes Monitor Endothelial Cells and Orchestrate Their Disposal. Cell, 2013, 153, 362-375.	28.9	621
1255	Pathogen Recognition Receptors: Ligands and Signaling Pathways by Toll-Like Receptors. International Reviews of Immunology, 2013, 32, 116-133.	3.3	156
1256	RIG-I-like receptors and intracellular Toll-like receptors in antiviral immunity. Future Virology, 2013, 8, 183-194.	1.8	2
1257	The history of Toll-like receptors — redefining innate immunity. Nature Reviews Immunology, 2013, 13, 453-460.	22.7	1,338
1258	Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. , 2013, 138, 441-451.		107
1259	Vaccination as a Control Measure. , 2013, , 113-141.		0
1260	A new role for microRNAs, as ligands of Toll-like receptors. RNA Biology, 2013, 10, 169-174.	3.1	125
1261	Antiviral Responses. , 2013, , 1-14.		0
1262	Current update on the treatment of genital warts. Expert Review of Dermatology, 2013, 8, 321-332.	0.3	4
1263	The Transcriptomic Response of Rat Hepatic Stellate Cells to Endotoxin: Implications for Hepatic Inflammation and Immune Regulation. PLoS ONE, 2013, 8, e82159.	2.5	38
1264	Type I and Type III Interferons Drive Redundant Amplification Loops to Induce a Transcriptional Signature in Influenza-Infected Airway Epithelia. PLoS Pathogens, 2013, 9, e1003773.	4.7	229
1265	TLR7/8 Agonists as Vaccine Adjuvants. , 2013, , 3-18.		3
1266	Sweeten PAMPs: role of sugar complexed PAMPs in innate immunity and vaccine biology. Frontiers in Immunology, 2013, 4, 248.	4.8	179

#	Article	IF	CITATIONS
1267	Learning from the Messengers: Innate Sensing of Viruses and Cytokine Regulation of Immunity — Clues for Treatments and Vaccines. Viruses, 2013, 5, 470-527.	3.3	42
1268	Transcriptome signature in young children with acute otitis media due to non-typeable Haemophilus influenzae. International Immunology, 2013, 25, 353-361.	4.0	21
1269	Human Plasmacytoid Dendritic Cells: From Molecules to Intercellular Communication Network. Frontiers in Immunology, 2013, 4, 372.	4.8	93
1270	Defective dendritic cell response to Toll-like receptor 7/8 agonists in perinatally HIV-infected children. Pathogens and Disease, 2013, 69, 184-193.	2.0	8
1271	CD4+ T Cell Expression of MyD88 Is Essential for Normal Resolution of <i>Chlamydia muridarum</i> Genital Tract Infection. Journal of Immunology, 2013, 191, 4269-4279.	0.8	15
1272	TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis. European Journal of Immunology, 2013, 43, 3138-3146.	2.9	226
1273	Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in <scp>J</scp> apanese patients. Journal of Dermatology, 2013, 40, 962-967.	1.2	13
1274	Aureobasidium pullulansculture supernatant significantly stimulates R-848-activated phagocytosis of PMA-induced THP-1 macrophages. Immunopharmacology and Immunotoxicology, 2013, 35, 455-461.	2.4	3
1275	The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. British Journal of Pharmacology, 2013, 170, 1676-1705.	5.4	148
1276	Tollâ€like receptor 7 stimulates production of specialized proâ€resolving lipid mediators and promotes resolution of airway inflammation. EMBO Molecular Medicine, 2013, 5, 762-775.	6.9	62
1277	RNA recognition by human TLR8 can lead to autoimmune inflammation. Journal of Experimental Medicine, 2013, 210, 2903-2919.	8.5	167
1278	The MyD88 Pathway in Plasmacytoid and CD4+Dendritic Cells Primarily Triggers Type I IFN Production against Measles Virus in a Mouse Infection Model. Journal of Immunology, 2013, 191, 4740-4747.	0.8	18
1279	Trial watch. Oncolmmunology, 2013, 2, e25771.	4.6	150
1280	Trial Watch. Oncolmmunology, 2013, 2, e25595.	4.6	83
1281	Trial Watch. Oncolmmunology, 2013, 2, e25238.	4.6	132
1282	Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene, 2013, 32, 5574-5581.	5.9	65
1283	Role of toll-like receptors in systemic sclerosis. Expert Reviews in Molecular Medicine, 2013, 15, e9.	3.9	40
1284	Targeting dendritic cells—why bother?. Blood, 2013, 121, 2836-2844.	1.4	106

		CITATION R	EPORT	
#	Article		IF	Citations
1285	Molluscum contagiosum virus: persistence pays off. Future Virology, 2013, 8, 561-573.		1.8	10
1286	Network Analysis Reveals Functional Cross-links between Disease and Inflammation Gene Reports, 2013, 3, 3426.	es. Scientific	3.3	22
1287	Oral administration of pentachlorophenol induces interferon signaling mRNAs in C57BL/6 liver. Journal of Toxicological Sciences, 2013, 38, 643-654.	; male mouse	1.5	13
1288	RNA 5â \in 2-end Maturation: A Crucial Step in the Replication of Viral Genomes. , 0, , .			5
1289	Respiratory Syncytial Virus Infection Induces Higher Toll-Like Receptor-3 Expression and T Production Than Human Metapneumovirus Infection. PLoS ONE, 2013, 8, e73488.	'NF-α	2.5	27
1290	Roles of TLR7 in Activation of NF- ${\rm l}^{\rm o} B$ Signaling of Keratinocytes by Imiquimod. PLoS ONE,	2013, 8, e77159.	2.5	55
1291	Toll-Like Receptors in Atherosclerosis. International Journal of Molecular Sciences, 2013, 14008-14023.	14,	4.1	99
1292	Understanding Dendritic Cells and Their Role in Cutaneous Carcinoma and Cancer Immur Clinical and Developmental Immunology, 2013, 2013, 1-14.	notherapy.	3.3	42
1293	Role of Dendritic Cell Subsets on HIV-Specific Immunity. , 0, , .			2
1294	Crystal Structures of Innate Immune RNA Receptor TLR8. Nihon Kessho Gakkaishi, 2013,	55, 285-289.	0.0	0
1295	IL-4 Suppresses the Responses to TLR7 and TLR9 Stimulation and Increases the Permissiv Retroviral Infection of Murine Conventional Dendritic Cells. PLoS ONE, 2014, 9, e87668.	eness to	2.5	20
1296	The TIR-Domain Containing Adaptor TRAM Is Required for TLR7 Mediated RANTES Produc 2014, 9, e107141.	tion. PLoS ONE,	2.5	13
1297	The Co-Stimulatory Effects of MyD88-Dependent Toll-Like Receptor Signaling on Activation T Cells. PLoS ONE, 2014, 9, e108156.	on of Murine Î ³ Î′	2.5	19
1298	IgG2 Antibodies against a Clinical Grade Plasmodium falciparum CSP Vaccine Antigen Ass Protection against Transgenic Sporozoite Challenge in Mice. PLoS ONE, 2014, 9, e11102	sociate with 0.	2.5	67
1299	The Effect of Imiquimod on Matrix Metalloproteinases and Tissue Inhibitors of Metallopro Malignant Melanoma Cell Invasion. Annals of Dermatology, 2014, 26, 363.	oteinases in	0.9	10
1300	Use of imiquimod for residual acral melanoma. BMJ Case Reports, 2014, 2014, bcr2014203826-bcr2014203826.		0.5	7
1301	Toll like receptors: an overview. International Journal of Pharmacology and Toxicology, 20	114, 2, .	0.2	2
1302	Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activati Immunology, 2014, 193, 4722-4731.	on. Journal of	0.8	136

ARTICLE IF CITATIONS Trial Watch. Oncolmmunology, 2014, 3, e29179. 1303 4.6 76 Percellome toxicogenomics project as a source of biomarkers of chemical toxicity., 2014, , 1019-1032. 1304 Recent insights into the evolution of innate viral sensing in animals. Current Opinion in 1305 5.1 12 Microbiology, 2014, 20, 170-175. Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. Nanomedicine, 2014, 9, 2587-2605. Friend retrovirus drives cytotoxic effectors through Toll-like receptor 3. Retrovirology, 2014, 11, 126. 1307 2.0 17 Endosomal Localization of TLR8 Confers Distinctive Proteolytic Processing on Human Myeloid Cells. 1308 0.8 Journal of Immunology, 2014, 193, 5118-5128. An ENU-induced splicing mutation reveals a role for Unc93b1 in early immune cell activation 1309 4.1 10 following influenza A HIN1 infection. Genes and Immunity, 2014, 15, 320-332. Adjuvants for foot-and-mouth disease virus vaccines: recent progress. Expert Review of Vaccines, 2014, 4.4 13, 1377-1385. 1311 Modes of action of TLR7 agonists in cancer therapy. Immunotherapy, 2014, 6, 1085-1095. 2.0 66 Role of Toll-like receptors in diabetic nephropathy. Clinical Science, 2014, 126, 685-694. 4.3 Small-molecule control of cytokine function: new opportunities for treating immune disorders. 1313 6.1 20 Current Opinion in Chemical Biology, 2014, 23, 23-30. Interferon Induction by RNA Viruses and Antagonism by Viral Pathogens. Viruses, 2014, 6, 4999-5027. 1314 3.3 54 Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome. Nature 1315 12.8 119 Communications, 2014, 5, 3492. Toll-like receptor agonists: a patent review (2011 – 2013). Expert Opinion on Therapeutic Patents, 2014, 5.0 24, 453-470 RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally 1317 0.8 38 Disparate Signaling Events. Journal of Immunology, 2014, 192, 5963-5973. Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced 54 liver fibrosis. Hepatology, 2014, 60, 237-249. RNA:DNA hybrids are a novel molecular pattern sensed by TLR9. EMBO Journal, 2014, 33, 542-558. 1319 7.8 133 Synthesis and immunoregulatory activities of conjugates of a Toll-like receptor 7 inert ligand. 2.2 Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5792-5795.
#	Article	IF	CITATIONS
1321	Pestiviral E rns blocks TLR-3-dependent IFN synthesis by LL37 complexed RNA. Veterinary Microbiology, 2014, 174, 399-408.	1.9	16
1322	<scp>TLR</scp> 7 signaling exacerbates <scp>CNS</scp> autoimmunity through downregulation of <scp>F</scp> oxp3 ⁺ <scp>T</scp> reg cells. European Journal of Immunology, 2014, 44, 46-57.	2.9	20
1323	Hydrolysis of 2â€23â€2-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nature Chemical Biology, 2014, 10, 1043-1048.	8.0	348
1324	Addressing diagnostic challenges in primary immunodeficiencies: Laboratory evaluation of Toll-like receptor- and NF-κB-mediated immune responses. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 112-123.	6.1	20
1325	The role of Toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes. Reviews in the Neurosciences, 2014, 25, 713-39.	2.9	26
1326	Rational design of small molecules as vaccine adjuvants. Science Translational Medicine, 2014, 6, 263ra160.	12.4	153
1327	Three Phase III Randomized Controlled Trials of Topical Resiquimod 0.01-Percent Gel To Reduce Anogenital Herpes Recurrences. Antimicrobial Agents and Chemotherapy, 2014, 58, 5016-5023.	3.2	6
1328	Immune sensing of nucleic acids in inflammatory skin diseases. Seminars in Immunopathology, 2014, 36, 519-529.	6.1	11
1329	Toll-Like Receptors and Prostate Cancer. Frontiers in Immunology, 2014, 5, 352.	4.8	86
1330	Sex differences in monocytes and TLR4 associated immune responses; implications for systemic lupus erythematosus (SLE). Journal of Immunotherapy Applications, 2014, 1, 1.	3.0	32
1331	Structural aspects of molecular recognition in the immune system. Part II: Pattern recognition receptors (IUPAC Technical Report). Pure and Applied Chemistry, 2014, 86, 1483-1538.	1.9	6
1332	Toll-Like Receptors and Skin Cancer. Frontiers in Immunology, 2014, 5, 135.	4.8	32
1333	Therapeutic Implications of Immunogenic Cell Death in Human Cancer. Frontiers in Immunology, 2014, 4, 503.	4.8	23
1334	Treatment of Molluscum Contagiosum in Adult, Pediatric, and Immunodeficient Populations. Journal of Cutaneous Medicine and Surgery, 2014, 18, 299-306.	1.2	22
1335	EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells. Anti-Cancer Drugs, 2014, 25, 624-632.	1.4	15
1336	Liposomes containing NY-ESO-1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines. Nanomedicine, 2014, 9, 435-449.	3.3	32
1337	Effects of TLR agonists and viral infection on cytokine and TLR expression in Atlantic salmon (Salmo) Tj ETQq0 0	0 rgBT /Ov	verlock 10 Tf 42

1338	Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients. Journal of Gastroenterology, 2014, 49, 126-137.	5.1	19	
------	---	-----	----	--

		CITATION REPORT		
#	Article		IF	CITATIONS
1339	The Yin and Yang of Toll-like receptors in cancer. Oncogene, 2014, 33, 3485-3495.		5.9	266
1340	Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence platelet-dependent thrombosis. Blood, 2014, 124, 791-802.	e of	1.4	209
1341	Innate Immune Sensing and Signaling of Cytosolic Nucleic Acids. Annual Review of Immuno 32, 461-488.	ology, 2014,	21.8	957
1342	Dosage of Xâ€ŀinked Tollâ€ŀike receptor 8 determines gender differences in the developme lupus erythematosus. European Journal of Immunology, 2014, 44, 1503-1516.	nt of systemic	2.9	52
1343	Biomaterials for Nanoparticle Vaccine Delivery Systems. Pharmaceutical Research, 2014, 3	1, 2563-2582.	3.5	258
1344	Toll-like receptor activation and expression in bovine alpha-herpesvirus infections. Research Veterinary Science, 2014, 96, 196-203.	ı in	1.9	17
1345	Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae mur model. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 310-317.	ine infection	4.3	29
1346	Toll-Like Receptors in Antiviral Innate Immunity. Journal of Molecular Biology, 2014, 426, 1	246-1264.	4.2	570
1347	Structure–Activity Relationship Analysis of Imidazoquinolines with Toll-like Receptors 7 a Selectivity and Enhanced Cytokine Induction. Journal of Medicinal Chemistry, 2014, 57, 33	ınd 8 9-347.	6.4	49
1348	Trafficking of endosomal Toll-like receptors. Trends in Cell Biology, 2014, 24, 360-369.		7.9	154
1349	Novel Small Molecule Inhibitors of TLR7 and TLR9: Mechanism of Action and Efficacy In Viv Molecular Pharmacology, 2014, 85, 429-440.	0.	2.3	117
1350	Imiquimod Inhibits Melanoma Development by Promoting pDC Cytotoxic Functions and Im Vascularization. Journal of Investigative Dermatology, 2014, 134, 2551-2561.	ipeding Tumor	0.7	65
1351	Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virology, 2014, 9, 811	-829.	1.8	76
1352	Intrabronchial Infection of Rhesus Macaques with Simian Varicella Virus Results in a Robust Response in the Lungs. Journal of Virology, 2014, 88, 12777-12792.	t Immune	3.4	18
1353	B Cell–Intrinsic TLR7 Signaling Is Essential for the Development of Spontaneous Germina Journal of Immunology, 2014, 193, 4400-4414.	al Centers.	0.8	144
1354	Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope A Responses in Rhesus Macaques. Journal of Virology, 2014, 88, 3329-3339.	ntibody	3.4	80
1355	Topical Resiquimod Protects against Visceral Infection with Leishmania infantum chagasi ir Vaccine Journal, 2014, 21, 1314-1322.	ı Mice.	3.1	15
1356	Independent of Plasmacytoid Dendritic Cell (pDC) infection, pDC Triggered by Virus-Infecter Mount Enhanced Type I IFN Responses of Different Composition as Opposed to pDC Stimu Free Virus. Journal of Immunology, 2014, 193, 2496-2503.	ed Cells Ilated with	0.8	46

#	Article	IF	CITATIONS
1357	Assembly and localization of Toll-like receptor signalling complexes. Nature Reviews Immunology, 2014, 14, 546-558.	22.7	653
1358	Imiquimod induces a Toll-like receptor 7-independent increase in intracellular calcium via IP3 receptor activation. Biochemical and Biophysical Research Communications, 2014, 450, 875-879.	2.1	17
1359	Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma. International Journal of Urology, 2014, 21, 702-706.	1.0	5
1360	Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. , 2014, 2, 12.		65
1361	TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7. Vaccine, 2014, 32, 5593-5599.	3.8	18
1362	Imiquimod in the Treatment of Breast Cancer Skin Metastasis. Journal of Clinical Oncology, 2014, 32, e22-e25.	1.6	33
1363	Stimulation of Innate Immune Cells by Light-Activated TLR7/8 Agonists. Journal of the American Chemical Society, 2014, 136, 10823-10825.	13.7	44
1364	IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals. Cytokine, 2014, 65, 202-209.	3.2	17
1365	B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice. Journal of Controlled Release, 2014, 184, 1-8.	9.9	23
1366	Innate immune responses regulate morphogenesis and degeneration: roles of Toll-like receptors and Sarm1 in neurons. Neuroscience Bulletin, 2014, 30, 645-654.	2.9	39
1367	Designing and building the next generation of improved vaccine adjuvants. Journal of Controlled Release, 2014, 190, 563-579.	9.9	129
1368	Toll-Like Receptor 7 Agonist Imiquimod in Combination with Influenza Vaccine Expedites and Augments Humoral Immune Responses against Influenza A(H1N1)pdm09 Virus Infection in BALB/c Mice. Vaccine Journal, 2014, 21, 570-579.	3.1	47
1369	Poly (Î ³ -glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy. Biomaterials, 2014, 35, 7992-8001.	11.4	63
1370	Itch Mechanisms and Circuits. Annual Review of Biophysics, 2014, 43, 331-355.	10.0	148
1371	Effect of Imiquimod as Compared With Surgery on the Cancerization Field in Basal Cell carcinoma. Actas Dermo-sifiliográficas, 2014, 105, 53-59.	0.4	3
1372	Functional Analysis via Standardized Whole-Blood Stimulation Systems Defines the Boundaries of a Healthy Immune Response to Complex Stimuli. Immunity, 2014, 40, 436-450.	14.3	192
1373	Structure and function of toll-like receptor 8. Microbes and Infection, 2014, 16, 273-282.	1.9	49
1374	Efecto del imiquimod comparado con la cirugÃa sobre el campo de cancerización en el carcinoma basocelular. Actas Dermo-sifiliográficas, 2014, 105, 53-59.	0.4	10

#	Article	IF	CITATIONS
1375	Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine, 2014, 32, 2882-2895.	3.8	144
1376	Downregulation of TLR4 and 7 mRNA Expression Levels in Broiler's Spleen Caused by Diets Supplemented with Nickel Chloride. Biological Trace Element Research, 2014, 158, 353-358.	3.5	11
1377	Influence of age, sex and rearing systems on Toll-like receptor 7 (<i>TLR7</i>) expression pattern in gut, lung and lymphoid tissues of indigenous ducks. British Poultry Science, 2014, 55, 59-67.	1.7	10
1378	Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFN ¹³ . Clinical Cancer Research, 2014, 20, 5456-5467.	7.0	49
1379	Treatment of extramammary Paget disease of the vulva with imiquimod: A retrospective, multicenter study by the German Colposcopy Network. Journal of the American Academy of Dermatology, 2014, 70, 644-650.	1.2	72
1380	Toll-like receptors in lymphoid malignancies: Double-edged sword. Critical Reviews in Oncology/Hematology, 2014, 89, 262-283.	4.4	25
1381	Innate Immunity to Viruses. , 0, , 183-196.		0
1382	Toll-Like Receptor Responses to Peste des petits ruminants Virus in Goats and Water Buffalo. PLoS ONE, 2014, 9, e111609.	2.5	28
1383	Imiquimod and Pulmonary Embolism: a Case Report. Therapie, 2014, 69, 180-181.	1.0	2
1384	APOBEC3 enzymes restrict marginal zone B cells. European Journal of Immunology, 2015, 45, 695-704.	2.9	12
1385	TLR7-expressing cells comprise an interfollicular epidermal stem cell population in murine epidermis. Scientific Reports, 2014, 4, 5831.	3.3	11
1386	Regular Exercise Enhances the Immune Response Against Microbial Antigens Through Up-Regulation of Toll-like Receptor Signaling Pathways. Cellular Physiology and Biochemistry, 2015, 37, 735-746.	1.6	63
1387	Pattern Recognition Receptors in Cancer Progression and Metastasis. Cancer Growth and Metastasis, 2015, 8, CGM.S24314.	3.5	75
1388	Bropirimine inhibits osteoclast differentiation through production of interferon-β. Biochemical and Biophysical Research Communications, 2015, 467, 146-151.	2.1	2
1389	Type I IFNâ€mediated synergistic activation of mouse and human DC subsets by TLR agonists. European Journal of Immunology, 2015, 45, 2798-2809.	2.9	17
1390	A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma. Journal of Translational Medicine, 2015, 13, 166.	4.4	9
1391	Expression profiling and functional analysis of Tollâ€like receptors in primary healthy human nasal epithelial cells shows no correlation and a refractory LPS response. Clinical and Translational Allergy, 2015, 5, 42.	3.2	21
1393	Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome. Thrombosis and Haemostasis, 2015, 113, 1071-1083.	3.4	54

#	Article	IF	CITATIONS
1394	PTPN22 Variant R620W Is Associated With Reduced Tollâ€like Receptor 7–Induced Type I Interferon in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2403-2414.	5.6	37
1395	Evasión de la respuesta inmune por virus herpes simplex. Revista Chilena De Infectologia, 2015, 32, 58-70.	0.1	10
1396	Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2015, 9, 2-14.	0.6	12
1397	The Modified JiuWei QiangHuo Decoction Alleviated Severe Lung Injury Induced by H1N1 Influenza Virus by Regulating the NF-I®B Pathway in Mice. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-12.	1.2	6
1398	Sensors of Infection: Viral Nucleic Acid PRRs in Fish. Biology, 2015, 4, 460-493.	2.8	35
1399	Structure Based Modeling of Small Molecules Binding to the TLR7 by Atomistic Level Simulations. Molecules, 2015, 20, 8316-8340.	3.8	27
1400	Retinal Microglial Activation Following Topical Application of Intracellular Toll-Like Receptor Ligands. , 2015, 56, 7377.		12
1401	Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products. Thrombosis and Haemostasis, 2015, 114, 268-276.	3.4	19
1402	Induction of Tolerogenic Dendritic Cells by a PEGylated TLR7 Ligand for Treatment of Type 1 Diabetes. PLoS ONE, 2015, 10, e0129867.	2.5	27
1403	Evasion of Early Antiviral Responses by Herpes Simplex Viruses. Mediators of Inflammation, 2015, 2015, 1-16.	3.0	55
1404	Principles of oncological therapy. , 2015, , 118-197.		3
1405	2'-O-Methylation within Bacterial RNA Acts as Suppressor of TLR7/TLR8 Activation in Human Innate Immune Cells. Journal of Innate Immunity, 2015, 7, 482-493.	3.8	43
1406	International Union of Basic and Clinical Pharmacology. XCVI. Pattern Recognition Receptors in Health and Disease. Pharmacological Reviews, 2015, 67, 462-504.	16.0	41
1407	Signaling Mechanisms Regulating Innate Immune Responses. , 2015, , 605-622.		2
1408	Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2015, 13, 204-209.e2.	1.9	17
1409	Synthesis, Characterization, and Crystal Structure of (E)-1-(4-(1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-ylamino)phenyl)-3-phenylprop-2-en-1-one. Molecular Crystals and Liquid Crystals, 2015, 623, 253-264.	0.9	0
1410	Translating nucleic acid-sensing pathways into therapies. Nature Reviews Immunology, 2015, 15, 529-544.	22.7	130
1411	Calcitonin geneâ€related peptide: key regulator of cutaneous immunity. Acta Physiologica, 2015, 213, 586-594.	3.8	65

ARTICLE IF CITATIONS Regulation of cellular innate antiviral signaling by ubiquitin modification. Acta Biochimica Et 1412 2.0 14 Biophysica Sinica, 2015, 47, 149-155. Tumor Necrosis Factor Superfamily in Innate Immunity and Inflammation. Cold Spring Harbor 1413 5.5 Perspectives in Biology, 2015, 7, a016279. Synthesis and Evaluation of Conjugates of Novel TLR7 Inert Ligands as Self-Adjuvanting 1414 2.8 12 Immunopotentiators. ACS Medicinal Chemistry Letters, 2015, 6, 249-253. Synergistic activation of Toll-like receptor 8 by two RNA degradation products. Nature Structural 1415 and Molecular Biology, 2015, 22, 99-101. An enzyme cofactor with a split personality. Nature Structural and Molecular Biology, 2015, 22, 1416 8.2 0 101-103. MicroRNA-146a and MicroRNA-146b Regulate Human Dendritic Cell Apoptosis and Cytokine Production by Targeting TRAF6 and IRAK1 Proteins. Journal of Biological Chemistry, 2015, 290, 2831-2841. 3.4 Molecular cloning, tissue distribution, and immune function of goose TLR7. Immunology Letters, 2015, 1418 2.513 163, 135-142. Chromatin remodelling and autocrine TNFα are required for optimal interleukin-6 expression in 1419 12.8 87 activated human neutrophils. Nature Communications, 2015, 6, 6061. Anti-WASP intrabodies inhibit inflammatory responses induced by AToll-like receptors 3, 7, and 9, in 1420 2.1 1 macrophages. Biochemical and Biophysical Research Communications, 2015, 458, 28-33. Development of non-traumatic osteonecrosis of the femoral head requires toll-like receptor 7 and 9 1421 stimulations and is boosted by repression on nuclear factor kappa B in rats. Laboratory Investigation, 2015, 95, 92-99. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nature Structural and 1422 312 8.2 Molecular Biology, 2015, 22, 109-115. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis: an 148 International Journal on Programmed Cell Death, 2015, 20, 196-209. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunology, 1424 4.2 152 Immunotherapy, 2015, 64, 419-427. Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1318-1323. 1425 2.2 24 Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil. 1426 2.319 Developmental and Comparative Immunology, 2015, 53, 123-133. Required Role of Apoptotic Myogenic Precursors and Tollâ€like Receptor Stimulation for the 1427 Establishment of Autoimmune Myositis in Experimental Murine Models. Arthritis and Rheumatology, 2015, 67, 809-822. A tug-of-war between the host and the pathogen generates strategic hotspots for the development of 1428 4.4 22 novel therapeutic interventions against infectious diseases. Virulence, 2015, 6, 566-580. TLR8 Senses Bacterial RNA in Human Monocytes and Plays a Nonredundant Role for Recognition of 1429 <i>Streptococcus pyogenes</i>. Journal of Immunology, 2015, 195, 1092-1099.

#	Article	IF	CITATIONS
1430	Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjugate Chemistry, 2015, 26, 1713-1723.	3.6	38
1432	Gene/environment interactions in the pathogenesis of autoimmunity: New insights on the role of Toll-like receptors. Autoimmunity Reviews, 2015, 14, 971-983.	5.8	41
1433	Metastatic Melanoma – A Review of Current and Future Treatment Options. Acta Dermato-Venereologica, 2015, 95, 516-524.	1.3	186
1434	Modulating the innate immune activity in murine tumor microenvironment by a combination of inducer molecules attached to microparticles. Cancer Immunology, Immunotherapy, 2015, 64, 1137-1149.	4.2	2
1435	Association of Symptoms and Severity of Rift Valley Fever with Genetic Polymorphisms in Human Innate Immune Pathways. PLoS Neglected Tropical Diseases, 2015, 9, e0003584.	3.0	30
1436	Bacterial RNA: An Underestimated Stimulus for Innate Immune Responses. Journal of Immunology, 2015, 195, 411-418.	0.8	78
1437	Archaea associated with human surfaces: not to be underestimated. FEMS Microbiology Reviews, 2015, 39, 631-648.	8.6	88
1438	Administration of TLR7 agonist, resiquimod, in different types of chicken induces a mixed Th1 and Th2 response in the peripheral blood mononuclear cells. Research in Veterinary Science, 2015, 100, 105-108.	1.9	18
1439	TLR8, but not TLR7, induces the priming of the NADPH oxidase activation in human neutrophils. Journal of Leukocyte Biology, 2015, 97, 1081-1087.	3.3	23
1440	Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility. Immunologic Research, 2015, 62, 234-252.	2.9	64
1441	CpG Oligonucleotides as Cancer Vaccine Adjuvants. Vaccines, 2015, 3, 390-407.	4.4	108
1442	Pharmacology of Itch. Handbook of Experimental Pharmacology, 2015, , .	1.8	3
1443	Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression. Cancer Immunology Research, 2015, 3, 1042-1051.	3.4	68
1444	Inhibitory effect of cucurbitacin B on imiquimod-induced skin inflammation. Biochemical and Biophysical Research Communications, 2015, 459, 673-678.	2.1	10
1445	Space and time: New considerations about the relationship between Toll-like receptors (TLRs) and type I interferons (IFNs). Cytokine, 2015, 74, 171-174.	3.2	37
1446	Tollâ€Like Receptors. Current Protocols in Immunology, 2015, 109, 14.12.1-14.12.10.	3.6	324
1447	Advances in Toll-like receptor biology: Modes of activation by diverse stimuli. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 359-379.	5.2	71
1448	TLR7 is required for optimal immune defense against bacterial infection in tongue sole (Cynoglossus) Tj ETQq1 1	0,784314	l rgBT /Overl

#	Article	IF	CITATIONS
1449	MiR-940 Inhibited Pancreatic Ductal Adenocarcinoma Growth by Targeting MyD88. Cellular Physiology and Biochemistry, 2015, 35, 1167-1177.	1.6	60
1450	Development of a cell system for siRNA screening of pathogen responses in human and mouse macrophages. Scientific Reports, 2015, 5, 9559.	3.3	21
1451	Cardiac RNA Induces Inflammatory Responses in Cardiomyocytes and Immune Cells via Toll-like Receptor 7 Signaling. Journal of Biological Chemistry, 2015, 290, 26688-26698.	3.4	50
1452	SARM1, Not MyD88, Mediates TLR7/TLR9-Induced Apoptosis in Neurons. Journal of Immunology, 2015, 195, 4913-4921.	0.8	45
1453	Nanomedicine and cancer immunotherapy – targeting immunosuppressive cells. Journal of Drug Targeting, 2015, 23, 656-671.	4.4	32
1454	The Suppressive Effect of Quercetin on Toll-Like Receptor 7-Mediated Activation in Alveolar Macrophages. Pharmacology, 2015, 96, 201-209.	2.2	22
1455	Neuroimmune interactions in itch: Do chronic itch, chronic pain, and chronic cough share similar mechanisms?. Pulmonary Pharmacology and Therapeutics, 2015, 35, 81-86.	2.6	60
1456	RNA sensing by conventional dendritic cells is central to the development of lupus nephritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6195-204.	7.1	49
1457	Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells. Clinical and Experimental Dermatology, 2015, 40, 27-30.	1.3	10
1458	Immune effects of R848: Evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus). Developmental and Comparative Immunology, 2015, 49, 113-120.	2.3	50
1459	Facile syntheses of functionalized toll-like receptor 7 agonists. Tetrahedron Letters, 2015, 56, 458-460.	1.4	5
1460	A randomized trial of efficacy of beta-sitosterol and its glucoside as adjuvant to cryotherapy in the treatment of anogenital warts. Journal of Dermatological Treatment, 2015, 26, 139-142.	2.2	3
1461	Antiviral drug discovery: broad-spectrum drugs from nature. Natural Product Reports, 2015, 32, 29-48.	10.3	148
1462	Homeostatic Inflammation as Environmental-Adaptation Strategy. , 2016, , 25-52.		0
1463	Clinical Significance of Toll-Like Receptor and Toll-Like Receptor Blocker. Urogenital Tract Infection, 2016, 11, 1.	0.2	1
1464	COPD disease severity and innate immune response to pathogen-associated molecular patterns. International Journal of COPD, 2016, 11, 467.	2.3	15
1465	The Importance of Mammalogy, Infectious Disease Research, and Biosafety in the Field. , 2016, 2016, 3.		1
1466	Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity. ELife, 2016, 5, .	6.0	113

#	Article	IF	Citations
1467	Holding the Inflammatory System in Check: TLRs and Their Targeted Therapy in Asthma. Mediators of Inflammation, 2016, 2016, 1-8.	3.0	27
1468	Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7. Vaccines, 2016, 4, 3.	4.4	20
1469	Potential of PEGylated Toll-Like Receptor 7 Ligands for Controlling Inflammation and Functional Changes in Mouse Models of Asthma and Silicosis. Frontiers in Immunology, 2016, 7, 95.	4.8	11
1470	Interplay between Inflammation and Cellular Stress Triggered by Flaviviridae Viruses. Frontiers in Microbiology, 2016, 7, 1233.	3.5	50
1471	Cancer Vaccines in Ovarian Cancer: How Can We Improve?. Biomedicines, 2016, 4, 10.	3.2	47
1472	Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Pharmaceutics, 2016, 8, 7.	4.5	147
1473	Nucleic Acid Recognition Mechanisms by Toll-Like Receptors. Kagaku To Seibutsu, 2016, 54, 318-323.	0.0	0
1474	Imiquimod-induced CCR9 Ameliorates murine TNBS Colitis. Fukushima Journal of Medical Sciences, 2016, 62, 90-100.	0.4	8
1475	Toll-Like Receptors, Systemic Lupus Erythematosus. , 2016, , 143-151.		1
1476	<i>Ampelopsis japonica</i> Makino Extract Inhibits the Inflammatory Reaction Induced by Pathogen-Associated Molecular Patterns in Epidermal Keratinocytes. Annals of Dermatology, 2016, 28, 352.	0.9	2
1478	High-Mobility Group Box-1 Protein a Potential Inflammatory Biomarker in Diabetic Retinopathy. , 2016, , .		0
1479	Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. Melanoma Research, 2016, 26, 409-412.	1.2	20
1480	Effects of Imiquimod on Hair Follicle Stem Cells and Hair Cycle Progression. Journal of Investigative Dermatology, 2016, 136, 2140-2149.	0.7	26
1481	Nucleic acidâ€sensing <scp>TLR</scp> s and autoimmunity: novel insights from structural and cell biology. Immunological Reviews, 2016, 269, 60-75.	6.0	108
1482	Nucleic Acid-Targeting Pathways Promote Inflammation in Obesity-Related Insulin Resistance. Cell Reports, 2016, 16, 717-730.	6.4	77
1483	The link between TLR7 signaling and hepatitis B virus infection. Life Sciences, 2016, 158, 63-69.	4.3	28
1484	pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8098-8103.	7.1	164
1485	IFNα enhances the production of IL-6 by human neutrophils activated via TLR8. Scientific Reports, 2016, 6, 19674.	3.3	80

#	Article	IF	CITATIONS
1486	TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes. Retrovirology, 2016, 13, 83.	2.0	15
1487	Increased adipose tissue expression of TLR8 in obese individuals with or without type-2 diabetes: significance in metabolic inflammation. Journal of Inflammation, 2016, 13, 38.	3.4	31
1488	Modeling of viral–bacterial coinfections at the molecular level using agonists of innate immunity receptors. Doklady Biochemistry and Biophysics, 2016, 471, 393-395.	0.9	5
1489	Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method. Tetrahedron Letters, 2016, 57, 2063-2066.	1.4	9
1490	<i>In vivo</i> / <i>ex vivo</i> targeting of Langerhans cells after topical application of the immune response modifier TMX-202: confocal Raman microscopy and histology analysis. Journal of Biomedical Optics, 2016, 21, 055004.	2.6	5
1491	Conjugation of weak ligands with weak antigens to activate TLR-7: A step toward better vaccine adjuvants. European Journal of Medicinal Chemistry, 2016, 120, 111-120.	5.5	6
1492	The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 105, 1-8.	4.3	14
1493	Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation. Oncology Reports, 2016, 35, 793-800.	2.6	10
1494	Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands. Cancer Immunology, Immunotherapy, 2016, 65, 689-700.	4.2	10
1495	Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease. Transfusion Medicine and Hemotherapy, 2016, 43, 114-119.	1.6	15
1496	Recognition of Endogenous Nucleic Acids by the Innate Immune System. Immunity, 2016, 44, 739-754.	14.3	390
1497	Symptomatic Improvement in Human Papillomavirus-Induced Epithelial Neoplasia by Specific Targeting of the CXCR4 Chemokine Receptor. Journal of Investigative Dermatology, 2016, 136, 473-480.	0.7	16
1498	Alveolar Type II Epithelial Cells Contribute to the Anti-Influenza A Virus Response in the Lung by Integrating Pathogen- and Microenvironment-Derived Signals. MBio, 2016, 7, .	4.1	49
1499	Programming of donor T cells using allogeneic δ-like ligand 4–positive dendritic cells to reduce GVHD in mice. Blood, 2016, 127, 3270-3280.	1.4	22
1500	Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Current Opinion in Pharmacology, 2016, 30, 93-105.	3.5	25
1501	Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA. Immunity, 2016, 45, 737-748.	14.3	321
1502	Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant. Vaccine, 2016, 34, 5225-5234.	3.8	31
1503	K + Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria. Immunity, 2016, 45, 761-773.	14.3	364

#	Article	IF	CITATIONS
1504	The effect of imiquimod on taste bud calcium transients and transmitter secretion. British Journal of Pharmacology, 2016, 173, 3121-3133.	5.4	5
1505	Covalent Conjugation of Small-Molecule Adjuvants to Nanoparticles Induces Robust Cytotoxic T Cell Responses via DC Activation. Bioconjugate Chemistry, 2016, 27, 2007-2013.	3.6	28
1506	Synthesis and immunostimulatory activity of substituted TLR7 agonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4246-4249.	2.2	7
1507	Immune Monitoring of Trans-endothelial Transport by Kidney-Resident Macrophages. Cell, 2016, 166, 991-1003.	28.9	154
1508	Strategies for designing synthetic immune agonists. Immunology, 2016, 148, 315-325.	4.4	25
1509	TLR2 controls random motility, while TLR7 regulates chemotaxis of microglial cells via distinct pathways. Brain, Behavior, and Immunity, 2016, 58, 338-347.	4.1	27
1511	TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function. Oncolmmunology, 2016, 5, e1230578.	4.6	65
1512	Core/shell protein-reactive nanogels via a combination of RAFT polymerization and vinyl sulfone postmodification. Nanomedicine, 2016, 11, 2631-2645.	3.3	19
1513	Toll-like receptors targeting technology for the treatment of lymphoma. Expert Opinion on Drug Discovery, 2016, 11, 1047-1059.	5.0	5
1514	Toll-like receptors for pathogen detection in water: challenges and benefits. International Journal of Environmental Analytical Chemistry, 0, , 1-9.	3.3	4
1515	Bridging the importance of Toll like receptors in human viral infections. Asian Pacific Journal of Tropical Disease, 2016, 6, 573-580.	0.5	2
1516	Toll-like receptors signaling: A complex network for NF-κB activation in B-cell lymphoid malignancies. Seminars in Cancer Biology, 2016, 39, 15-25.	9.6	65
1517	IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod). Journal of Immunology, 2016, 197, 4219-4227.	0.8	32
1518	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature, 2016, 540, 284-287.	27.8	246
1519	Tongue Epithelium Cells from shRNA Mediated Transgenic Goat Show High Resistance to Foot and Mouth Disease Virus. Scientific Reports, 2016, 5, 17897.	3.3	5
1520	Cancer Drug Discovery. , 2016, , .		6
1521	CD72 negatively regulates B lymphocyte responses to the lupus-related endogenous toll-like receptor 7 ligand Sm/RNP. Journal of Experimental Medicine, 2016, 213, 2691-2706.	8.5	42
1522	Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. Vaccine, 2016, 34, 5886-5894.	3.8	19

# 1523	ARTICLE Inhibition of IL-1R1/MyD88 signalling promotes mesenchymal stem cell-driven tissue regeneration. Nature Communications, 2016, 7, 11051.	IF 12.8	Citations
1524	TLR7 Structure: Cut in Z-Loop. Immunity, 2016, 45, 705-707.	14.3	35
1525	Clinical significance of tumor-infiltrating lymphocytes in breast cancer. , 2016, 4, 59.		530
1526	Plasmacytoid dendritic cells orchestrate TLR7-mediated innate and adaptive immunity for the initiation of autoimmune inflammation. Scientific Reports, 2016, 6, 24477.	3.3	66
1527	Acute Exacerbations of Airway Inflammation. , 2016, , 5-20.		1
1528	Antiviral Responses. , 2016, , 117-129.		0
1529	Pin1â€Targeted Therapy for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2016, 68, 2503-2513.	5.6	22
1530	Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization. Cellular Immunology, 2016, 308, 35-43.	3.0	16
1531	The pathophysiology of pruritus – A review for clinicians. Progress in Palliative Care, 2016, 24, 133-146.	1.2	8
1532	Imiquimod induces ER stress and Ca 2+ influx independently of TLR7 and TLR8. Biochemical and Biophysical Research Communications, 2016, 473, 789-794.	2.1	17
1533	TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target. Journal of Leukocyte Biology, 2016, 100, 27-45.	3.3	138
1534	Activation of toll-like receptor signaling pathways leading to nitricÂoxide-mediated antiviral responses. Archives of Virology, 2016, 161, 2075-2086.	2.1	65
1535	A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. Oncolmmunology, 2016, 5, e1189051.	4.6	22
1537	<i>In silico</i> analysis of human Tollâ€like receptor 7 ligand binding domain. Biotechnology and Applied Biochemistry, 2016, 63, 441-450.	3.1	7
1538	Biologics to Treat Substance Use Disorders. , 2016, , .		3
1539	Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery. Nanoscale, 2016, 8, 938-948.	5.6	93
1540	Advances in Antiviral Therapies Targeting Toll-like Receptors. Expert Opinion on Investigational Drugs, 2016, 25, 437-453.	4.1	20
1541	Toll-like receptors mediating vascular malfunction: Lessons from receptor subtypes. , 2016, 158, 91-100.		52

	CITATION R	EPORT	
#	Article	IF	CITATIONS
1542	Structural aspects of nucleic acid-sensing Toll-like receptors. Biophysical Reviews, 2016, 8, 33-43.	3.2	35
1543	Molecular cloning and functional characterization of murine toll-like receptor 8. Molecular Medicine Reports, 2016, 13, 1119-1126.	2.4	18
1544	The role of toll like receptors in giant cell arteritis. Rheumatology, 2016, 55, 1921-1931.	1.9	24
1545	TLR-7 activation enhances IL-22–mediated colonization resistance against vancomycin-resistant enterococcus. Science Translational Medicine, 2016, 8, 327ra25.	12.4	77
1546	Innate immune receptor Toll-like receptor 4 signalling in neuropsychiatric diseases. Neuroscience and Biobehavioral Reviews, 2016, 64, 134-147.	6.1	126
1547	Autoinhibition and relief mechanism by the proteolytic processing of Toll-like receptor 8. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3012-3017.	7.1	47
1548	Prophylactic potential of resiquimod against very virulent infectious bursal disease virus (vvIBDV) challenge in the chicken. Veterinary Microbiology, 2016, 187, 21-30.	1.9	18
1549	Human Respiratory Syncytial Virus: Role of Innate Immunity in Clearance and Disease Progression. Viral Immunology, 2016, 29, 11-26.	1.3	25
1550	Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use. Science Signaling, 2016, 9, ra3.	3.6	66
1551	Nanoparticle-Based Nicotine Vaccine. , 2016, , 249-278.		2
1552	Dysregulation of Toll-Like Receptor 7 Compromises Innate and Adaptive T Cell Responses and Host Resistance to an Attenuated West Nile Virus Infection in Old Mice. Journal of Virology, 2016, 90, 1333-1344.	3.4	27
1553	Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis. Nature Reviews Drug Discovery, 2016, 15, 125-142.	46.4	115
1554	Trp channels and itch. Seminars in Immunopathology, 2016, 38, 293-307.	6.1	63
1555	HCV-infected cells and differentiation increase monocyte immunoregulatory galectin-9 production. Journal of Leukocyte Biology, 2016, 99, 495-503.	3.3	39
1556	Therapeutic Developments Targeting Tollâ€like Receptorâ€4â€Mediated Neuroinflammation. ChemMedChem, 2016, 11, 154-165.	3.2	64
1557	Activation of TLR7 increases CCND3 expression via the downregulation of miR-15b in B cells of systemic lupus erythematosus. Cellular and Molecular Immunology, 2016, 13, 764-775.	10.5	25
1558	Association of Toll-Like Receptor 3 and Toll-Like Receptor 9 Single Nucleotide Polymorphisms with Hepatitis C Virus Infection and Hepatic Fibrosis in Egyptian Patients. American Journal of Tropical Medicine and Hygiene, 2017, 96, 16-0644.	1.4	20
1560	Surgical Denervation in the Imiquimod-Induced Psoriasiform Mouse Model. Methods in Molecular Biology, 2017, 1559, 75-81.	0.9	6

#	Article	IF	CITATIONS
1561	Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells. International Reviews of Immunology, 2017, 36, 57-73.	3.3	174
1562	A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects. Journal of Immunology, 2017, 198, 1595-1605.	0.8	46
1563	Intralesional treatment of metastatic melanoma: a review of therapeutic options. Cancer Immunology, Immunotherapy, 2017, 66, 647-656.	4.2	34
1564	Intracellular Nucleic Acid Detection in Autoimmunity. Annual Review of Immunology, 2017, 35, 313-336.	21.8	176
1565	Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1713-1732.	2.5	12
1566	Quercetin ameliorates imiquimod-induced psoriasis-like skin inflammation in mice via the NF-κB pathway. International Immunopharmacology, 2017, 48, 110-117.	3.8	98
1567	Mouse nidovirus LDV infection alleviates graft versus host disease and induces type I IFN-dependent inhibition of dendritic cells and allo-responsive T cells. Immunity, Inflammation and Disease, 2017, 5, 200-213.	2.7	5
1569	Transcutaneous pollinosis immunotherapy using a solidâ€inâ€oil nanodispersion system carrying T cell epitope peptide and R848. Bioengineering and Translational Medicine, 2017, 2, 102-108.	7.1	16
1570	Stimulating Innate Immunity to Enhance Radiation Therapy–Induced Tumor Control. International Journal of Radiation Oncology Biology Physics, 2017, 99, 362-373.	0.8	43
1571	Posttranslational Modification as a Critical Determinant of Cytoplasmic Innate Immune Recognition. Physiological Reviews, 2017, 97, 1165-1209.	28.8	63
1572	Toll-Like Receptor Agonists: Can They Exact a Toll on Human Immunodeficiency Virus Persistence?. Clinical Infectious Diseases, 2017, 64, 1696-1698.	5.8	4
1573	Elevated Expression of the NLRP3 Inflammasome and Its Correlation with Disease Activity in Adult-onset Still Disease. Journal of Rheumatology, 2017, 44, 1142-1150.	2.0	53
1574	TLR7 and TLR8, Resiquimod, and 852A. , 2017, , 487-494.		0
1575	Fully degradable protein nanocarriers by orthogonal photoclick tetrazole–ene chemistry for the encapsulation and release. Nanoscale Horizons, 2017, 2, 297-302.	8.0	15
1576	Chemical Tools for Studying TLR Signaling Dynamics. Cell Chemical Biology, 2017, 24, 801-812.	5.2	34
1577	Structural insights into ligand recognition and regulation of nucleic acid-sensing Toll-like receptors. Current Opinion in Structural Biology, 2017, 47, 52-59.	5.7	32
1578	Sinecatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults. International Journal of STD and AIDS, 2017, 28, 1433-1443.	1.1	13
1579	Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines. Immunobiology, 2017, 222, 989-997.	1.9	34

	CITATION	REPORT	
#	Article	IF	CITATIONS
1580	Use of adjuvants for immunotherapy. Human Vaccines and Immunotherapeutics, 2017, 13, 1774-1777.	3.3	27
1581	Recognition of Viral RNA by Pattern Recognition Receptors in the Induction of Innate Immunity and Excessive Inflammation During Respiratory Viral Infections. Viral Immunology, 2017, 30, 408-420.	1.3	47
1582	Vaccine Adjuvants' Mode of Action. , 2017, , 1-22.		2
1583	Effects of dietary n-3 fatty acids on Toll-like receptor activation in primary leucocytes from Atlantic salmon (Salmo salar). Fish Physiology and Biochemistry, 2017, 43, 1065-1080.	2.3	12
1584	Induction of tumor regression by intratumoral STING agonists combined with anti–programmed death‣1 blocking antibody in a preclinical squamous cell carcinoma model. Head and Neck, 2017, 39, 1086-1094.	2.0	38
1585	Engaging Natural Killer T Cells as â€~Universal Helpers' for Vaccination. Drugs, 2017, 77, 1-15.	10.9	29
1586	Expression of Tollâ€Like Receptors in Peripheral Blood Mononuclear Cells of Patients with Primary SjA¶gren's Syndrome. Scandinavian Journal of Immunology, 2017, 85, 220-226.	2.7	19
1587	Efficacy of 5% imiquimod for the treatment of Vaginal intraepithelial neoplasia—A systematic review of the literature and a meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 218, 129-136.	1.1	30
1588	Small-Molecule Targets in Immuno-Oncology. Cell Chemical Biology, 2017, 24, 1148-1160.	5.2	44
1589	Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8. ACS Medicinal Chemistry Letters, 2017, 8, 1148-1152.	2.8	32
1590	Tumor-derived exosomes modulate PD-L1 expression in monocytes. Science Immunology, 2017, 2, .	11.9	236
1591	Tumour viruses and innate immunity. Philosophical Transactions of the Royal Society B: Biological Sciences, 2017, 372, 20160267.	4.0	24
1592	Toward a structural understanding of nucleic acidâ€sensing Tollâ€like receptors in the innate immune system. FEBS Letters, 2017, 591, 3167-3181.	2.8	29
1593	Towards an evidence based approach for the development of adjuvanted vaccines. Current Opinion in Immunology, 2017, 47, 93-102.	5.5	86
1594	Identification of an optimized 2′- <i>O</i> -methylated trinucleotide RNA motif inhibiting Toll-like receptors 7 and 8. Rna, 2017, 23, 1344-1351.	3.5	21
1595	Systematic Investigation of Multi-TLR Sensing Identifies Regulators of Sustained Gene Activation in Macrophages. Cell Systems, 2017, 5, 25-37.e3.	6.2	48
1596	Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation. Journal of Virology, 2017, 91, .	3.4	18
1597	Antitumor effect of <i>Batf2</i> through IL-12 p40 up-regulation in tumor-associated macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7331-E7340.	7.1	41

		CITATION REPORT		
#	Article		IF	CITATIONS
1598	Self-Assembled Ligands Targeting TLR7: A Molecular Level Investigation. Langmuir, 201	.7, 33, 14460-14471.	3.5	5
1599	The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduction and Therapy, 2017, 2, 17055.	d Targeted	17.1	61
1600	Mer Receptor Tyrosine Kinase Signaling Prevents Self-Ligand Sensing and Aberrant Sele Germinal Centers. Journal of Immunology, 2017, 199, 4001-4015.	ection in	0.8	9
1601	Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Part Synergistically Enhances Innate and Adaptive Immune Responses. Scientific Reports, 2	ticles 017, 7, 2530.	3.3	62
1602	Therapy with transcutaneous administration of imiquimod combined with oral adminis sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model. Onc 2017, 14, 1162-1166.	tration of ology Letters,	1.8	1
1603	Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced transcutaneous immunization. Journal of Dermatological Science, 2017, 87, 300-306.	by	1.9	10
1604	Paying for the Tolls: The High Cost of the Innate Immune System for the Cardiac Myocy Experimental Medicine and Biology, 2017, 1003, 17-34.	/te. Advances in	1.6	15
1605	Identification and Optimization of Pyrrolo[3,2- <i>d</i>]pyrimidine Toll-like Receptor 7 Agonists for the Treatment of Hepatitis B. Journal of Medicinal Chemistry, 2017, 60, 61	(TLR7) Selective 37-6151.	6.4	15
1606	TLR7 Signaling Regulates Th17 Cells and Autoimmunity: Novel Potential for Autoimmu Journal of Immunology, 2017, 199, 941-954.	ne Therapy.	0.8	27
1607	Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior responses and virus protection. Journal of Dermatological Science, 2017, 87, 252-259.	T cell	1.9	22
1608	Rhododendrin inhibits toll-like receptor-7-mediated psoriasis-like skin inflammation in r Experimental and Molecular Medicine, 2017, 49, e349-e349.	nice.	7.7	25
1609	Fatty Acid-Mimetic Micelles for Dual Delivery of Antigens and Imidazoquinoline Adjuva Biomaterials Science and Engineering, 2017, 3, 179-194.	nts. ACS	5.2	25
1610	Molecular requirements for sensing of intracellular microbial nucleic acids by the innate system. Cytokine, 2017, 98, 4-14.	e immune	3.2	33
1611	Toll-like receptors in mycobacterial infection. European Journal of Pharmacology, 2017	, 808, 1-7.	3.5	20
1612	Sexy again: the renaissance of neutrophils in psoriasis. Experimental Dermatology, 201	7, 26, 305-311.	2.9	71
1614	Production of Adjuvant-Loaded Biodegradable Particles for Use in Cancer Vaccines. Me Molecular Biology, 2017, 1494, 201-213.	thods in	0.9	9
1615	Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7. Antiviral 2017, 137, 108-111.	Research,	4.1	16
1616	Bovine milk RNases modulate pro-inflammatory responses induced by nucleic acids in a and epithelial cells. Developmental and Comparative Immunology, 2017, 68, 87-97.	cultured immune	2.3	12

#	Article	IF	CITATIONS
1617	Nanoparticle-based B-cell targeting vaccines: Tailoring of humoral immune responses by functionalization with different TLR-ligands. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 173-182.	3.3	37
1618	Myeloid differentiation primary response gene (MyD) 88 signalling is not essential for intestinal fibrosis development. Scientific Reports, 2017, 7, 17678.	3.3	6
1619	TLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host Disease. Immune Network, 2017, 17, 144.	3.6	26
1620	Cancer Immunotherapy—An Emerging Field That Bridges Oncology andÂlmmunology Research. , 2017, , 357-394.		1
1621	Extracellular Vesicles Deliver Host and Virus RNA and Regulate Innate Immune Response. International Journal of Molecular Sciences, 2017, 18, 666.	4.1	89
1622	Bioconjugation of Small Molecules to RNA Impedes Its Recognition by Toll-Like Receptor 7. Frontiers in Immunology, 2017, 8, 312.	4.8	8
1623	Human Blood CD1c+ Dendritic Cells Promote Th1 and Th17 Effector Function in Memory CD4+ T Cells. Frontiers in Immunology, 2017, 8, 971.	4.8	69
1624	The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome. Frontiers in Immunology, 2017, 8, 1075.	4.8	123
1625	Direct and Intestinal Epithelial Cell-Mediated Effects of TLR8 Triggering on Human Dendritic Cells, CD14+CD16+ Monocytes and γδT Lymphocytes. Frontiers in Immunology, 2017, 8, 1813.	4.8	4
1626	Co-Stimulation of BCR and Toll-Like Receptor 7 Increases Somatic Hypermutation, Memory B Cell Formation, and Secondary Antibody Response to Protein Antigen. Frontiers in Immunology, 2017, 8, 1833.	4.8	27
1627	Discovery of Immune Potentiators as Vaccine Adjuvants. , 2017, , 85-104.		7
1628	Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight, 2017, 2, .	5.0	203
1629	Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity. PLoS ONE, 2017, 12, e0182022.	2.5	20
1630	HRS plays an important role for TLR7 signaling to orchestrate inflammation and innate immunity upon EV71 infection. PLoS Pathogens, 2017, 13, e1006585.	4.7	31
1631	Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget, 2017, 8, 71249-71284.	1.8	138
1632	The Biological Function of Kupffer Cells in Liver Disease. , 0, , .		7
1633	Advances and Opportunities in Nanoparticle―and Nanomaterialâ€Based Vaccines against Bacterial Infections. Advanced Healthcare Materials, 2018, 7, e1701395.	7.6	74
1634	Type 2 Diabetes. , 2018, , 1236-1236.		0

			_
#	Article	IF	CITATIONS
1635	Genital warts treatment: Beyond imiquimod. Human Vaccines and Immunotherapeutics, 2018, 14, 1815-1819.	3.3	35
1636	Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 242.e1-242.e7.	1.6	2
1637	Small-molecule inhibition of TLR8 through stabilization of its resting state. Nature Chemical Biology, 2018, 14, 58-64.	8.0	97
1638	Innate immune receptors drive dengue virus immune activation and disease. Future Virology, 2018, 13, 287-305.	1.8	17
1639	The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells. Vaccine, 2018, 36, 1174-1182.	3.8	13
1640	Tertiary Structure Domains, Folds and Motifs. , 2018, , 1174-1178.		0
1641	The Preparation and Physicochemical Characterization of Aluminum Hydroxide/TLR7a, a Novel Vaccine Adjuvant Comprising a Small Molecule Adsorbed to Aluminum Hydroxide. Journal of Pharmaceutical Sciences, 2018, 107, 1577-1585.	3.3	10
1642	Nonâ€ŀgE mediated mast cell activation. Immunological Reviews, 2018, 282, 87-113.	6.0	143
1643	Investigating the effect of key mutations on the conformational dynamics of tollâ€like receptor dimers through molecular dynamics simulations and protein structure networks. Proteins: Structure, Function and Bioinformatics, 2018, 86, 475-490.	2.6	9
1644	Transcriptional Silencing. , 2018, , 1214-1214.		0
1645	TANK-Binding Kinase 1 (TBK1): Structure, Function, and Regulation. , 2018, , 1155-1163.		0
1646	Tetratricopeptide Repeat. , 2018, , 5372-5372.		0
1647	TR., 2018, , 5566-5566.		0
1648	Tryptophan 5-Monooxygenase 2. , 2018, , 5762-5762.		1
1649	GS-9620 inhibits enterovirus 71 replication mainly through the NF-κB and PI3K-AKT signaling pathways. Antiviral Research, 2018, 153, 39-48.	4.1	17
1650	Pulsating flow triggered by the laser induced phase change in microchannels with sawtooth-shaped baffles. Sensors and Actuators B: Chemical, 2018, 260, 1018-1024.	7.8	7
1651	Thyrotropin Receptor. , 2018, , 5419-5424.		0
1652	Temporal cytokine and lymphoid responses to an inhaled TLR7 antedrug agonist in the cynomolgus monkey demonstrates potential safety and tolerability of this approach. Toxicology and Applied Pharmacology, 2018, 338, 9-19.	2.8	8

# 1653	ARTICLE Innate Immune Receptors in the Regulation of Tumor Immunity. , 2018, , 407-427.	IF	Citations 0
1654	Activation of TLR3 and its adaptor TICAM-1 increases miR-21 levels in extracellular vesicles released from human cells. Biochemical and Biophysical Research Communications, 2018, 500, 744-750.	2.1	9
1655	Tollâ€Like Receptor 9 Deficiency Breaks Tolerance to RNAâ€Associated Antigens and Upâ€Regulates Tollâ€Like Receptor 7 Protein in <i>Sle1</i> Mice. Arthritis and Rheumatology, 2018, 70, 1597-1609.	5.6	12
1656	TRPA1 Acts in a Protective Manner in Imiquimod-Induced Psoriasiform Dermatitis in Mice. Journal of Investigative Dermatology, 2018, 138, 1774-1784.	0.7	51
1657	Synthesis and Applications of Imidazoquinolines: A Review. Organic Preparations and Procedures International, 2018, 50, 109-244.	1.3	5
1658	Routing dependent immune responses after experimental R848-adjuvated vaccination. Vaccine, 2018, 36, 1405-1413.	3.8	17
1659	Duplicated TLR5 of zebrafish functions as a heterodimeric receptor. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3221-E3229.	7.1	54
1660	The role of type I interferons in innate and adaptive immunity against viruses in Atlantic salmon. Developmental and Comparative Immunology, 2018, 80, 41-52.	2.3	71
1661	Toll-like receptors: Significance, ligands, signaling pathways, and functions in mammals. International Reviews of Immunology, 2018, 37, 20-36.	3.3	334
1662	Toll-Like Receptor 7/8 Ligand, S28463, Suppresses <i>Ascaris suum</i> –induced Allergic Asthma in Nonhuman Primates. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 55-65.	2.9	5
1663	Expression of TLR7, TLR9, JAK2, and STAT3 genes in peripheral blood mononuclear cells from patients with systemic sclerosis. Journal of Applied Genetics, 2018, 59, 59-66.	1.9	14
1664	Phenotypic changes of lymphocyte populations in psoriasiform dermatitis animal model. Experimental and Therapeutic Medicine, 2018, 17, 1030-1038.	1.8	12
1665	Excessive endosomal TLR signaling causes inflammatory disease in mice with defective SMCR8-WDR41-C9ORF72 complex function. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11523-E11531.	7.1	40
1666	Decreased TLR3 in Hyperplastic Adipose Tissue, Blood and Inflamed Adipocytes is Related to Metabolic Inflammation. Cellular Physiology and Biochemistry, 2018, 51, 1051-1068.	1.6	14
1667	Synthesis of indole–cycloalkyl[<i>b</i>]pyridine hybrids via a four-component six-step tandem process. Beilstein Journal of Organic Chemistry, 2018, 14, 2907-2915.	2.2	11
1668	TLR8: No gain, no pain. Journal of Experimental Medicine, 2018, 215, 2964-2966.	8.5	10
1669	Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells. Oncotarget, 2018, 9, 15895-15914.	1.8	13
1670	HMGN1 and R848 Synergistically Activate Dendritic Cells Using Multiple Signaling Pathways. Frontiers in Immunology, 2018, 9, 2982.	4.8	29

#	Article	IF	CITATIONS
1671	Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands. Cell Reports, 2018, 25, 3371-3381.e5.	6.4	98
1672	TLR7 (Toll-Like Receptor 7) Facilitates Heme Scavenging Through the BTK (Bruton Tyrosine Kinase)–CRT (Calreticulin)–LRP1 (Low-Density Lipoprotein Receptor–Related Protein-1)–Hx (Hemopexin) Pathway in Murine Intracerebral Hemorrhage. Stroke, 2018, 49, 3020-3029.	2.0	28
1673	Differential and Overlapping Immune Programs Regulated by IRF3 and IRF5 in Plasmacytoid Dendritic Cells. Journal of Immunology, 2018, 201, 3036-3050.	0.8	19
1674	A requirement for slc15a4 in imiquimod-induced systemic inflammation and psoriasiform inflammation in mice. Scientific Reports, 2018, 8, 14451.	3.3	10
1675	The immune cell infiltrate in the microenvironment of vulvar Paget disease. Gynecologic Oncology, 2018, 151, 453-459.	1.4	10
1676	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature, 2018, 563, 360-364.	27.8	246
1677	MicroRNA-451a in extracellular, blood-resident vesicles attenuates macrophage and dendritic cell responses to influenza whole-virus vaccine. Journal of Biological Chemistry, 2018, 293, 18585-18600.	3.4	35
1678	Degradationâ€Regulatable Architectured Implantable Macroporous Scaffold for the Spatiotemporal Modulation of Immunosuppressive Microenvironment and Enhanced Combination Cancer Immunotherapy. Advanced Functional Materials, 2018, 28, 1804490.	14.9	36
1679	Modular bioinformatics analysis demonstrates that a Toll‑like receptor signaling pathway is involved in the regulation of macrophage polarization. Molecular Medicine Reports, 2018, 18, 4313-4320.	2.4	15
1680	p53 mediated IFN-Î ² signaling to affect viral replication upon TGEV infection. Veterinary Microbiology, 2018, 227, 61-68.	1.9	8
1681	Innate Immunity Induces the Accumulation of Lung Mast Cells During Influenza Infection. Frontiers in Immunology, 2018, 9, 2288.	4.8	9
1682	IFN-Î ³ synergism with poly I:C reduces growth of murine and human cancer cells with simultaneous changes in cell cycle and immune checkpoint proteins. Cancer Letters, 2018, 438, 1-9.	7.2	8
1683	Detection of Microbial Infections Through Innate Immune Sensing of Nucleic Acids. Annual Review of Microbiology, 2018, 72, 447-478.	7.3	336
1684	Effects of different principles of Traditional Chinese Medicine treatment on TLR7/NF-ήB signaling pathway in influenza virus infected mice. Chinese Medicine, 2018, 13, 42.	4.0	26
1685	Toll-Like Receptors: The Key of Immunotherapy in MSCs. , 0, , .		5
1686	Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections. Expert Opinion on Drug Discovery, 2018, 13, 661-670.	5.0	22
1687	A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model. World Journal of Urology, 2018, 36, 1719-1725.	2.2	7
1688	Dibutyl phthalate modulates phenotype of granulocytes in human blood in response to inflammatory stimuli. Toxicology Letters, 2018, 296, 23-30.	0.8	22

ARTICLE IF CITATIONS Therapeutic vaccination for HIV. Current Opinion in HIV and AIDS, 2018, 13, 408-415. 3.8 31 1689 Adjuvants. Current Topics in Microbiology and Immunology, 2018, 428, 103-127. 1.1 High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation. 1691 4.0 9 European Journal of Pharmaceutical Sciences, 2018, 123, 268-276. Respiratory Influenza A Virus Infection Triggers Local and Systemic Natural Killer Cell Activation via 4.8 Toll-Like Receptor 7. Frontiers in Immunology, 2018, 9, 245. Toll-like receptors in immunity and inflammatory diseases: Past, present, and future. International 1693 438 3.8 Immunopharmacology, 2018, 59, 391-412. Toll-Like Receptor-7 Signaling Promotes Nonalcoholic Steatohepatitis by Inhibiting Regulatory T Cells in Mice. American Journal of Pathology, 2018, 188, 2574-2588. 1694 3.8 Roles of Toll-Like Receptors in Pathophysiology of Alzheimer's Disease and Multiple Sclerosis. , 2018, , 1695 3 541-562. Management of Melanoma Locoregional Recurrence., 2018,, 351-359. 1696 Innate Immunity in Inflammation., 2018, , 179-190. 1697 1 The Role of Flaviviral Proteins in the Induction of Innate Immunity. Sub-Cellular Biochemistry, 2018, 2.4 88, 407-442. Immunomodulating Pharmaceuticals., 2019, , 1177-1184.e1. 1699 1 Cell Type Specific Expression of Toll-Like Receptors in Human Brains and Implications in Alzheimer's 1700 Disease. BioMed Research International, 2019, 2019, 1-18. Atmospheric H2S triggers immune damage by activating the TLR-7/MyD88/NF-κB pathway and NLRP3 1701 8.2 85 inflammasome in broiler thymus. Chemosphere, 2019, 237, 124427. TLRs in pulmonary diseases. Life Sciences, 2019, 233, 116671. 1702 4.3 63 Protective effects of delayed intraventricular TLR7 agonist administration on cerebral white and gray 1703 3.3 12 matter following asphyxia in the preterm fetal sheep. Scientific Reports, 2019, 9, 9562. TLR7 Protein Expression in Mild and Severe Lupus-Prone Models Is Regulated in a Leukocyte, Genetic, 1704 4.8 and IRAK4 Dependent Manner. Frontiers in Immunology, 2019, 10, 1546. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. 1705 12.8 123 Nature Communications, 2019, 10, 4682. Real-time MRI-guided Prostate Stereotactic Body Radiation Therapy: Impact on Treatment Delivery and 1706 Implications. International Journal of Radiation Oncology Biology Physics, 2019, 105, E260.

# 1707	ARTICLE Screening for new macrophage therapeutics. Theranostics, 2019, 9, 7714-7729.	IF 10.0	CITATIONS 26
1708	Chicken toll-like receptors and their significance in immune response and disease resistance. International Reviews of Immunology, 2019, 38, 284-306.	3.3	36
1709	Identification of U11snRNA as an endogenous agonist of TLR7-mediated immune pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23653-23661.	7.1	16
1710	Literature review of baseline information on nonâ€coding RNA (ncRNA) to support the risk assessment of ncRNAâ€based genetically modified plants for food and feed. EFSA Supporting Publications, 2019, 16, 1688E.	0.7	31
1711	Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors. Immuno-Oncology Technology, 2019, 3, 15-23.	0.3	14
1712	RNA-Based Adjuvants: Immunoenhancing Effect on Antiviral Vaccines and Regulatory Considerations. Critical Reviews in Immunology, 2019, 39, 1-14.	0.5	2
1713	Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods. Pharmaceutics, 2019, 11, 441.	4.5	20
1714	Synthetic Toll-like Receptors 7 and 8 Agonists: Structure–Activity Relationship in the Oxoadenine Series. ACS Omega, 2019, 4, 15665-15677.	3.5	14
1715	Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles. Nature Reviews Drug Discovery, 2019, 18, 845-867.	46.4	126
1716	Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7. Journal of Biomolecular Structure and Dynamics, 2019, 37, 4721-4736.	3.5	17
1717	Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8+ T Cell Responses. Cell Reports, 2019, 26, 1242-1257.e7.	6.4	23
1718	Intrinsic cancer vaccination. Advanced Drug Delivery Reviews, 2019, 151-152, 2-22.	13.7	30
1719	Immunotherapy for malignant tumors with focus on tollâ€ŀike receptors. Oral Science International, 2019, 16, 3-7.	0.7	2
1720	Herpes Simplex Virus Evasion of Early Host Antiviral Responses. Frontiers in Cellular and Infection Microbiology, 2019, 9, 127.	3.9	89
1721	Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds. European Journal of Medicinal Chemistry, 2019, 179, 109-122.	5.5	18
1722	Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. American Journal of Clinical Dermatology, 2019, 20, 781-796.	6.7	11
1723	Melanoma on chronically sun-damaged skin: Lentigo maligna and desmoplastic melanoma. Journal of the American Academy of Dermatology, 2019, 81, 823-833.	1.2	44
1724	TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer. Human Gene Therapy Methods, 2019, 30, 81-92.	2.1	22

#	Article	IF	CITATIONS
1725	Therapeutic application of the CRISPR system: current issues and new prospects. Human Genetics, 2019, 138, 563-590.	3.8	16
1726	The Toll-like receptor agonist imiquimod is metabolized by aryl hydrocarbon receptor-regulated cytochrome P450 enzymes in human keratinocytes and mouse liver. Archives of Toxicology, 2019, 93, 1917-1926.	4.2	16
1727	PA-X antagonises MAVS-dependent accumulation of early type I interferon messenger RNAs during influenza A virus infection. Scientific Reports, 2019, 9, 7216.	3.3	25
1728	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Frontiers in Immunology, 2019, 10, 999.	4.8	47
1729	Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma. Clinical Immunology, 2019, 203, 154-161.	3.2	12
1730	TLR7 Controls VSV Replication in CD169+ SCS Macrophages and Associated Viral Neuroinvasion. Frontiers in Immunology, 2019, 10, 466.	4.8	11
1732	Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice. PLoS Neglected Tropical Diseases, 2019, 13, e0007316.	3.0	21
1733	Tollâ€like receptors in the functional orientation of cardiac progenitor cells. Journal of Cellular Physiology, 2019, 234, 19451-19463.	4.1	1
1734	Vaccine-Induced Protection Against Furunculosis Involves Pre-emptive Priming of Humoral Immunity in Arctic Charr. Frontiers in Immunology, 2019, 10, 120.	4.8	18
1735	Innate sensors that regulate vaccine responses. Current Opinion in Immunology, 2019, 59, 31-41.	5.5	21
1736	The Otubain YOD1 Suppresses Aggregation and Activation of the Signaling Adaptor MAVS through Lys63-Linked Deubiquitination. Journal of Immunology, 2019, 202, 2957-2970.	0.8	34
1737	The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1/IgE class switching and germline lµ transcription through the induction of BCL6 expression in B cells. Cellular Immunology, 2019, 338, 1-8.	3.0	13
1738	Oral Mucosal Epithelial Cells. Frontiers in Immunology, 2019, 10, 208.	4.8	225
1739	Pattern Recognition Receptors in Autoinflammation. , 2019, , 61-87.		2
1740	Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production. Vaccine, 2019, 37, 1630-1637.	3.8	40
1741	Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis. Infection, Genetics and Evolution, 2019, 70, 27-35.	2.3	23
1742	Nucleic Acid Sensing in Allergic Disorders. International Review of Cell and Molecular Biology, 2019, 345, 1-33.	3.2	1
1743	Percellome Toxicogenomics Project as a Source of Biomarkers of Chemical Toxicity. , 2019, , 1135-1151.		0

#	Article	IF	CITATIONS
1744	Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor onditioned macrophages. European Journal of Immunology, 2019, 49, 801-811.	2.9	38
1745	Advances in immunotherapy delivery from implantable and injectable biomaterials. Acta Biomaterialia, 2019, 88, 15-31.	8.3	127
1746	ADP-ribosylation factor-like 8b is required for the development of mouse models of systemic lupus erythematosus. International Immunology, 2019, 31, 225-237.	4.0	0
1747	Transmissible Cancers and Immune Downregulation in Tasmanian Devil (<i>Sacrophilus harrisii</i>) and Canine Populations. Comparative Medicine, 2019, 69, 291-298.	1.0	0
1748	Immune Responses Alter Taste Perceptions: Immunomodulatory Drugs Shape Taste Signals during Treatments. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 684-691.	2.5	1
1749	Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy. Theranostics, 2019, 9, 8426-8436.	10.0	65
1750	Microbial Danger Signals Control Transcriptional Induction of Distinct MHC Class I L Lineage Genes in Atlantic Salmon. Frontiers in Immunology, 2019, 10, 2425.	4.8	9
1751	let-7 MicroRNAs Regulate Microglial Function and Suppress Glioma Growth through Toll-Like Receptor 7. Cell Reports, 2019, 29, 3460-3471.e7.	6.4	64
1752	The TLR7 ligand R848 prevents mouse graft- <i>versus</i> -host disease and cooperates with anti-interleukin-27 antibody for maximal protection and regulatory T-cell upregulation. Haematologica, 2019, 104, 392-402.	3.5	10
1753	Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-ήB and TLR7 pathways in mice. Biomedicine and Pharmacotherapy, 2019, 109, 1876-1883.	5.6	30
1754	Discrimination Between Self and Non-Self-Nucleic Acids by the Innate Immune System. International Review of Cell and Molecular Biology, 2019, 344, 1-30.	3.2	38
1755	RNA-Dependent RNA Polymerases and Their Emerging Roles in Antiviral Therapy. , 2019, , 1-42.		10
1756	Endosomal Toll-Like Receptors 7 and 9 Cooperate in Detection of Murine Gammaherpesvirus 68 Infection. Journal of Virology, 2019, 93, .	3.4	21
1757	Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer. Biomaterials, 2019, 195, 86-99.	11.4	79
1758	Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity. Nature Materials, 2019, 18, 175-185.	27.5	172
1759	Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation. Biomaterials, 2019, 190-191, 111-120.	11.4	43
1760	Infection Prevention: Oil- and Lipid-Containing Products in Vaccinology. , 2019, , 1-31.		0
1761	Management of local or regional nonâ€nodal disease. Journal of Surgical Oncology, 2019, 119, 187-199.	1.7	8

#	Article	lF	CITATIONS
1762	Nucleic Acid Sensing in Mammals and Plants: Facts and Caveats. International Review of Cell and Molecular Biology, 2019, 345, 225-285.	3.2	25
1764	A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response. Journal of Investigative Dermatology, 2020, 140, 869-877.e16.	0.7	15
1765	LGI3 is secreted and binds to ADAM22 via TRIF-dependent NF-κB pathway in response to LPS in human keratinocytes. Cytokine, 2020, 126, 154872.	3.2	7
1766	Frontline Science: Targeting the TLR7 signalosome assembly. Journal of Leukocyte Biology, 2020, 108, 1697-1706.	3.3	2
1767	Deoxyguanosine is a TLR7 agonist. European Journal of Immunology, 2020, 50, 56-62.	2.9	19
1768	Kiss of Death: Ring Finger 216 Regulates Toll-like Receptor 8 Stability through Ubiquitination. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 125-127.	2.9	2
1769	Resiquimod inhibits Newcastle disease virus replication by modulating host cytokines: An understanding towards its possible therapeutics. Cytokine, 2020, 125, 154811.	3.2	5
1770	Sensing of HIV-1 by TLR8 activates human T cells and reverses latency. Nature Communications, 2020, 11, 147.	12.8	62
1771	Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126840.	2.2	3
1772	Developments in anticancer vaccination: budding new adjuvants. Biological Chemistry, 2020, 401, 435-446.	2.5	2
1773	Recent progress in the design of DNA vaccines against tuberculosis. Drug Discovery Today, 2020, 25, 1971-1987.	6.4	19
1774	A method to differentiate chicken monocytes into macrophages with proinflammatory properties. Immunobiology, 2020, 225, 152004.	1.9	16
1775	Temporal dynamics of innate and adaptive immune responses in broiler birds to oral delivered chitosan nanoparticle-based Salmonella subunit antigens. Veterinary Immunology and Immunopathology, 2020, 228, 110111.	1.2	5
1776	Intratumoral administration of the Tollâ€like receptor 7/8 agonist 3Mâ€052 enhances interferonâ€driven tumor immunogenicity and suppresses metastatic spread in preclinical tripleâ€negative breast cancer. Clinical and Translational Immunology, 2020, 9, e1177.	3.8	22
1777	Porcine deltacoronavirus nucleocapsid protein species-specifically suppressed IRF7-induced type I interferon production via ubiquitin-proteasomal degradation pathway. Veterinary Microbiology, 2020, 250, 108853.	1.9	17
1778	Sex and Gender Disparities in Melanoma. Cancers, 2020, 12, 1819.	3.7	69
1779	Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic Acids. Immunity, 2020, 53, 54-77.	14.3	115
1780	A Novel Small-Molecule Inhibitor of Endosomal TLRs Reduces Inflammation and Alleviates Autoimmune Disease Symptoms in Murine Models. Cells, 2020, 9, 1648.	4.1	8

#	Article	IF	CITATIONS
1781	Regulatory Considerations on the Development of mRNA Vaccines. Current Topics in Microbiology and Immunology, 2020, , 187-205.	1.1	16
1782	Zebrafish IL-4–like Cytokines and IL-10 Suppress Inflammation but Only IL-10 Is Essential for Gill Homeostasis. Journal of Immunology, 2020, 205, 994-1008.	0.8	36
1783	A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner. Frontiers in Immunology, 2020, 11, 580974.	4.8	10
1784	Electric Pulse Responsive Magnetic Nanoclusters Loaded with Indoleamine 2,3-Dioxygenase Inhibitor for Synergistic Immuno-Ablation Cancer Therapy. ACS Applied Materials & Interfaces, 2020, 12, 54415-54425.	8.0	19
1785	Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy. Frontiers in Immunology, 2020, 11, 599083.	4.8	68
1786	AIM2 Stimulation Impairs Reendothelialization and Promotes the Development of Atherosclerosis in Mice. Frontiers in Cardiovascular Medicine, 2020, 7, 582482.	2.4	14
1787	Role of toll-like receptor 7 (TLR7) in voluntary alcohol consumption. Brain, Behavior, and Immunity, 2020, 89, 423-432.	4.1	21
1788	HPV11E7 inhibits IMQ-induced chemokine and colony-stimulating factor production in keratinocytes. Gene, 2020, 760, 145003.	2.2	5
1789	The Role of Dendritic Cells During Infections Caused by Highly Prevalent Viruses. Frontiers in Immunology, 2020, 11, 1513.	4.8	41
1790	TLR7 Sensing by Neutrophils Is Critical for the Control of Cutaneous Leishmaniasis. Cell Reports, 2020, 31, 107746.	6.4	21
1791	Effect of Imiquimod on Tachyzoites of Toxoplasma gondii and Infected Macrophages in vitro and in BALB/c Mice. Frontiers in Cellular and Infection Microbiology, 2020, 10, 387.	3.9	6
1792	<p>Toll-Like Receptor 9 Agonists in Cancer</p> . OncoTargets and Therapy, 2020, Volume 13, 10039-10061.	2.0	74
1793	JCPyV VP1 Mutations in Progressive Multifocal Leukoencephalopathy: Altering Tropism or Mediating Immune Evasion?. Viruses, 2020, 12, 1156.	3.3	6
1794	A dual and conflicting role for imiquimod in inflammation: A TLR7 agonist and a cAMP phosphodiesterase inhibitor. Biochemical Pharmacology, 2020, 182, 114206.	4.4	6
1795	A Role of Intracellular Toll-Like Receptors (3, 7, and 9) in Response to Mycobacterium tuberculosis and Co-Infection with HIV. International Journal of Molecular Sciences, 2020, 21, 6148.	4.1	14
1796	Vaccination Strategies Against Highly Variable Pathogens. Current Topics in Microbiology and Immunology, 2020, , .	1.1	1
1797	Activation of TRPA1 nociceptor promotes systemic adult mammalian skin regeneration. Science Immunology, 2020, 5, .	11.9	28
1798	Toll-Like Receptor as a Potential Biomarker in Renal Diseases. International Journal of Molecular Sciences, 2020, 21, 6712.	4.1	10

#	Article	IF	CITATIONS
1799	Extracellular miR-574-5p Induces Osteoclast Differentiation via TLR 7/8 in Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 585282.	4.8	30
1800	Aging-Associated Extracellular Vesicles Contain Immune Regulatory microRNAs Alleviating Hyperinflammatory State and Immune Dysfunction in the Elderly. IScience, 2020, 23, 101520.	4.1	24
1801	Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control. International Journal of Radiation Oncology Biology Physics, 2020, 108, 27-37.	0.8	22
1802	Pattern Recognition Receptor Signaling and Innate Responses to Influenza A Viruses in the Mallard Duck, Compared to Humans and Chickens. Frontiers in Cellular and Infection Microbiology, 2020, 10, 209.	3.9	30
1803	Inhibitory Effects of Dietary N-Glycans From Bovine Lactoferrin on Toll-Like Receptor 8; Comparing Efficacy With Chloroquine. Frontiers in Immunology, 2020, 11, 790.	4.8	12
1804	Targeted Knockout of MDA5 and TLR3 in the DF-1 Chicken Fibroblast Cell Line Impairs Innate Immune Response Against RNA Ligands. Frontiers in Immunology, 2020, 11, 678.	4.8	30
1805	PathWalks: identifying pathway communities using a disease-related map of integrated information. Bioinformatics, 2020, 36, 4070-4079.	4.1	7
1806	Treatment with a Tollâ€like Receptor 7 ligand evokes protective immunity against atherosclerosis in hypercholesterolaemic mice. Journal of Internal Medicine, 2020, 288, 321-334.	6.0	11
1807	Lymph node-targeted immune-activation mediated by imiquimod-loaded mesoporous polydopamine based-nanocarriers. Biomaterials, 2020, 255, 120208.	11.4	66
1808	Excessive Polyamine Generation in Keratinocytes Promotes Self-RNA Sensing by Dendritic Cells in Psoriasis. Immunity, 2020, 53, 204-216.e10.	14.3	69
1809	Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, 2020, , .	1.6	7
1810	<i>Streptococcus pneumoniae</i> PepO promotes host anti-infection defense via autophagy in a Toll-like receptor 2/4 dependent manner. Virulence, 2020, 11, 270-282.	4.4	16
1811	IL-33 Is Essential for Adjuvant Effect of Hydroxypropyl-β-Cyclodexrin on the Protective Intranasal Influenza Vaccination. Frontiers in Immunology, 2020, 11, 360.	4.8	12
1812	Toll-Like Receptor 7 Stimulation Promotes the Development of Atherosclerosis in Apolipoprotein E-Deficient Mice. International Heart Journal, 2020, 61, 364-372.	1.0	8
1813	Circadian control of interferon-sensitive gene expression in murine skin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5761-5771.	7.1	38
1814	Toll-like Receptors and the Control of Immunity. Cell, 2020, 180, 1044-1066.	28.9	1,099
1815	Respiratory microbiome and epithelial interactions shape immunity in the lungs. Immunology, 2020, 160, 171-182.	4.4	103
1816	Toll-like receptor 7 contributes to neuropathic pain by activating NF-κB in primary sensory neurons. Brain, Behavior, and Immunity, 2020, 87, 840-851.	4.1	37

		CITATION REPORT		
# 1817	ARTICLE Small-Molecule Modulators of Toll-like Receptors. Accounts of Chemical Research, 2020, 53,	, 1046-1055.	IF 15.6	CITATIONS
1818	The E3 Ubiquitin Ligase SIAH1 Targets MyD88 for Proteasomal Degradation During Dengue Infection. Frontiers in Microbiology, 2020, 11, 24.	Virus	3.5	16
1819	Molecular cloning, tissue distribution and function analysis of duck TLR7. Animal Biotechnol 2020, , 1-8.	ogy,	1.5	1
1820	RNA Sensing by Gut Piezo1 Is Essential for Systemic Serotonin Synthesis. Cell, 2020, 182, 60	09-624.e21.	28.9	74
1821	Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines,	2020, 8, 313.	4.4	12
1822	Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127366.	J.	2.2	7
1823	Biomaterials for Immunoengineering. , 2020, , 1199-1215.			1
1824	Integrative analysis suggests cell type–specific decoding of NF-κB dynamics. Science Sign	aling, 2020, 13, .	3.6	33
1825	TLR7 trafficking and signaling in B cells is regulated by the MHCII-associated invariant chain. of Cell Science, 2020, 133, .	Journal	2.0	6
1826	Omiganan Enhances Imiquimodâ€Induced Inflammatory Responses in Skin of Healthy Volun and Translational Science, 2020, 13, 573-579.	teers. Clinical	3.1	15
1827	Characterization and expression analysis of rockfish (Sebastes schlegelii) myeloid differentia factor-88 (SsMyD88) and evaluation of its ability to induce inflammatory cytokines through and Shellfish Immunology, 2020, 99, 59-72.	tion NF-Ä,B. Fish	3.6	9
1828	Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy. Journal of Immunology Research, 2020, 2020, 1-9.		2.2	48
1829	Keratinocyte transglutaminase 2 promotes CCR6+ γÎT-cell recruitment by upregulating CCL psoriatic inflammation. Cell Death and Disease, 2020, 11, 301.	.20 in	6.3	12
1830	Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. European Journal of Medicinal Chemistry, 2020, 193, 112238.		5.5	77
1831	Supramolecular Assembly of Toll-like Receptor 7/8 Agonist into Multimeric Water-Soluble Co Enables Superior Immune Stimulation <i>In Vitro</i> and <i>In Vivo</i> . ACS Applied Bio Ma 2020, 3, 3187-3195.	onstructs Iterials,	4.6	23
1832	Genome-wide identification, expression signature and immune functional analysis of two car (CTSS) genes in turbot (Scophthalmus maximus L.). Fish and Shellfish Immunology, 2020, 1	thepsin S 02, 243-256.	3.6	7
1833	Activation of plasmacytoid dendritic cells and B cells with two structurally different Tollâ€lik receptor 7 agonists. Scandinavian Journal of Immunology, 2020, 91, e12880.	е	2.7	5
1834	RNA/DNA sensing in SLE—Toll-like receptors and beyond. , 2021, , 159-170.			0

#	Article	IF	CITATIONS
1835	R848 or influenza virus can induce potent innate immune responses in the lungs of neonatal mice. Mucosal Immunology, 2021, 14, 267-276.	6.0	11
1836	Current Management of Melanoma. Updates in Surgery Series, 2021, , .	0.1	0
1837	Tollâ€like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists. IUBMB Life, 2021, 73, 10-25.	3.4	42
1838	Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes. Biomaterials, 2021, 268, 120601.	11.4	67
1839	Controlling the semi-permeability of protein nanocapsules influences the cellular response to macromolecular payloads. Journal of Materials Chemistry B, 2021, 9, 8389-8398.	5.8	4
1840	R848 Is Involved in the Antibacterial Immune Response of Golden Pompano (Trachinotus ovatus) Through TLR7/8-MyD88-NF-κB-Signaling Pathway. Frontiers in Immunology, 2020, 11, 617522.	4.8	11
1841	In silico analyses on the comparative sensing of SARSâ€CoVâ€2 mRNA by the intracellular TLRs of humans. Journal of Medical Virology, 2021, 93, 2476-2486.	5.0	65
1842	TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases. Pharmaceutics, 2021, 13, 142.	4.5	129
1843	Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles. RSC Medicinal Chemistry, 2021, 12, 1065-1120.	3.9	15
1844	Vaccine as immunotherapy for leishmaniasis. , 2021, , 29-46.		0
1845	GDF15 promotes glioma stem cell-like phenotype via regulation of ERK1/2–c-Fos–LIF signaling. Cell Death Discovery, 2021, 7, 3.	4.7	18
1846	Toll-Like Receptor 7 (TLR7) Mediated Transcriptomic Changes on Human Mast Cells. Annals of Dermatology, 2021, 33, 402.	0.9	3
1847	Herpes Simplex Viruses Type 1 and Type 2 Infection and Immunity. , 2021, , .		2
1848	Neurosteroid allopregnanolone (3î±,5î±-THP) inhibits inflammatory signals induced by activated MyD88-dependent toll-like receptors. Translational Psychiatry, 2021, 11, 145.	4.8	44
1849	Cancer Immunoprevention: Current Status and Future Directions. Archivum Immunologiae Et Therapiae Experimentalis, 2021, 69, 3.	2.3	15
1850	TLR7 Is Critical for Anti-Viral Humoral Immunity to EV71 Infection in the Spinal Cord. Frontiers in Immunology, 2020, 11, 614743.	4.8	7
1851	Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics. Expert Opinion on Drug Discovery, 2021, 16, 869-880.	5.0	16
1852	Glyco-Nanoadjuvants: Sugar Structures on Carriers of a Small Molecule TLR7 Ligand Affect Their Immunostimulatory Activities. ACS Applied Bio Materials, 2021, 4, 2732-2741.	4.6	5

#	Article	IF	CITATIONS
1853	Protein N-myristoylation: functions and mechanisms in control of innate immunity. Cellular and Molecular Immunology, 2021, 18, 878-888.	10.5	53
1854	Sterilizing Immunity against SARSâ€CoVâ€2 Infection in Mice by a Singleâ€Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonistâ€Adjuvanted Recombinant Spike Protein Vaccine**. Angewandte Chemie - International Edition, 2021, 60, 9467-9473.	13.8	45
1855	Sterilizing Immunity against SARS oVâ€2 Infection in Mice by a Singleâ€5hot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonistâ€Adjuvanted Recombinant Spike Protein Vaccine**. Angewandte Chemie, 2021, 133, 9553-9559.	2.0	4
1856	Phagocytosis of microparticles increases responsiveness of macrophage-like cell lines U937 and THP-1 to bacterial lipopolysaccharide and lipopeptide. Scientific Reports, 2021, 11, 6782.	3.3	7
1857	Psoriatic skin inflammation is promoted by câ€Jun/APâ€1â€dependent CCL2 and ILâ€23 expression in dendritic cells. EMBO Molecular Medicine, 2021, 13, e12409.	6.9	42
1858	The Skin–Liver Axis Modulates the Psoriasiform Phenotype and Involves Leucine-Rich α-2 Glycoprotein. Journal of Immunology, 2021, 206, 1469-1477.	0.8	6
1859	Differential TLR7-mediated cytokine expression by R848 in M-CSF- versus GM-CSF-derived macrophages after LCMV infection. Journal of General Virology, 2021, 102, .	2.9	4
1860	Targeted Repolarization of Tumorâ€Associated Macrophages via Imidazoquinoline‣inked Nanobodies. Advanced Science, 2021, 8, 2004574.	11.2	38
1861	Human plasmacytoid dendritic cells at the crossroad of type I interferon-regulated B cell differentiation and antiviral response to tick-borne encephalitis virus. PLoS Pathogens, 2021, 17, e1009505.	4.7	6
1862	Immune gustatory processing: immune responses to drugs shape peripheral taste signals. Current Opinion in Physiology, 2021, 20, 112-117.	1.8	0
1863	The synergistic strategies for the <scp>immunoâ€oncotherapy</scp> with photothermal nanoagents. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1717.	6.1	9
1865	Transcriptomic analysis identifies differences in gene expression in actinic keratoses after treatment with imiquimod and between responders and non responders. Scientific Reports, 2021, 11, 8775.	3.3	2
1866	Targeting Toll-Like Receptors in Sepsis: From Bench to Clinical Trials. Antioxidants and Redox Signaling, 2021, 35, 1324-1339.	5.4	23
1868	A STING antagonist modulating the interaction with STIM1 blocks ER-to-Golgi trafficking and inhibits lupus pathology. EBioMedicine, 2021, 66, 103314.	6.1	31
1869	Toll-Like Receptors Gene Polymorphisms in Autoimmune Disease. Frontiers in Immunology, 2021, 12, 672346.	4.8	34
1870	Immunopotentiating and Delivery Systems for HCV Vaccines. Viruses, 2021, 13, 981.	3.3	7
1871	Sustained IL-4 priming of macrophages enhances the inflammatory response to TLR7/8 ligand R848. Journal of Leukocyte Biology, 2022, 111, 401-413.	3.3	4
1872	Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation. Biomedicine and Pharmacotherapy, 2021, 137, 111276.	5.6	14

# 1873	ARTICLE Viral Venereal Diseases of the Skin. American Journal of Clinical Dermatology, 2021, 22, 523-540.	IF 6.7	Citations 3
1874	Signalâ€ŧransducing innate receptors in tumor immunity. Cancer Science, 2021, 112, 2578-2591.	3.9	8
1875	Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nature Reviews Clinical Oncology, 2021, 18, 558-576.	27.6	202
1876	TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nature Immunology, 2021, 22, 829-838.	14.5	364
1877	Identification of key genes in the tumor microenvironment of lung adenocarcinoma. Medical Oncology, 2021, 38, 83.	2.5	7
1878	Therapeutic Targeting of Transcription Factors to Control the Cytokine Release Syndrome in COVID-19. Frontiers in Pharmacology, 2021, 12, 673485.	3.5	10
1879	Transcriptomic Analysis and C-Terminal Epitope Tagging Reveal Differential Processing and Signaling of Endogenous TLR3 and TLR7. Frontiers in Immunology, 2021, 12, 686060.	4.8	3
1880	Single-Cell Transcriptional Heterogeneity of Lymphatic Endothelial Cells in Normal and Inflamed Murine Lymph Nodes. Cells, 2021, 10, 1371.	4.1	19
1881	Immunomodulatory Responses Of Toll Like Receptors Against 2019nCoV. Russian Open Medical Journal, 2021, 10, .	0.3	0
1882	Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors. Journal of Medicinal Chemistry, 2021, 64, 8010-8041.	6.4	25
1884	Differential Effects of Toll-Like Receptor Activation and Differential Mediation by MAP Kinases of Immune Responses in Microglial Cells. Cellular and Molecular Neurobiology, 2022, 42, 2655-2671.	3.3	6
1885	Tetrasubstituted imidazoles as incognito Toll-like receptor 8 a(nta)gonists. Nature Communications, 2021, 12, 4351.	12.8	12
1886	Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?. Frontiers in Immunology, 2021, 12, 710044.	4.8	18
1887	TLR7 Activation of Macrophages by Imiquimod Inhibits HIV Infection through Modulation of Viral Entry Cellular Factors. Biology, 2021, 10, 661.	2.8	6
1888	Perspectives on immunometabolism at the biomaterials interface. Molecular Aspects of Medicine, 2022, 83, 100992.	6.4	1
1889	Lipid Nature and Alkyl Length Influence Lymph Node Accumulation of Lipidâ€Polyethylene Glycol Amphiphiles. Advanced Therapeutics, 2021, 4, 2100079.	3.2	6
1890	Molecular mechanisms of nonself nucleic acid recognition by the innate immune system. European Journal of Immunology, 2021, 51, 1897-1910.	2.9	27
1891	Chitosan-Poly(Acrylic Acid) Nanoparticles Loaded with R848 and MnCl2 Inhibit Melanoma via Regulating Macrophage Polarization and Dendritic Cell Maturation. International Journal of Nanomedicine, 2021, Volume 16, 5675-5692.	6.7	10

#	Article	IF	CITATIONS
1892	Overexpression of cathepsin S exacerbates lupus pathogenesis through upregulation TLR7 and IFN-1± in transgenic mice. Scientific Reports, 2021, 11, 16348.	3.3	5
1893	Pattern recognition receptors in health and diseases. Signal Transduction and Targeted Therapy, 2021, 6, 291.	17.1	510
1894	Mitochondrial Reactive Oxygen Species Are Essential for the Development of Psoriatic Inflammation. Frontiers in Immunology, 2021, 12, 714897.	4.8	24
1895	Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. Advanced Drug Delivery Reviews, 2021, 175, 113803.	13.7	76
1896	X-linked recessive TLR7 deficiency in \sim 1% of men under 60 years old with life-threatening COVID-19. Science Immunology, 2021, 6, .	11.9	267
1897	Regulatory Effects of Clock and Bmal1 on Circadian Rhythmic TLR Expression. International Reviews of Immunology, 2023, 42, 101-112.	3.3	6
1898	Immunostimulant Bathing Influences the Expression of Immune- and Metabolic-Related Genes in Atlantic Salmon Alevins. Biology, 2021, 10, 980.	2.8	1
1899	The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. Biology, 2021, 10, 856.	2.8	21
1900	Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy. Kidney Diseases (Basel, Switzerland), 2022, 8, 26-43.	2.5	16
1901	Virusâ€Mimic mRNA Vaccine for Cancer Treatment. Advanced Therapeutics, 2021, 4, 2100144.	3.2	11
1902	Lymph-Node-Targeted Cholesterolized TLR7 Agonist Liposomes Provoke a Safe and Durable Antitumor Response. Nano Letters, 2021, 21, 7960-7969.	9.1	22
1903	A review of methods for detecting single-nucleotide polymorphisms in the Toll-like receptor gene family. Biomarkers in Medicine, 2021, 15, 1187-1198.	1.4	0
1904	Prospects for the Global Elimination of Hepatitis B. Annual Review of Virology, 2021, 8, 437-458.	6.7	26
1905	Positive Allosteric Modulation of A2AR Alters Immune Cell Responses and Ameliorates Psoriasis-Like Dermatitis in Mice. Journal of Investigative Dermatology, 2022, 142, 624-632.e6.	0.7	5
1907	Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB/c mice. Microbial Pathogenesis, 2021, 158, 105021.	2.9	5
1908	Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) drives the resolution of allergic asthma. IScience, 2021, 24, 103163.	4.1	6
1909	Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. BioMed Research International, 2021, 2021, 1-14.	1.9	92
1910	Pharmacological inhibition of MyD88 suppresses inflammation in tubular epithelial cells and prevents diabetic nephropathy in experimental mice. Acta Pharmacologica Sinica, 2022, 43, 354-366.	6.1	12

#	Article	IF	CITATIONS
1911	Distinct endocytosis and immune activation of poly(lactic-co-glycolic) acidÂnanoparticles prepared by single- and double-emulsion evaporation. Nanomedicine, 2021, 16, 2075-2094.	3.3	4
1912	Non-Operative Options for Loco-regional Melanoma. Clinics in Plastic Surgery, 2021, 48, 631-642.	1.5	1
1913	Genome-wide identification, characterization, and expression of the Toll-like receptors in Japanese flounder (Paralichthys olivaceus). Aquaculture, 2021, 545, 737127.	3.5	11
1914	The mitochondrial protein ERAL1 suppresses RNA virus infection by facilitating RIG-I-like receptor signaling. Cell Reports, 2021, 34, 108631.	6.4	24
1915	Sexual dimorphism, aging and immunity. Vitamins and Hormones, 2021, 115, 367-399.	1.7	7
1916	Signaling Through Nucleic Acid Sensors and Their Roles in Inflammatory Diseases. Frontiers in Immunology, 2020, 11, 625833.	4.8	58
1917	Actinic Keratoses. Cancer Treatment and Research, 2009, 146, 227-239.	0.5	7
1918	Topical Treatment of Field Cancerization. Cancer Treatment and Research, 2009, 146, 439-446.	0.5	19
1919	Molecular and Cellular Aspects of Macrophage Aging. , 2009, , 919-945.		12
1920	Immune Signatures and Systems Biology of Vaccines. , 2011, , 141-167.		2
1921	Investigating TLR Signaling Responses in Murine Dendritic Cells Upon Bacterial Infection. Methods in Molecular Biology, 2014, 1197, 209-225.	0.9	1
1922	Toll-Like Receptors: Ligands, Cell-Based Models, and Readouts for Receptor Action. Methods in Molecular Biology, 2016, 1390, 3-27.	0.9	17
1923	Gene Expression Profiling of Dendritic Cells by Microarray. Methods in Molecular Biology, 2007, 380, 215-224.	0.9	6
1924	Ligands, Cell-Based Models, and Readouts Required for Toll-Like Receptor Action. Methods in Molecular Biology, 2009, 517, 15-32.	0.9	5
1925	Pyrosequencing of Toll-Like Receptor Polymorphisms of Functional Relevance. Methods in Molecular Biology, 2009, 496, 73-87.	0.9	6
1926	The Immunology of Acne. , 2008, , 217-222.		1
1927	Phage Interaction with the Mammalian Immune System. , 2019, , 91-122.		6
1928	The Biology of Toll-Like Receptors and NOD-Like Receptors: The Toggles of Inflammation. , 2013, , 1-25.		2

		CITATION REPORT		
#	Article		IF	CITATIONS
1929	Current and potential therapies for the treatment of herpesvirus infections. , 2003, 60	, 263-307.		61
1930	Funktion der Pathogenrezeptoren bei entzündlichen Hauterkrankungen. Fortschritte Dermatologie Und Venerologie, 2007, , 30-37.	e Der Praktischen	0.0	2
1931	Beyond Double-Stranded RNA-Type I IFN Induction by 3pRNA and Other Viral Nucleic A Topics in Microbiology and Immunology, 2007, 316, 207-230.	.cids. Current	1.1	27
1932	Type I Interferon: The Ever Unfolding Story. , 2007, 316, 41-70.			27
1933	TLR-Mediated Activation of Type I IFN During Antiviral Immune Responses: Fighting the War. , 2007, 316, 167-192.	? Battle to Win the		42
1934	Structure of Toll-Like Receptors. Handbook of Experimental Pharmacology, 2008, , 181	1-200.	1.8	20
1935	Prophylactic HPV Vaccines. , 2011, , 681-691.			1
1936	Macrophage Immunity and Mycobacterium tuberculosis. Handbook of Experimental Ph 2003, , 409-457.	harmacology,	1.8	2
1937	Itch Control by Toll-Like Receptors. Handbook of Experimental Pharmacology, 2015, 22	26, 135-150.	1.8	20
1938	Genomics of host-pathogen interactions. , 2007, 64, 311-343.			3
1939	TLR Agonists as Vaccine Adjuvants. , 2012, , 205-228.			10
1940	Small Molecular Immune Modulators as Anticancer Agents. Advances in Experimental I Biology, 2020, 1248, 547-618.	Medicine and	1.6	6
1941	Genetics of Lupus in Mice. , 2011, , 63-105.			3
1942	CpG oligodeoxynucleotides as vaccine adjuvants. , 2006, , 73-92.			3
1943	Induction of Autoimmunity by Adjuvant Hydrocarbons. , 2004, , 87-104.			1
1944	Molecular Biology of the Host-Microbe Interaction in Periodontal Diseases. , 2012, , 28	5-293.		3
1946	Ethanol suppresses cytokine responses induced through Toll-like receptors as well as in resistance to Escherichia coli in a mouse model for binge drinking. Alcohol, 2004, 33, 1	nnate 147-155.	1.7	64
1947	Nucleic Acid Innate Immune Receptors. RSC Drug Discovery Series, 2019, , 292-305.		0.3	1

#	Article	IF	CITATIONS
1948	Crystal structure of human IRAK1. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13507-13512.	7.1	59
1949	2. Imiquimod: Mode of Action and Therapeutic Potential. Acta Dermato-Venereologica, 2003, 83, 8-11.	1.3	8
1950	Inducible RasGEF1B circular RNA is a positive regulator of ICAM-1 in the TLR4/LPS pathway. RNA Biology, 2016, 13, 861-871.	3.1	123
1953	Toll-Like Receptors: Ligands and Signaling. , 0, , 255-270.		4
1954	Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis. Journal of Clinical Investigation, 2019, 129, 2251-2265.	8.2	70
1955	Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. Journal of Clinical Investigation, 2020, 130, 2845-2858.	8.2	31
1956	Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. Journal of Clinical Investigation, 2011, 121, 1782-1796.	8.2	153
1957	Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. Journal of Clinical Investigation, 2012, 122, 575-585.	8.2	250
1958	Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. Journal of Clinical Investigation, 2018, 128, 2356-2369.	8.2	118
1959	The imidazoquinolines — mechanism of action and therapeutic potential in HPV-associated disease. Papillomavirus Report, 2005, 16, 141-146.	0.2	2
1960	Recognition of lipopeptides by Toll-like receptors. Journal of Endotoxin Research, 2002, 8, 459-463.	2.5	158
1961	Lactate Dehydrogenase-Elevating Virus Induces Systemic Lymphocyte Activation via TLR7-Dependent IFNα Responses by Plasmacytoid Dendritic Cells. PLoS ONE, 2009, 4, e6105.	2.5	39
1962	Poly-Thymidine Oligonucleotides Mediate Activation of Murine Glial Cells Primarily Through TLR7, Not TLR8. PLoS ONE, 2011, 6, e22454.	2.5	6
1963	Regulatory T Cells and IL-10 Independently Counterregulate Cytotoxic T Lymphocyte Responses Induced by Transcutaneous Immunization. PLoS ONE, 2011, 6, e27911.	2.5	16
1964	The Combination of Early and Rapid Type I IFN, IL-1α, and IL-1β Production Are Essential Mediators of RNA-Like Adjuvant Driven CD4+ Th1 Responses. PLoS ONE, 2011, 6, e29412.	2.5	7
1965	Treatment of Autoimmune Inflammation by a TLR7 Ligand Regulating the Innate Immune System. PLoS ONE, 2012, 7, e45860.	2.5	20
1966	Toll-Like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies. PLoS ONE, 2013, 8, e56514.	2.5	14
1967	Antioxidant N-Acetylcysteine Attenuates Hepatocarcinogenesis by Inhibiting ROS/ER Stress in TLR2 Deficient Mouse. PLoS ONE, 2013, 8, e74130.	2.5	44

#	Article	IF	CITATIONS
1968	A Single Naturally Occurring 2'-O-Methylation Converts a TLR7- and TLR8-Activating RNA into a TLR8-Specific Ligand. PLoS ONE, 2015, 10, e0120498.	2.5	25
1969	Immunomodulator-Based Enhancement of Anti Smallpox Immune Responses. PLoS ONE, 2015, 10, e0123113.	2.5	13
1970	Differential Adjuvant Activities of TLR7 and TLR9 Agonists Inversely Correlate with Nitric Oxide and PGE2 Production. PLoS ONE, 2015, 10, e0123165.	2.5	4
1971	Molecular Determinants of GS-9620-Dependent TLR7 Activation. PLoS ONE, 2016, 11, e0146835.	2.5	17
1972	Interleukin 6 Accelerates Mortality by Promoting the Progression of the Systemic Lupus Erythematosus-Like Disease of BXSB.Yaa Mice. PLoS ONE, 2016, 11, e0153059.	2.5	28
1973	The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines. PLoS ONE, 2016, 11, e0168068.	2.5	12
1974	Differential gene expression following TLR stimulation in rag1-/- mutant zebrafish tissues and morphological descriptions of lymphocyte-like cell populations. PLoS ONE, 2017, 12, e0184077.	2.5	18
1975	Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice. PLoS ONE, 2017, 12, e0186138.	2.5	18
1976	Tumor Progression Locus 2 Promotes Induction of IFNλ, Interferon Stimulated Genes and Antigen-Specific CD8+ T Cell Responses and Protects against Influenza Virus. PLoS Pathogens, 2015, 11, e1005038.	4.7	18
1977	Toll-Like Receptors and Immune Response in Allergic Disease. Clinical Reviews in Allergy and Immunology, 2004, 26, 115-126.	6.5	9
1978	B Cell Toll-like Receptors with Respect to the Pathogenesis of Sjögren's Syndrome. Acta Medica (Hradec Kralove), 2011, 54, 51-57.	0.5	8
1979	Andrographolide Modulate some Toll-like Receptors and Cytokines Expressions in HL-60 Cell Line. Pharmacy & Pharmacology International Journal, 2015, 2, .	0.2	1
1980	Melanoma Immunotherapy: Mechanisms and Opportunities. Investigative Dermatology and Venereology Research, 2016, 2, 1-7.	0.1	1
1981	AN INTRODUCTION TO SELECTED INNATE IMMUNE-RELEVANT GENES IN FISH. Applied Ecology and Environmental Research, 2018, 16, 955-976.	0.5	20
1983	The inhibition of malignant melanoma cell invasion of bone by the TLR7 agonist R848 is dependent upon pro-inflammatory cytokines produced by bone marrow macrophages. Oncotarget, 2018, 9, 29934-29943.	1.8	8
1984	Natural Interferon- \hat{l}_{\pm} Producing Cells: The Plasmacytoid Dendritic Cells. BioTechniques, 2002, 33, S16-S29.	1.8	66
1985	Targeting Toll like Receptors in Cancer: Role of TLR Natural and Synthetic Modulators. Current Pharmaceutical Design, 2020, 26, 5040-5053.	1.9	11
1986	Latest Advances in Small Molecule TLR 7/8 Agonist Drug Research. Current Topics in Medicinal Chemistry, 2019, 19, 2228-2238.	2.1	21
#	Article	IF	CITATIONS
------	--	-----	-----------
1987	From the Obscure and Mysterious Acute Phase Response to Toll-Like Receptors and the Cytokine Network. Current Immunology Reviews, 2008, 4, 199-214.	1.2	2
1988	The Therapeutic Potential of Toll-Like Receptor 7 Stimulation in Asthma. Inflammation and Allergy: Drug Targets, 2012, 11, 484-491.	1.8	36
1989	Generation of Eosinophils from Unselected Bone Marrow Progenitors: Wild-Type, TLR- and Eosinophil-Deficient Mice. The Open Immunology Journal, 2009, 2, 163-167.	1.5	10
1990	Dissecting the role of infections in atopic dermatitis. Acta Dermato-Venereologica, 2006, 86, 99-109.	1.3	63
1991	Type I interferon production by nucleic acid-stimulated dendritic cells. Frontiers in Bioscience - Landmark, 2008, Volume, 6034.	3.0	8
1993	Systematic Review of Imiquimod for the Treatment of External Genital Wart. International Journal of Pharmacology, 2006, 3, 1-10.	0.3	8
1994	Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants. ImmunoHorizons, 2018, 2, 185-197.	1.8	120
1995	Extracellular miR-146a-5p Induces Cardiac Innate Immune Response and Cardiomyocyte Dysfunction. ImmunoHorizons, 2020, 4, 561-572.	1.8	25
1996	Increased Adipose Tissue Expression of Toll-Like Receptor (TLR)-7 in Obese Individuals: Significance in Metabolic Disease. Journal of Glycomics & Lipidomics, 2015, 05, .	0.4	17
1997	Expression patterns of innate immunity-related genes in response to polyinosinic:polycytidylic acid (poly[I:C]) stimulation in DF-1 chicken fibroblast cells. Journal of Animal Science and Technology, 2020, 62, 385-395.	2.5	9
1998	Immune therapy for human papillomaviruses-related cancers. World Journal of Clinical Oncology, 2014, 5, 1002.	2.3	54
1999	IRF-5 - A New Link to Autoimmune Diseases. , 0, , .		1
2000	Reduction of voluntary physical activity in mice induced by toll-like receptor 7 agonist R-848. The Journal of Physical Fitness and Sports Medicine, 2018, 7, 177-184.	0.3	2
2001	Lipopolysaccharide, Mediator of Sepsis Enigma: Recognition and Signaling. International Journal of Biochemistry Research & Review, 2011, 1, 1-13.	0.1	7
2003	Synergistic Anti-Leishmanial Activities of Morphine and Imiquimod on Leishmania infantum (MCAN/ES/98/LIM-877). Iranian Journal of Arthropod-borne Diseases, 2021, 15, 236-254.	0.8	0
2004	Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions. Brain, Behavior, & Immunity - Health, 2021, 18, 100361.	2.5	22
2005	Infektion und Entzündung. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2003, , 36-42.	0.0	0
2006	Imiquimod: Kritische Wertung der mĶglichen Indikationen. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2003, , 140-147.	0.0	0

#	Article	IF	CITATIONS
2007	Antigen-Presenting Cells and Vaccine Design. Handbook of Experimental Pharmacology, 2003, , 67-87.	1.8	0
2008	Pathogen Associated Molecular Pattern Recognition in Innate Immunity. Ensho Saisei, 2003, 23, 211-217.	0.2	2
2009	Interaction of Innate and Acquired Immune Response: Toll Receptors— Potential Link of Infection to Rejection. , 2004, , 459-475.		0
2011	Immunoadjuvants in Prospective Testing for Contact Allergens. , 2004, , 775-791.		0
2013	Innate immune mechanisms and the identification of immune potentiators as vaccine adjuvants. , 2006, , 57-72.		0
2014	Microbial Pathogenesis and the Discovery of Toll-Like Receptor Function. , 2006, , 1-24.		Ο
2015	Dendritic cells as targets and tools in vaccines. , 2006, , 17-33.		0
2016	T cell adjuvants and novel strategies for their identification. , 2006, , 275-288.		0
2017	Toll-like family. British Journal of Pharmacology, 2006, , S132-S133.	5.4	0
2018	Dendritic Cell Biology: Subset Heterogeneity and Functional Plasticity. , 2007, , 3-43.		3
2019	Adjuvants, Dendritic Cells, and Cytokines: Strategies for Enhancing Vaccine Efficacy. , 2007, , 171-202.		0
2020	Toll-like Receptors in Host Defense and Immune Disorders. Toxicological Research, 2007, 23, 97-105.	2.1	0
2021	Therapeutic Strategies Targeting the Innate Antiviral Immune Response. , 2008, , 223-251.		0
2022	Toll-Like Receptors in the Mammalian Innate Immune System. Nucleic Acids and Molecular Biology, 2008, , 135-167.	0.2	0
2023	Recognition of RNA and Synthetic Compounds by TLR7 and TLR8. , 2008, , 227-239.		0
2024	Characteristics of Dendritic Cell Responses to Nucleic Acids. , 2008, , 43-58.		0
2025	Recognition of Virus Invasion by Toll-Like Receptors and RIG-I-Like Helicases. , 2008, , 31-41.		0
2026	Activation of Innate Pattern Recognition Pathways by Single-Stranded Ribonucleic Acids. , 2008, , 189-205.		0

# 2027	ARTICLE Antiviral Signaling Through TLRs and RLHs. , 2008, , 17-29.	IF	CITATIONS 0
2028	Toll-Like Receptors and Infectious Diseases: Role of Heat Shock Proteins. Heat Shock Proteins, 2009, , 153-167.	0.2	1
2029	Modification of Dendritic Cells to Enhance Cancer Vaccine Potency. , 2009, , 133-157.		0
2030	Toll-like family. British Journal of Pharmacology, 2009, 158, S178-S179.	5.4	0
2032	Squamous Cell Carcinoma In Situ. , 2010, , 51-59.		0
2033	Infection Prevention: Oil- and Lipid-Containing Products in Vaccinology. , 2010, , 3311-3331.		0
2034	Stimulation of Toll-Like Receptor-7 Enhances BAFF and APRIL Pathways of Survival in Chronic Lymphocytic Leukemia Cells. The Open Leukemia Journal, 2010, 3, 24-33.	1.0	0
2038	Immune Response Modulators in the Treatment of Skin Cancer. , 2011, , 477-496.		0
2040	Clinical perspectives in cancer vaccines for hematological diseases. , 2011, , 126-139.		0
2042	Utilizing Mouse Models of Human Cancer for Assessing Immune Modulation of Cancer Development. , 2012, , 443-463.		0
2043	Adult Human T Cell Leukemia. , 0, , .		0
2044	Innate Immune Receptors in Atherosclerosis. , 0, , .		0
2045	Anti-inflammatory Activity of <i>Carpinus tschonoskii</i> Leaves Extract in R848-stimulated Bone Marrow-derived Macrophages and Dendritic Cells. Journal of Bacteriology and Virology, 2012, 42, 77.	0.1	6
2046	Toll Like Receptors in Dual Role: Good Cop and Bad Cop. , 0, , .		0
2047	TLRâ€7 Agonists for the Treatment of Viral Hepatitis. RSC Drug Discovery Series, 2013, , 365-383.	0.3	1
2048	Toll-Like Receptor Function and Evolution in Primates. , 2013, , 91-116.		0
2049	Polymeric Micelle-Based Nanomedicine for siRNA Delivery. RSC Polymer Chemistry Series, 2013, , 158-189.	0.2	0
2050	Immunomodulating pharmaceuticals. , 2013, , 1077-1084.		1

# 2051	ARTICLE ALERGIA A FÃRMACOS COM MANIFESTAÇÕES CUTÃ,NEAS - ABORDAGEM DIAGNÓSTICA. Journal of the Portuguese Society of Dermatology and Venereology, 2013, 70, 277.	IF 0.0	Citations 0
2052	TLR7 and TLR8, Resiquimod, and 852A. , 2013, , 1-8.		0
2053	Toll-Like Receptors: Evolution and Structure. , 2014, , 1-7.		0
2054	Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines. Dermatology Online Journal, 2014, 20, .	0.5	3
2055	Toll-Like Receptors. , 0, , 107-122.		0
2056	Role of Toll-Like Receptors in the Innate Immune Response to RNA Viruses. , 0, , 7-27.		0
2057	Treatment of Lentigomaligna in Dark Skin with Topical Imiquimod Results in Dark Hyperpigmentation. International Journal of Clinical Dermatology & Research, 0, , 19-20.	0.0	0
2058	Evidence-Based Treatment of Actinic Keratoses in Older Adults. , 2015, , 89-96.		0
2059	Combined Immunotherapy Against Cancer: Limited Efficacy of Transcutaneous Immunization and Low-dose Cyclophosphamide. Cancer and Oncology Research, 2015, 3, 1-9.	0.2	0
2060	Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs. , 2016, , 135-153.		0
2061	TLR7., 2016,, 1-7.		0
2062	Cell type-specific role of Raftlin in the regulation of endosomal TLR signaling. Inflammation and Cell Signaling, 0, , .	1.6	1
2063	Innate and Adaptive Components of the Cutaneous Immune Barrier: The Central Role of Dendritic Cells. , 2017, , 1-10.		1
2064	Topical Immune Response Modifiers: Adjuvants. , 2017, , 775-790.		0
2066	Toll-Like Receptors: Evolution and Structure. , 2018, , 1192-1198.		0
2067	TLR7. , 2018, , 5492-5498.		0
2068	VulvÃ r e intraepitheliale Neoplasie (VIN). , 2018, , 29-56.		0
2069	Characteristics of Asian skin–revision. Journal of Dermatology & Cosmetology, 2018, 2, .	0.2	4

#	ARTICLE	IF	CITATIONS
2070	Synthetic Agonists of Toll-like Receptors and Therapeutic Applications. RSC Drug Discovery Series, 2019, , 306-338.	0.3	0
2073	Fourth defence molecule completes antiviral line-up. Nature, 2020, 581, 266-267.	27.8	0
2075	Pharmacological Challenge Models in Clinical Drug Developmental Programs. , 0, , .		1
2077	Infection Prevention: Oil- and Lipid-Containing Products in Vaccinology. , 2020, , 285-315.		0
2080	Biomaterial-mediated modulation of oral microbiota synergizes with PD-1 blockade in mice with oral squamous cell carcinoma. Nature Biomedical Engineering, 2022, 6, 32-43.	22.5	57
2081	Recognition of Pathogens: Toll-Like Receptors. , 2008, , 1-36.		0
2086	Knockout and Disease Models in Toll-Like Receptor-Mediated Immunity. , 2006, , 41-61.		0
2087	Topical Immune Response Modifiers: Adjuvants. , 2008, , 527-537.		0
2091	Bowen's disease - a review of newer treatment options. Therapeutics and Clinical Risk Management, 2008, 4, 1085-95.	2.0	39
2093	Expression of toll-like receptors in human limbal and conjunctival epithelial cells. Molecular Vision, 2007, 13, 813-22.	1.1	40
2095	Nonsurgical innovations in the treatment of nonmelanoma skin cancer. Journal of Clinical and Aesthetic Dermatology, 2010, 3, 20-34.	0.1	13
2096	Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses. Journal of Clinical and Aesthetic Dermatology, 2009, 2, 20-8.	0.1	5
2097	Topical imiquimod therapy for actinic keratosis: is long-term clearance a realistic benefit?. Journal of Clinical and Aesthetic Dermatology, 2008, 1, 44-7.	0.1	2
2098	Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream. Journal of Clinical and Aesthetic Dermatology, 2011, 4, 39-43.	0.1	2
2101	Melanoma in Situ Treated with Topical Imiquimod for Management of Persistently Positive Margins: A Review of Treatment Methods. Ochsner Journal, 2015, 15, 443-7.	1.1	8
2102	Mycobacterium tuberculosis DNA Increases Vitamin D Receptor mRNA Expression and the Production of Nitric Oxide and Cathelicidin in Human Monocytes. The Malaysian Journal of Medical Sciences, 2015, 22, 18-24.	0.5	2
2103	Evaluation of Morphine with Imiquimod as Opioid Growth Factor Receptor or Nalmefene as Opioid Blocking Drug on Leishmaniasis Caused by in Vitro. Iranian Journal of Parasitology, 2019, 14, 394-403.	0.6	4
2104	Virus in the pathogenesis of inflammatory bowel disease: role of Toll-like receptor 7/8/3. Gastroenterology and Hepatology From Bed To Bench, 2021, 14, 295-303.	0.6	0

#	Article	IF	CITATIONS
2105	TLRs in COVID-19: How they drive immunopathology and the rationale for modulation. Innate Immunity, 2021, 27, 503-513.		32
2106	Engaging innate immunity in HIV-1 cure strategies. Nature Reviews Immunology, 2022, 22, 499-512.	22.7	39
2108	lmmunomodulatory Response of Toll-like Receptor Ligand–Peptide Conjugates in Food Allergy. ACS Chemical Biology, 2021, 16, 2651-2664.	3.4	7
2109	Autophagy and antiviral defense. IUBMB Life, 2022, 74, 317-338.	3.4	9
2110	Human innate lymphoid cells in influenza infection and vaccination. Critical Reviews in Immunology, 2021, 41, 57-82.	0.5	1
2111	Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness. Journal of Neuroinflammation, 2022, 19, 8.	7.2	12
2112	Evaluation of the Effect of Topical Artemisia dracunculus Administration on Serum Levels of Selected Interleukins and Spleen Index in Imiquimod-Induced Psoriasis in Male Mice Compared to Clobetasol Propionate (Dermovate (R)) Ointment. Iraqi Journal of Pharmaceutical Sciences, 2020, 29, 176-184.	0.3	0
2113	Therapeutic Interventions Targeting Innate Immune Receptors: A Balancing Act. Chemical Reviews, 2022, 122, 3414-3458.	47.7	10
2114	Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022, 603, 587-598.	27.8	216
2115	Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy. Acta Biomaterialia, 2022, 141, 398-407.	8.3	21
2116	RNA-Cholesterol Nanoparticles Function as Potent Immune Activators via TLR7 and TLR8. Frontiers in Immunology, 2021, 12, 658895.	4.8	7
2117	Evolution of RNA sensing receptors in birds. Immunogenetics, 2022, 74, 149-165.	2.4	11
2118	Elucidation of the hepatoprotective effect and mechanism of Melastoma dodecandrum Lour. based on network pharmacology and experimental validation. Journal of Traditional Chinese Medical Sciences, 2022, 9, 47-58.	0.2	0
2121	Systemic Administration of the TLR7/8 Agonist Resiquimod (R848) to Mice Is Associated with Transient, In Vivo-Detectable Brain Swelling. Biology, 2022, 11, 274.	2.8	2
2122	Paradoxical immune response in leishmaniasis: The role of tollâ€like receptors in disease progression. Parasite Immunology, 2022, 44, e12910.	1.5	7
2123	NSC-Mice Reveal the Importance of a Functional Innate and Adaptive Immune Response to Overcome RVFV Infection. Viruses, 2022, 14, 350.	3.3	6
2124	Molecular signaling of inflammatory responses in macrophages. , 2022, , 73-97.		0
2125	Adjuvants, immunomodulators, and adaptogens. , 2022, , 223-280.		0

#	Article		CITATIONS
2126	Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases. Pharmaceutics, 2022, 14, 423.		38
2127	Coevolutionary Analysis Implicates Toll-Like Receptor 9 in Papillomavirus Restriction. MBio, 2022, 13, e0005422.	4.1	5
2128	Evaluating the Efficacy of Combined Intralesional Sodium Stibogluconate Plus Topical Imiquimod on Healing and Risk of Scarring of Cutaneous Leishmaniasis: A Case-Control Study. Cureus, 2022, , .	0.5	0
2129	Applying Modeling and Simulations for Rational Dose Selection of Novel Tollâ€Like Receptor 7/8 9 Inhibitor Enpatoran for Indications of High Medical Need. Clinical Pharmacology and Therapeutics, 2022, 112, 297-306.		7
2130	Roles of neuronal toll-like receptors in neuropathic pain and central nervous system injuries and diseases. Brain, Behavior, and Immunity, 2022, 102, 163-178.	4.1	17
2131	Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype. Methods in Molecular Biology, 2022, 2410, 609-626.	0.9	2
2132	Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases. International Journal of Molecular Sciences, 2021, 22, 13397.	4.1	77
2133	Distinct trans-placental effects of maternal immune activation by TLR3 and TLR7 agonists: implications for schizophrenia risk. Scientific Reports, 2021, 11, 23841.	3.3	11
2134	RNA metabolism and links to inflammatory regulation and disease. Cellular and Molecular Life Sciences, 2022, 79, 21.	5.4	3
2135	TLR8 is activated by 5Ê1-methylthioinosine, a Plasmodium falciparum-derived intermediate of the purine salvage pathway. Cell Reports, 2022, 39, 110691.	6.4	6
2136	Immune therapy against papillomavirus-related tumors in humans. , 2006, , 373-394.		0
2173	Topical Immunotherapy. , 0, , 468-476.		0
2174	The Tollâ€like receptor 7 agonist imiquimod increases ethanol selfâ€administration and induces expression of Tollâ€like receptor related genes. Addiction Biology, 2022, 27, e13176.	2.6	9
2175	Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8. PLoS ONE, 2022, 17, e0260565.	2.5	7
2176	Topical Application of Imiquimod Induces Alterations in Peripheral Blood Lymphocytes in Healthy Individuals*. Acta Dermato-Venereologica, 2008, 89, 134-139.	1.3	5
2177	Upregulated influenza A viral entry factors and enhanced interferon-alpha response in the nasal epithelium of pregnant rats. Heliyon, 2022, 8, e09407.	3.2	2
2178	Expression of toll like receptor 8 (TLR8) in specific groups of mouse hippocampal interneurons. PLoS ONE, 2022, 17, e0267860.	2.5	2
2179	Characterization, evolution and expression analysis of Toll-like receptor 7 (TLR7) in turbot (Scophthalmus maximus L.). Fish and Shellfish Immunology, 2022, 125, 9-16.	3.6	3

#	Article		CITATIONS
2180	Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine. Journal of Controlled Release, 2022, 347, 476-488.		15
2181	Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma. Frontiers in Oncology, 0, 12, .	2.8	6
2184	Cyprinidâ€specific duplicated membrane TLR5 senses dsRNA as functional homodimeric receptors. EMBO Reports, 2022, 23, .	4.5	11
2185	Nanaomycin E inhibits NLRP3 inflammasome activation by preventing mitochondrial dysfunction. International Immunology, 2022, 34, 505-518.	4.0	6
2186	Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms. Pharmaceutics, 2022, 14, 1448.	4.5	6
2189	Androgen receptor, oxidative stress and inflammation at the crossroads of skin diseases. International Journal of Dermatology and Clinical Research, 2022, 8, 012-015.	0.2	1
2190	Pilot study of the efficacy of treatment of urticaria by using two traditional Vietnamese herbs administered systemically. International Journal of Dermatology and Clinical Research, 2022, 8, 007-011.	0.2	0
2191	Unified Therapeuticâ€Prophylactic Vaccine Demonstrated with a Postoperative Filler Gel to Prevent Tumor Recurrence and Metastasis. Advanced Functional Materials, 2022, 32, .	14.9	17
2192	Tumor immunotherapy boosted by R837 nanocrystals through combining chemotherapy and mild hyperthermia. Journal of Controlled Release, 2022, 350, 841-856.	9.9	15
2193	Bifurcation of signalling in human innate immune pathways to NF-kB and IRF family activation. Biochemical Pharmacology, 2022, 205, 115246.	4.4	5
2194	Dendritic cell maturation and IL-12 synthesis induced by the synthetic immune-response modifier S-28463. Journal of Leukocyte Biology, 2002, 72, 932-938.	3.3	17
2195	Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer Immunology Research, 2022, 10, 1441-1461.	3.4	18
2196	Identification of an Optimal TLR8 Ligand by Alternating the Position of 2′-O-Ribose Methylation. International Journal of Molecular Sciences, 2022, 23, 11139.	4.1	3
2197	Advanced Acral Melanoma Therapies: Current Status and Future Directions. Current Treatment Options in Oncology, 2022, 23, 1405-1427.	3.0	9
2198	Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment. Pharmaceutics, 2022, 14, 2076.	4.5	10
2199	Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88â€Dependent Inflammation. Advanced Science, 2022, 9, .	11.2	11
2200	Manganese-doped mesoporous polydopamine nanoagent for T1–T2 magnetic resonance imaging and tumor therapy. Nano Research, 2023, 16, 2991-3003.	10.4	10
2201	When does hepatitis B virus meet long-stranded noncoding RNAs?. Frontiers in Microbiology, 0, 13, .	3.5	2

#	Article	IF	Citations
2202	Intralesional interleukinâ€⊋ augmentation therapy in treatmentâ€refractory melanoma. Dermatologic Therapy, 0, , .	1.7	2
2203	Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review. Vaccines, 2022, 10, 1727.	4.4	5
2204	Assessing Antipsoriatic Effects of Bitter Pu'er Tea and Its Three Major Compounds, Strictinin, Theacrine and Epigallocatechin Gallate, in Imiquimod-Treated Mice. Compounds, 2022, 2, 293-306.	1.9	4
2205	Toll-like receptor 7 regulates cardiovascular diseases. International Immunopharmacology, 2022, 113, 109390.	3.8	4
2206	Receptores tipo Toll: bases moleculares de la relación entre respuestas innatas y adaptativas del sistema inmunitario. , 0, , 29-33.		0
2209	Enteric Toll-like receptor 7 stimulation causes acute exacerbation in lupus-susceptible mice. Clinical Rheumatology, 0, , .	2.2	0
2210	Effectiveness of seasonal influenza vaccine in elementary and middle schools: a 10-year follow-up investigation. BMC Infectious Diseases, 2022, 22, .	2.9	0
2211	Dissecting the role of tollâ \in like receptor 7 in pancreatic cancer. Cancer Medicine, 0, , .	2.8	1
2212	Recent Advances on Small-Molecule Antagonists Targeting TLR7. Molecules, 2023, 28, 634.	3.8	6
2213	Complexing CpG adjuvants with cationic liposomes enhances vaccine-induced formation of liver TRM cells. Vaccine, 2023, 41, 1094-1107.	3.8	5
2214	Toll-like Receptors and Thrombopoiesis. International Journal of Molecular Sciences, 2023, 24, 1010.	4.1	5
2215	Emerging adjuvants for intradermal vaccination. International Journal of Pharmaceutics, 2023, 632, 122559.	5.2	9
2216	Poly(I:C) Treatment Prevents Skin Tumor Formation in the Preclinical HPV8 Transgenic Mouse Model. Journal of Investigative Dermatology, 2023, 143, 1197-1207.e3.	0.7	2
2217	Viral infection and its management. , 2023, , 189-207.		0
2218	Targeting Toll-Like Receptors in Cancer Immunotherapy. , 2023, , 1-25.		0
2219	A liposomal vaccine promotes strong adaptive immune responses via dendritic cell activation in draining lymph nodes. Journal of Controlled Release, 2023, 356, 386-401.	9.9	8
2220	Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882.	3.8	2
2222	TLR7/8 agonist (R848) inhibit bovine X sperm motility via PI3K/CSK3α/β and PI3K/NFκB pathways. International Journal of Biological Macromolecules, 2023, 232, 123485.	7.5	1

#	Article	IF	Citations
2224	Effects of Aire on perforin expression in BMDCs via TLR7/8 and its therapeutic effect on type 1 diabetes. International Immunopharmacology, 2023, 117, 109890.		3
2225	Immunostimulatory nanoparticles go viral. Nature Materials, 2023, 22, 273-275.	27.5	1
2226	Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review. International Journal of Molecular Sciences, 2023, 24, 4989.	4.1	5
2227	3-(5-Hydroxyphenyl)-5-Phenyl-2-Pyrazolines as Toll-Like Receptor 7 Agonists. Journal of Chemistry, 2023, 2023, 1-10.	1.9	Ο
2228	An antibody that targets cellâ€surface glucoseâ€regulated proteinâ€78 inhibits expression of inflammatory cytokines and plasminogen activator inhibitors by macrophages. Journal of Cellular Biochemistry, 2023, 124, 743-752.	2.6	3
2229	Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2. Vaccines, 2023, 11, 713.	4.4	3
2230	Multimodal control of dendritic cell functions by nociceptors. Science, 2023, 379, .	12.6	15
2231	Immunomodulating Drugs. , 2023, , 1072-1079.		0
2232	Placenta-specific 8 facilitates the infection of duck hepatitis A virus type 1 by inhibiting the TLR7 MyD88-dependent signaling pathway. Poultry Science, 2023, 102, 102724.	3.4	0
2233	Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. Science Advances, 2023, 9, .	10.3	9
2234	Targeted therapy. , 2023, , 205-411.		0
2235	Azideâ€Masked Resiquimod Activated by Hypoxia for Selective Tumor Therapy. Advanced Materials, 2023, 35, .	21.0	10
2236	Toll-like receptor-7 signaling in Kupffer cells exacerbates concanavalin A-induced liver injury in mice. International Immunopharmacology, 2023, 119, 110238.	3.8	0
2237	A Biological Perspective of TLR8 Signaling in Host Defense and Inflammation. Infectious Microbes & Diseases, 2023, 5, 44-55.	1.3	2
2238	Pathogenicity and innate immune responses induced by fowl adenovirus serotype 8b in specific pathogen-free chicken. Poultry Science, 2023, 102, 102846.	3.4	1
2239	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. , 2023, 11, e006624.		6
2240	Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo. Frontiers in Immunology, 0, 14, .	4.8	1
2241	The Safety Assessment of Cosmetic Perfumes by Using <i>In Chemico</i> and <i>In Vitro</i> Methods in Combination with GC-MS/MS Analysis. ATLA Alternatives To Laboratory Animals, 0, , .	1.0	2

#	ARTICLE	IF	CITATIONS
2242	Neuroimmune Interactions in Acute and Chronic Itch. , 2023, , 171-195.		0
2243	Toll-Like Receptors in Pain and Itch. , 2023, , 197-222.		0
2244	Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics. Journal of Medicinal Chemistry, 2023, 66, 6437-6462.	6.4	9
2245	Enantioselective Effect of Chiral Small Molecules in SARS oVâ€2 Vaccineâ€Induced Immune Response. Angewandte Chemie - International Edition, 2023, 62, .	13.8	3
2246	Enantioselective Effect of Chiral Small Molecules in SARS oVâ€2 Vaccineâ€Induced Immune Response. Angewandte Chemie, 2023, 135, .	2.0	0
2248	Sex differences in susceptibility to substance use disorder: Role for X chromosome inactivation and escape?. Molecular and Cellular Neurosciences, 2023, 125, 103859.	2.2	3
2249	EGF-Receptor–Dependent TLR7 Signaling in Macrophages Promotes Glomerular Injury in Crescentic Glomerulonephritis. Laboratory Investigation, 2023, 103, 100190.	3.7	0
2250	Biological applications of imiquimod analogues: An update (Review). World Academy of Sciences Journal, 2023, 5, .	0.6	1
2251	Cytokine Storm in Acute Viral Respiratory Injury: Role of Qing-Fei-Pai-Du Decoction in Inhibiting the Infiltration of Neutrophils and Macrophages through TAK1/IKK/NF-κB Pathway. The American Journal of Chinese Medicine, 2023, 51, 1153-1188.	3.8	3
2252	Platelet TLR7 is essential for the formation of platelet–neutrophil complexes and low-density neutrophils in lupus nephritis. Rheumatology, 0, , .	1.9	Ο
2253	Carboxymethylated Alginate-Resiquimod Micelles Reverse the Immunosuppressive Tumor Microenvironment and Synergistically Enhance the Chemotherapy and Immunotherapy for Gastric Cancer. ACS Applied Materials & Interfaces, 2023, 15, 35999-36012.	8.0	5
2254	Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy. Journal of Controlled Release, 2023, 360, 858-871.	9.9	3
2255	Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment. IScience, 2023, 26, 107487.	4.1	0
2256	Lightâ€Activatable Liquid Metal Immunostimulants for Cancer Nanotheranostics. Advanced Functional Materials, 0, , .	14.9	1
2257	Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics. Acta Pharmacologica Sinica, 2023, 44, 2358-2375.	6.1	4
2259	Imiquimod liposome gel preparations and their ability to inhibit hypertrophic scars. , 2021, 2, 123-134.		0
2260	Absence of toll-like receptor 7 ameliorates survival and reduces intestinal injury in mice after Clostridium difficile infection. Microbes and Infection, 2023, 25, 105210.	1.9	0
2261	A comprehensive review on the dynamic role of toll-like receptors (TLRs) in frontier aquaculture research and as a promising avenue for fish disease management. International Journal of Biological Macromolecules, 2023, 253, 126541.	7.5	0

		CITATION REPORT		
#	Article		IF	CITATIONS
2262	A single dominant locus restricts retrovirus replication in YBR/Ei mice. Journal of Virology,	2023, 97, .	3.4	0
2263	Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associat macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy. Nature Cor 2023, 14, .	ed mmunications,	12.8	5
2264	An Analysis of Linker-Dependent Effects on the APC Activation and In Vivo Immunogenici R848-Conjugated Influenza Vaccine. Vaccines, 2023, 11, 1261.	ty of an	4.4	1
2265	Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovacci International Journal of Molecular Sciences, 2023, 24, 12174.	ne Efficacy.	4.1	2
2266	Nucleic acid sensing Toll-like receptors 3 and 9 play complementary roles in the developm bacteremia after nasal colonization associated with influenza co-infection. Experimental 2024, 73, 50-60.	nent of Animals,	1.1	0
2267	TLR7 activation at epithelial barriers promotes emergency myelopoiesis and lung antivira ELife, 0, 12, .	immunity.	6.0	0
2268	Viral Diseases of the Hair and Scalp. , 2023, , 219-260.			0
2269	Profiling of bovine toll like receptors (TLRs) in foot and mouth disease vaccinated cattle. Journal of Animal Sciences, 2016, 86, .	Indian	0.2	1
2270	Maternal di-(2-ethylhexyl) phthalate exposure elicits offspring IFN-λ upregulation: Insights from birth cohort, murine model, and in vitro mechanistic analysis. Food and Chemical Toxicology, 2023, 179, 113993.		3.6	1
2272	Reactive Oxygen Species-Sensitive Biodegradable Mesoporous Silica Nanoparticles Harbo Elicit Tumor-Specific Immunity for Colon Tumor Treatment. ACS Nano, 2023, 17, 19740-	pring TheraVac 19752.	14.6	3
2273	Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immune Frontiers in Immunology, 0, 14, .	otherapy.	4.8	1
2274	Small molecule modulators of immune pattern recognition receptors. RSC Chemical Biolo	ogy, 0, , .	4.1	0
2275	Keratinocyte FABP5-VCP complex mediates recruitment of neutrophils in psoriasis. Cell R 42, 113449.	eports, 2023,	6.4	0
2276	Epigenetic and Genetic Keys to Fight HPV-Related Cancers. Cancers, 2023, 15, 5583.		3.7	1
2278	Toll-like receptor agonists as cancer vaccine adjuvants. Human Vaccines and Immunothe 2024, 20, .	rapeutics,	3.3	1
2279	Gender Control of Mouse Embryos by Activation of TLR7/8 on X Sperm via Ligands dsRN/ dsRNA-DR. Molecules, 2024, 29, 262.	A-40 and	3.8	0
2280	Downregulation of transcription 1 hinders the replication of Dabie bandavirus by promot expression of TLR7, TLR8, and TLR9 signaling pathway. Ticks and Tick-borne Diseases, 20	ing the 24, 15, 102307.	2.7	0
2281	Spatiotemporal Controllable Sonoâ€Nanovaccines Driven by Freeâ€Field Based Wholeâ€ for Personalized Cancer Therapy. Advanced Science, 2024, 11, .	Body Ultrasound	11.2	0

#	Article	IF	CITATIONS
2282	T-bet+ B cells are activated by and control endogenous retroviruses through TLR-dependent mechanisms. Nature Communications, 2024, 15, .	12.8	0
2283	<scp>TLR7</scp> activation by imiquimod worsens glycemic control in female <scp>FVB</scp> /N mice consuming a highâ€fat diet. Physiological Reports, 2024, 12, .	1.7	0
2284	Unique pathways downstream of TLR-4 and TLR-7 activation: sex-dependent behavioural, cytokine, and metabolic consequences. Frontiers in Cellular Neuroscience, 0, 18, .	3.7	0
2286	Effect of DON and ZEN and their metabolites DOM-1 and HZEN on B cell proliferation and antibody production. Frontiers in Immunology, 0, 15, .	4.8	0
2287	miR-154-5p Is a Novel Endogenous Ligand for TLR7 Inducing Microglial Activation and Neuronal Injury. Cells, 2024, 13, 407.	4.1	0
2288	Nanomaterials-Involved Tumor-Associated Macrophages' Reprogramming for Antitumor Therapy. ACS Nano, 2024, 18, 7769-7795.	14.6	Ο
2289	Polymorphism in the leucine-rich repeats of TLR7 in different breeds of chicken and in silico analysis of its effect on TLR7 structure and function. Gene, 2024, 912, 148373.	2.2	0
2290	Vaccine adjuvants for infectious disease in the clinic. Bioengineering and Translational Medicine, 0, , .	7.1	0